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Abstract 
Triple negative breast cancer (TNBC) is a subtype of breast cancer which is negative for 
the oestrogen receptor, progesterone receptor and lacks over-expression of HER2. The 
aim of this PhD was to examine c-Met and its ligand HGF as potential targets for 
TNBC.  Expression of c-Met was higher in TNBC relative to other subtypes of BC. c-
Met expression did not show a significant association with patient outcome (DFS/OS). 
We evaluated 3 c-Met/HGF selective inhibitors (CpdA, PRS110 and rilotumumab) in 
the panel of TNBC cell lines. Only CpdA showed moderate responses in proliferation 
assays. Cell lines were significantly more sensitive to c-Met inhibition by either CpdA 
or PRS110 in clonogenic assays. 3D growth assays were all significantly less sensitive 
to c-Met inhibition. Co-expression of c-Met and Src/p-Src (Y418) was detected in 86.6 
/38.8 % respectively. No significant association was seen between clinico- pathological 
variables. Combined treatment with c-Met inhibitors and HGF, EGFR or Src inhibitors 
enhanced response in some cell lines suggesting a potential role in specific subsets of 
TNBC.  
A dasatinib resistant and a cetuximab resistant TN cell line (231-DasB and MDA-MB-
CR) showed increased sensitivity to CpdA compared to the parental cells. The parental 
cell lines show synergistic inhibition of growth with combination of CpdA and dasatinib 
or cetuximab.  
We identified 7 receptor tyrosine kinases (FGFR1, FGFR3, VEGFR1, PDGFRβ, ROS1, 
TIE1 and EPHA5) which are associated with poor outcome (DFS/OS). Combined 
expression of FGFR3, EPHA5 and ROS1 shows significantly stronger association than 
the RTKs as single prognostic indicators.  FGFR3 was associated with histological 
subtype and EPHA5 was significantly associated with increased age at diagnosis.  
Based on our in vitro evaluation, targeting c-Met/HGF signalling does not appear to be 
a promising therapeutic strategy for TNBC.  We identified FGFR3 and EPHA5 as 
potential targets which warrant further investigation in TNBC. 
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Introduction  
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1.1 Breast cancer 
The normal breast is one of the few organs which undergoes continued development 
throughout the lifetime of a woman. This development occurs in key stages; embryonic, 
prepubertal, pubertal, pregnancy, lactation and involution. In the mammary gland there 
are two key cellular compartments; the epithelium (which lines ducts and lobules) and 
the surrounding supportive stroma. Various pathways and hormones regulate the 
different stages of development [1].  Breast cancer is one of the most common invasive 
cancers observed in women. It was the most frequently diagnosed (31%) and the second 
most common cause of cancer deaths in women resulting in 687 deaths (16.6%) 
between 2009 and 2011 in Ireland. Breast cancer incidence has increased at an average 
annual rate of 1.7% between 1994 and 2011 [2]. Breast cancer develops within the 
epithelia of the breast; however, interaction between epithelial cells and the 
mesenchymal compartment of the breast is known to be important for both the 
development of normal breast and in carcinogenesis.  The stroma provides important 
growth and regulation signals e.g. parathyroid hormone related protein; which is 
involved in the fates of the cells of the nipple, ductal mammary epithelium and the 
mesenchymal portion of the breast [3, 4]. 
 
1.2 Breast cancer sub-types 
Breast cancer is a highly heterogeneous disease. The heterogeneity of breast cancer 
often results in variable responses to treatments. Breast cancer has been sub-divided 
using various approaches. The tumour, node, metastasis system (TNM) takes into 
account size of the primary tumour, regional lymph node status and the presence of 
distant metastases [5]. Histological grading is based on the degree of differentiation and 
proliferative activity.  Certain specific morphological and cytological patterns are 
associated with certain clinical presentations and outcomes [6] 
The development of microarray technology ushered in a new era of classifying breast 
cancer. Four main molecular subtypes were identified composed of luminal, HER2 
positive, normal like, and basal (Table 1-1). Luminal breast cancer was further 
classified into subtypes luminal A and luminal B. Of these subtypes only the luminal are 
positive for the oestrogen receptor (ER) while the basal type, HER2 positive and normal 
like are negative for the ER receptor [7-9]. 
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Table 1 - 1 Receptor status and treatment options for the molecular subtypes of 
breast cancer (ER- Oestrogen receptor, PR-Progesterone receptor). 
Subtype Receptor 
Status 
Treatment options based on 
molecular subtype 
Luminal ER +ive 
HER2 normal 
Tamoxifen is standard of care 
however a range of drugs known as 
selective oestrogen receptor 
modulator (SERMS) now exist 
which act in mainly the same way 
[10]. 
HER2+ ER +/–ive 
HER2 
overexpression 
Herceptin (trastuzumab) [11] 
Pertuzumab [12] 
TDM1[13] 
Lapatinib in refractory metastatic 
breast cancer [14] 
Normal 
like 
ER -ive 
HER2 normal 
Tumours are usually small and are 
treated with surgery and radiotherapy 
Basal-
like 
ER –ive 
HER2 normal 
PR-ive 
Cytotoxic chemotherapies 
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1.3 Triple negative breast cancer (TNBC)/basal-like breast cancer 
In general, the mortality rate of breast cancer is falling. This is thought to predominantly 
to be due to early detection, screening programmes and the development of targeted and 
neo-adjuvant therapies. TNBC remains a disease with a poorer prognosis than other 
subtypes. It also lacks the expression of ER, PR and the over-expression HER2 positive 
receptors on the tumour cell surface. To be categorised as TNBC the American Society 
of Clinical Oncologists have published the following guidelines; ER/PR positivity as 
determined by immunoreactivity of tumour cell nuclei is <1% [15]. Due to the lack of 
receptor expression, currently approved targeted therapies have no beneficial effect. 
 
TNBC accounts for 15% of all breast cancer and displays a higher incidence rate in 
African and African-American pre-menopausal women. Women with TNBC are 
significantly younger when diagnosed. Diagnosis tends to be of more locally advanced 
disease and with a higher occurrence of dissemination to the lymph nodes. However, 
unlike other types of breast cancer, no correlation with tumour size and lymph node 
invasion has been seen. Also, TNBC tends towards visceral metastases [16]. Mortality 
rates also differ dramatically when compared to other subtypes of breast cancer [17]. 
Dent et al. showed a 42.2% death rate within 5 years in TNBC compared to 28% in 
other breast cancer subtypes and all mortality occurring as a result of TNBC occurring 
within 10 years in comparison to 18 years for non-TNBC [17]. Distant recurrence was 
also increased in TNBC however, recurrence seems to occur within 1-4 years compared 
to up to 17 years for other subtypes [17].   
 
Basal-like tumours can be characterised by expression of cytokeratin 5/6 and 
morphologically with increased mitotic count, stromal lymphocytic response, central 
tumour necrosis and a pushing border of invasion [18]. They also show high level of 
p53 protein as a result of mutations in TP53, and high c-Kit expression correlating with 
a poorer clinical prognosis [19, 19-22]. Basal-like breast cancers have also 
demonstrated a high level of expression of the epithelial growth factor receptor 
(EGFR/HER1) with levels of overexpression ranging from 18-60% and also show a 
higher mutation load than other subtypes. [20, 23-26].  
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Basal-like (BL) tumours were initially thought be derived from myoepithelial cells, 
however, Livasy et al. recorded the expression of luminal markers (cytokeratin 8/18) in 
basal like breast tumours with the absence of some myoepithelial markers (SMA 4/18, 
p63 and CD 10) [18].  
 
Another subtype of breast cancer which presents predominantly with triple negativity is 
the claudin-low subtype.  As the name suggests, claudin low tumours are characterised 
by low expression of Claudins 3, 4 and 7 and other genes involved in tight junctions and 
cell-cell adhesion [27]. Similarly to BL tumours they show high genomic instability and 
can be characterised by high expression of epithelial to mesenchymal, immune 
response, angiogenesis and cancer stem cell markers [28-30]. Claudin low tumours 
cluster with the Mesenchymal (M) and Mesenchymal stem-like subtypes of TNBC 
described in Table 1 - 2 [31].  
 
TNBC and BL sub-types have been considered interchangeable to date, however, it is 
important to note, the groups are not mutually exclusive but do show high levels of 
overlap.  
 
TNBC/basal like breast cancer (BLBC) contains a large number of tumours types who 
may, despite their shared triple negatively/expression of cytokeratins may in fact 
represent separate distinct disease entities [32]. TNBC which identifies genetically as 
luminal or with HER2 gene enrichment (despite low expression of HER2), show almost 
indistinguishable gene profiling to luminal/HER2 overexpressing tumours. TNBC 
tumours of basal origin show their own distinct genetic profiles. This would suggest that 
triple negativity is not a sufficient biomarker to classify patients in clinical trials [33]. c-
Kit has shown potential as a biomarker for luminal cells and could help characterise 
these luminal TNBC patients [34, 35]. Lehmann et al. published a study of 386 TNBC 
from 21 publically available data sets and identified 6 groups [31]. These include 2 
basal-like (BL1 and BL2), immunomodulatory (IM), mesenchymal (M), mesenchymal 
stem-like (MSL), luminal androgen receptor (LAR) type [31]. These subtypes are 
described in detail in Table 1 - 2. These subtypes were supported by a recent publication 
by Burnstein et al. which identified four subtypes including, luminal-AR, mesenchymal, 
basal like-immuno-suppressed, basal-like immnuo-activated. The basal-like immune-
suppressed group showed the poorest prognosis in this analysis [34].  
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Table 1 - 2 Sub-groups within TNBC and pathways implicated in each sub-type [31] 
Sub-Group Associated with Elevated gene expression 
Basal like-1 (BL1) Cell cycle and cell division pathways AURKA, AURKB, CENPA, CENPF, 
BUB1, TTK, CCNA2, PRC1, MYC, NRAS, 
PLK1, BIRC5 
Basal-like 2 (BL2) Growth factor signalling EGF, NGF, MET, Wnt/β-catenin, IGF1R 
signalling, EGFR, EPHA2, c-Met receptor 
Immunomodulatory (IM) Immune cell processes TH1/TH2 pathway, NK cell pathway, B cell 
receptor signalling pathway, DC pathway 
and T cell receptor signalling, cytokine 
pathway, IL-12 and IL-7, NFκB, TNF, 
JAK/STAT signaling 
Mesenchymal (M) Cell motility, ECM receptor interaction and 
cell differentiation 
TGFB1L1, BGN, SMAD6, SMAD7, 
NOTCH1, TGFB1, TGFB2, TGFB3, 
TGFBR2, TGFBR3, MMP2, ACTA2, 
SNA12, SPARC, TAGLN, TCF4, TWIST1, 
ZEB1, COL3A1, COL5A2, GNG11, ZEB2, 
FGF, IGF, PDGF, CTNNBI, DKK2, DKK3, 
SFRP4, TCF4, TCF7L2, FZD4, CAV1, 
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Sub-Group Associated with Elevated gene expression 
Mesenchymal stem-like Similar to M subtype with low levels of 
proliferation genes and enrichment of genes 
associated with stem cells 
ABCA8, PROCP, END, ALDHA1, PER1, 
ABCB1, TERF2IP, BCL2, BMP2, THY1, 
HOXA5, HOXA10, MEIS1, MEIS2, 
MEOX1, MEOX2, MSX1, BMP2, ENG, 
ITGAV, KDR, NGFR, NT5E, PDGFRβ, 
THY1 AND VCAM1 
Luminal androgen receptor (LAR) Hormonally regulated pathways DHCR24, ALCAM, FASN, FKBP5, APOD, 
PIP, SPDEF, CLDN8, FOXA1, KRT18, 
XBP1 
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Basal-like breast cancer demonstrates large similarity in its development to familial 
breast cancer caused by the mutation in the tumour suppressor gene BRCA (Table 1-3). 
Mutations in BRCA1 predispose women to developing breast cancer with an 80% 
lifetime risk associated with those harbouring the mutation [36]. Characterisation of 
normal and preneoplastic tissue from heterozygous BRCA1 mutant women was 
examined for early epithelial cell subsets. Three subsets were identified, a basal 
stem/progenitor group, a luminal progenitor group and mature luminal cells. The 
luminal progenitor group was expanded and showed enhanced clonogenic activity in 
vitro in BRCA1 cancers suggesting that BRCA cancers are derived from luminal 
progenitors and not basal-like stem cells as previously believed [35].  
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Table 1 - 3 Similarities between familial BRCA1 associated cancers and basal-like 
sporadic cancers [36]. IDC = invasive ductal carcinoma, NR= not reported. 
Parameter BRCA1 cancers Basal-like sporadic 
cancers 
Histological type IDC  
Medullary-like 
IDC  
Medullary/atypical 
Metaplastic breast cancer 
Grade High (3) High (3) 
Borders Pushing Pushing 
Medullary/atypical medullary 
features 
Present Present 
Proliferation rates High High 
Brisk lymphocytic infiltrated Present Present 
Central necrosis Present Present 
Metaplastic elements NR Yes 
ER Negative Negative 
PR Negative Negative 
HER2 Rare Rare 
EGFR Overexpression – 60–
70% 
Amplification – NR 
Overexpression – 60–80% 
Amplification – 15–35% 
Basal keratins Positive Positive 
Cyclin D1 expression Low levels Low levels 
Ploidy Aneuploid Aneuploid 
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1.4 Breast Cancer Treatment 
The mainstays of treatment for breast cancer include radio- and chemo-therapy 
regimens. The optimal use of the radio- and/or chemo- therapies is defined in guidelines 
established by the U.S. Food and Drug Administration (FDA) and the European 
Medicines Agency (EMA) [37].  
1.4.1 Chemotherapy 
For early stage breast cancer chemotherapy can be administered in two ways, as an 
adjuvant or neo-adjuvant therapy. Adjuvant therapy is administered post primary 
therapy (usually surgery), whereas neo-adjuvant therapy is given prior. Neo-adjuvant 
therapy may be useful in cases where at initial diagnosis the tumour bulk is too large for 
surgical removal. In previous meta-analyses no significant difference was observed 
between adjuvant and neo-adjuvant therapy however recently in TNBC neo-adjuvant 
therapy has been associated with improved survival outcome but only in patients who 
achieved a complete pathological response [38, 39]. There are currently 20 approved 
chemotherapy drugs for the treatment of breast cancer (described in Table 1 - 4).  
 
Table 1 - 4 Chemotherapy drugs approved for treatment of breast cancer [40] 
Brand Name(s) Chemical Name Family Mode of Action 
Abraxane  Albumin bound or 
nab-paclitaxel 
Taxanes/Mitotic Inhibitor 
Adriamycin 
Doxil  
Doxorubicin Anthracyclines/Inhibition of DNA and RNA 
synthesis 
Inhibition of topoisomerase II 
Generation of oxygen free radicals 
Induction of histone eviction from chromatin 
Paraplatin  Carboplatin Platinum based chemotherapy/DNA alkylating 
agent. 
16 
 
 
Brand Name(s) Chemical Name  Family Mode of Action  
Cytoxan 
Revimmune 
Clafen 
Neosar 
Cyclophosphamide Nitrogen mustard family/alkylating agent 
Cerubidine 
DaunoXome 
Daunorubicin Anthracyclines/Inhibition of DNA and RNA 
synthesis 
Inhibition of topoisomerase II 
Generation of oxygen free radicals 
Induction of histone eviction from chromatin 
Ellence Epirubicin Anthracyclines/Inhibition of DNA and RNA 
synthesis 
Inhibition of topoisomerase II 
Generation of oxygen free radicals 
Induction of histone eviction from chromatin 
Adrucil 
Efudex 
Fluoroplex 
5-fluorouracil Antimetabolite chemotherapy/Induce cell death 
through interfering with DNA and RNA 
synthesis. 
Gemzar Gemcitibine Antimetabolite chemotherapy/Induce cell death 
through interfering with DNA and RNA 
synthesis. 
Halaven Eribulin Microtubule inhibitor/disruption of microtubule 
formation.  
Ixempra Ixabepilone Epothilone chemotherapy/disruption of 
microtubule formation.  
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Brand Name(s)  Chemical Name  Family Mode of Action  
Abitrexate 
Folex PFS 
Folex 
Methotrexate 
LPF 
Mexate-AQ 
Mexate 
 
Methotrexate Antimetabolite chemotherapy/Induce cell death 
through interfering with DNA and RNA 
synthesis. 
Mitomycin Mutamycin Antitumour antibiotic chemotherapy/ DNA 
crosslinking 
Novatrone Mitoxantrone Anthracyclines/Inhibition of DNA and RNA 
synthesis 
Inhibition of topoisomerase II 
Generation of oxygen free radicals 
Induction of histone eviction from chromatin 
Navelbine Vinorelbine Vinca alkaloid chemotherapy/disruption of 
microtubule formation 
Taxol Paclitaxel TaxanesMitotic Inhbitor 
Taxotere Docetaxel TaxanesMitotic Inhbitor 
Thioplex Thiotepa Alkylating agent chemotherapy 
Oncovin 
Vincasar PES 
Vincrex 
Vincristine Vinca alkaloid chemotherapy/disruption of 
microtubule formation 
Xeloda Capcetibine Antimetabolite chemotherapy/Induce cell death 
through interfering with DNA and RNA 
synthesis. 
 
Chemotherapy is often most effective when given in combinations or regimens. 
Preferred regimens include a doxorubicin/cyclophosamide combination alone or 
followed by two weekly/weekly paclitaxel. For HER2 positive disease preferred 
regimens also include a HER2 targeted agent such as trastuzumab or pertuzumab and 
ER positive disease includes a hormone targeted therapy such tamoxifen or aromatase 
inhibitors [41].  
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1.4.2 Radiotherapy 
Radiation therapy is used to prevent local recurrence from undetectable cells in patients 
who have undergone breast conserving surgery (BCS) or mastectomy. Radiotherapy 
may be administered as whole breast irradiation involving the majority of the breast 
tissue, chest wall irradiation which also incorporates the ipsilateral chest wall, 
mastectomy scar and drain sites and finally regional node irradiation. Radiotherapy post 
BCS/mastectomy has shown an enhanced long term survival (>15years) however no 
significant difference is observed in 5 year recurrence or survival [42]. Additionally, 
higher/additional dose radiotherapy demonstrated a significant decrease in recurrence 
rates at 5 years in women under 40 years of age [43]. 
1.5 Current treatments for TNBC and basal-like breast cancer 
Currently there is no recommended systemic treatment regimen for TNBC due to the 
lack of a proven molecular target, leaving only cytotoxic chemotherapies. TNBC 
demonstrates higher sensitivity to anthracycline based neoadjuvant chemotherapy than 
ER positive subtypes, however, higher rates of reoccurrence and shorter periods of 
disease free survival are observed in TNBC. This may be due to the treatment of ER 
positive tumours with targeted endocrine therapies, suggesting that in cases of TNBC 
where a pathological complete response (pCR) is not achieved the risk of reoccurrence 
and earlier mortality rates are significantly higher [44]. This has also been shown with 
paclitaxel and doxorubicin containing chemotherapies and platinum based 
chemotherapy in the neo-adjuvant setting [45][46].  Overall basal-like tumours show 
high levels of chemosensitivity in comparison to other subtypes, however, when pCR is 
not achieved the prognosis for patients is significantly worse, indicating the need for the 
development of targeted treatments [47].  
1.6 Targeted therapies  
Targeted therapies are treatments that target specific molecules expressed in or on the 
surface of cancer cells, which are involved in carcinogenesis and/or tumour growth. 
Conventional chemotherapy and radiotherapy lack selectivity for tumour tissue and are 
highly systemically toxic [14].  Most of the molecules targeted have a function in 
normal cell growth and development but are aberrantly expressed to confer 
proliferation/growth advantages on the tumour cell. Examples of targeted therapies in 
breast cancer include tamoxifen for the treatment of ER positive tumours and 
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trastuzumab in the treatment of HER2 positive tumours. Receptor tyrosine kinases 
(RTKs) are attractive targets for targeted therapy because more than half of RTKs have 
been found to be over expressed or mutated in human hypoproliferative diseases and are 
therefore considered rational targets for cancer therapy [48, 49]. Targeted therapies 
include both small molecule inhibitors and monoclonal antibodies.   
1.6.1 Small molecule inhibitors 
Small molecule inhibitors are chemically synthesised compounds, which generally work 
by targeting intracellular signalling pathways, in particular kinases. They are usually 
administered as an oral treatment and are generally less specific than monoclonal 
antibodies. Most small molecule inhibitors are metabolized by cytochrome 450 
enzymes. This can result in interactions with other medicines including antibiotics and 
anticoagulants. They additionally have a short half-life indicating the need for daily 
dosing [50, 51].  
1.6.2 Monoclonal antibodies 
Monoclonal antibodies were first established in 1975 by Kohler et al. Early antibodies 
had the drawback of allergic and anti-antibody responses due to their murine or 
chimeric nature. This was overcome by the creation and manufacture of fully 
humanised antibodies [51, 52].Monoclonal antibodies bind specifically to their target 
molecule through the fragment antigen binding (Fab) portion which recognises specific 
sequences in the antigen of interest [50]. Upon binding monoclonal antibodies exert 
their effect through a number of mechanisms including; inhibition of signal 
transduction, induction of apoptosis, inhibition of angiogenesis, enhancement of 
immune response and finally delivery of cytotoxic drugs. 
Inhibition of signal transduction can occur through interaction directly with the receptor 
to block ligand binding or indirectly by binding and blocking interaction of the ligand, 
removing the activating stimulus. Cetuximab, an anti-EGFR monoclonal antibody, 
competitively binds to EGFR blocking ligand binding thereby inhibiting downstream 
signalling  [53], Bevacizumab in contrast binds to the ligand (VEGF-A) of the receptor 
(VEGFR) inhibiting interaction and thus inhibiting downstream signalling. VEGF is 
implicated in tumour mediated angiogenesis and therefore bevacizumab anti-tumour 
effects may be attributable to anti-angiogenesis [54].  
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Monoclonal antibodies may also act as ligand mimics targeted at death receptors in the 
tumour necrosis factor (TNF) family [55]. An antibody termed anti-APO-1 targeted 
CD20 on B lymphocytes cell surfaces and led to rapid induction of apoptosis. Anti-
APO-1 was later identified as FAS (a TNF family ligand) which led to death receptor 
activation [55, 56]. Enhancement of the immune response can occur through two 
mechanisms; complement mediated cytotoxity (CDC) and antibody dependent 
cytoxicity (ADCC). CDC can only be activated when IgM and IgG classes of 
monoclonal antibodies are utilised. The Fc portion of the antibody is capable of binding 
the first component of the complement cascade (C1). This triggers the complement 
cascade which results in the recruitment of phagocytic cells and resultant death of the 
antibody bound cells [57, 58]. Additionally the Fc portion of the antibody can bind an 
Fc gamma receptor (FcgR) on effector cells. ADCC is triggered when both Fc and Fab 
portion of the Ab engage both tumour cell antigen and FcgR of the effector cells. 
Effector cells include natural killer cells, macrophages, neutrophils and eosinophils. 
These effector cells then release perforins and granzymes to lyse the antibody labelled 
cell [57, 59, 60]. ADCC has been implicated as a critical mechanism of action of 
monoclonal antibodies and polymorphisms in the FcgR region of effector cells have 
been attributed to a reduction in activity of a number of monoclonal antibodies 
including trastuzumab, rituximab and cetuximab [60]. 
Finally, antibody drug conjugates are currently under investigation as a mechanism of 
selected delivery of cytotoxic drugs. Trastuzumab emtansine (TDM-1) incorporates the 
monoclonal antibody trastuzumab and the microtubule inhibitor DM1 [61]. Emtansine 
was developed in 1980s, however was deem too toxic for patient treatment. Conjugation 
of low concentrations to trastuzumab allow directed delivery of drug to HER2 
expressing cells. TDM-1 significantly increased progression-free and overall survival in 
HER2 positive metastatic patients [13].  
1.7 Receptor tyrosine kinases (RTKs) 
RTKs are a family of cell surface receptors whose functions are diverse and many. In 
most instances they function as receptors for growth factors. The primary structure of a 
RTK was initially demonstrated through the EGFR. The RTK class of cell surface 
receptors now comprises 58 known members that are distributed among 20 subfamilies. 
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However, despite the large number of members and their diverse biological functions, 
most demonstrate the same core structure as described below [62].   
RTKs consist of four main domains. The extra-cellular domain with responsibility for 
ligand binding, the intracellular tyrosine kinase domain which is responsible for activity 
and biological response, the transmembrane domain which connects the two and finally 
a regulatory domain [63, 64].  The general mechanism for activation of a RTK is as 
follows; a ligand will bind to the receptor which induces a transformational change 
through dimerisation (either hetero- or homo). This transformational change triggers 
autophosphorylation of tyrosine residues, causing subsequent downstream 
phosphorylation propagating the signal. The phosphorylated tyrosines serve as docking 
sites for secondary messengers, such as growth factor receptor bound protein-2 GRB2. 
Upon activation GRB2 binds to the cytoplasmic domain of the RTK through its Src 
homology 2 (SH2) region. GRB2 consists of one SH2 domain and two SH3 domains. 
The SH3 domains are responsible for the binding of the next protein in the cascade. 
SH3 domains recognise proline rich areas in other proteins such as son of sevenless 
(Sos). Sos is a guanine exchange factor which switches RAS from its GDP-bound 
inactive form to its GTP bound active form. RAS is known to activate numerous 
pathways including MAPK and AKT which are involved in cellular growth and 
regulation of transcription factors. Another downstream pathway activated by RTKs is 
the PI3K pathway which is also involved growth, proliferation differentiation, motility 
and survival [48]. RTKs are subject to both positive and negative feedback loops. 
Positive feedback increases the sensitivity of the system to signalling inputs by 
amplifying the stimulus [65]. 
1.8 RTKs implicated in TNBC 
1.8.1 EGFR 
EGFR is overexpressed in BL/TNBC with expression levels reported between 18 and 
60 % [20, 66-69]. EGFR overexpression has been associated with larger tumour size 
and poorer progression free/overall survival, poor response to therapy and development 
of resistance to chemotherapeutics [68, 70-73]. TNBC cell lines show resistance to 
EGFR specific inhibitors and signal agent clinical trials with gefitinib and erlotinib 
showed limited activity [74-77] One mechanism suggested for poor activity has been 
through interaction with c-Met as described below in section 1.15.1.  
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1.8.2 c-Kit 
The proto-oncogene c-Kit encodes a transmembranse receptor tyrosine kinase c-Kit. c-
Kit is activated by its ligand colony stimulating factor. Its functionality in normal 
tissues includes haematopoiesis, melanogenesis, spermatogenesis and the development 
of the interstitial cells of Cajal. c-Kit is normally expressed in haematopoietic stem 
cells, tissue mast cells, germ cells, melanocytes, interstitial cells of Cajal and mammary 
gland epithelium [78]. A loss of c-Kit expression has been associated with embryonic 
lethality in mice and more advanced disease and poor prognosis in basal-like breast 
cancer [59, 60]. Imatinib is a c-Kit targeting small molecule which showed activity in 
vitro however, a phase II trial in metastatic breast cancer showed no activity of imatinib 
in reducing primary tumour burden [79]. Previous pre-clinical data from our laboratory 
supports this as imatinib showed limited effect on the proliferation of five TNBC cell 
lines with IC50 > 20 µM [80].  
1.9 c-Met  
c-Met has previously been implicated in the development of basal-like tumours in mice 
[81]. Expression has been documented in breast cancer in a number of studies described 
below (Table 1 - 3). In early gene studies Ponzo et al., identified a c-Met gene signature 
which was significantly associated with the BLBC [82]. Despite all the evidence 
supporting c-Met as a potential target in TNBC/BLBC it had not been fully evaluated as 
a potential therapeutic target for TNBC/BLBC. Thus, the main aim of this thesis was to 
examine the expression and function of c-Met in TNBC and to evaluate c-Met and it’s 
ligand hepatocyte growth factor (HGF) selective and non-selective inhibitors as a 
potential therapeutic option. The currently available literature about the 
structure/function of c-Met is discussed in detail below. Additionally, we discuss 
previous research on c-Met/HGF in breast cancer specifically TNBC, and the current 
stage of development of c-Met/HGF inhibitors.  
The MET oncogene was originally identified from a chemically transformed 
osteosarcoma-derived cell line and was mapped to chromosome 7 between 7p11.4 and 
7q22. Direct hybridisation indicated this oncogene was unrelated to other known 
oncogenes [83].  The MET oncogene spans more than 120 kb in length and consists of 
21 exons, 20 introns and a single open reading frame of 4224 nucleotides. In vitro the 
MET oncogene is activated by chromosomal rearrangement and fusion between the 
unrelated TPR gene on chromosome 1 and MET oncogenes [84]. The product of the 
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MET oncogene is a RTK known as HGFR or c-Met [85]. Initially c-Met is translated as 
a 150 kDa polypeptide that is partially glycosylated to produce a 170 kDa precursor 
protein. Following further glycosylation the precursor is cleaved into a 50 kDa α chain 
(completely extracellular) and 140 kDa β-chain [86]. The large extracellular domain is 
cysteine rich, a characteristic typical of ligand binding domains and residues are 
dispersed throughout the extracellular domain (ECD) [85, 87].  
 
The mature c-Met protein is post-translationally cleaved at the amino acid sequence 
Arg-Lys-Lys-Arg-Ser, dividing the receptor into α (25 kDa) and β (165 kDa) subunits. 
The α-subunit (N terminal peptide) then associates with the membrane bound β subunit 
via disulphide bonds similar to that of the human insulin receptor [88]. Homology exists 
between c-Met and the semaphorins confined to the N-terminal cysteine rich domain 
[87].  Semaphorins play a role in axon guidance and are also thought to play a role in 
regulating developmental processes including morphogenesis and cell migration. The 
conserved domain of c-Met called the sema domain consists of approximately 500 
amino acids. Semaphorins have been shown to be responsible for biological activity and 
receptor specificity [88, 89]. 
 
c-Met is the prototypic member and the most characterised of a family of Met receptors 
consisting of c-Met, and recepteur d’origine nantais (RON). RON’s ligand, macrophage 
stimulating protein (MSP), is also involved in cell scattering. c-Met and RON share a 
region of homology referred to as the Met related structure (MRS) which maps the 
conserved nature of the positions of cysteine residues within the receptors [90-94].  
 
1.10 c-Met signalling pathway 
c-Met activation occurs when its ligand HGF binds to the receptor resulting in the 
autophosphorylation of tyrosine residues on the intracellular region of the β chain. 
Tyrosines are the only residues phosphorylated to any detectable level and the activation 
process seems to require ATP as phosphate donors for phosphorylation to occur. The 
initial sites for autophosphorylation are at Y1234 and Y1235, within the activation loop 
of the tyrosine kinase domain. This then triggers the phosphorylation of Y1349 and 
Y1356 located in a cluster of amino acids in the C-terminal of c-Met activating the 
multifunctional docking site [86, 95]. c-Met then interacts with a number of Src 
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Homology 2 (SH2) containing signalling molecules. These include (PI3K), 
phospholipase Cγ, pp60c-src and GRB-2-Sos complex. The SH2 domains are responsible 
for the interaction of the cytoplasmic mediators with the phosphotyrosine residues on 
the tyrosine kinase receptor.  
In c-Met the diverse biological events seen are almost exclusively thought to be due to 
an interaction of these SH2 containing molecules with a single multifunctional docking 
site made of a tandemly arranged degenerate sequence [96].  Met can also be 
constitutively activated in cancer through somatic mutations in the kinase domain and 
chromosomal translocations [97, 98]. Y1349 and Y1356 also bind N- and C- terminal 
SH2 domains in PLC-γ, pp60c-Scr . Activation of either Y1349 or Y1356 is sufficient to 
facilitate binding however, binding affinity is much stronger when both Y1349 and 
Y1356 are involved (Figure 1 - 1) [99] . 
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 Figure 1 - 1 Schematic structure of the c-Met receptor and downstream signalling pathway [100]. 
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1.11 Hepatocyte growth factor (HGF) 
Hepatocyte growth factor/scatter factor (SF) is the only known ligand to bind to c-Met. 
HGF/SF is so called because they were initially identified as individual molecules, each 
with its own biological activity [101, 102]. Through analysis of numerous parameters 
e.g. growth, motility, binding affinities etc. the ligands were shown to be 
indistinguishable [101, 102]. Hepatocyte growth factor was identified as a hepatotrophic 
factor playing a role in the regeneration of hepatocytes in rats [103]. Scatter factor was 
identified as a growth factor responsible for movement and positioning of cells released 
from fibroblast cells acting only on the epithelial cells. HGF is similar in sequence to 
that of some proteases involved in fibrinolysis and blood coagulation.  HGF is made up 
of two polypeptide chains; an α-chain of molecular weight 69 kDa and a β-chain of 
molecular weight 34kDa, linked covalently via a disulphide bond to form a 
heterodimeric molecule (Figure 1 - 2)  [104].    
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Figure 1 - 2 Schematic structure of HGF [100]. 
 
The gene for HGF is located on chromosome 7, is approximately 70 kbp in length and 
consists of 18 exons and 17 introns. Nucleotide sequencing predicted the translation of a 
404 residue protein and an untranslated 3’ sequence. HGF is sequenced from a single 
open reading frame to produce a 728 amino acid polypeptide which includes both an α 
and a β chain. The chains are cleaved by a trypsin like protease e.g. urokinase/tissue 
plasminogen activator) (uPA/tPA) at an Arg-Val site. Factor XIIa of the blood 
coagulation system is also known to be able to activate HGF in vitro via a cleavage 
reaction [105-108]. Cleavage is essential for biological activity [109].   
Of the first 54 amino acids, the first 29 are hydrophobic typical of a signalling sequence 
while the rest constitute the pro-sequence. The pro-HGF molecule shows approximately 
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40% homology to plasminogen with its α chain containing 4 kringle structures and 
plasminogen containing 5 kringle structures. These kringle structures are thought to 
play a role in protein-protein interaction although there full biological role is as yet 
unknown. The β chain also shows homology to plasminogen in its serine protease 
domain but histidine and serine residues in the active site in plasminogen are replaced 
by glutamine and tyrosine in HGF indicating HGF has no serine protease activity. In the 
mature molecule homology is also seen with plasmin in the formation of an interchain 
bridge at Cys 604 in the β chain and Cys 487 in the α chain [105]. Each chain contains 
two Asn-Xaa-Thr/Ser sequences, potential sites for N-linked glycosylation; these are at 
residues 240-242 and 348-350 of the α chain and at residues 74-76 and 161-163 of the β 
chain [103].  
 
HGF is unique by virtue of its binding of the c-Met receptor as the only kringle 
containing protein known to bind to a transmembrane receptor. It has been shown that 
the α chain N-terminal region and the first kringle domain is sufficient to produce this 
activity [105, 110]. While the β chain is not exclusively necessary for receptor binding, 
certain residues (Y673 and V692) are essential for structure, regulation and activity of 
HGF [105]. Amino acids 28-210 comprise the first kringle domain. HGF contains two 
natural splice elements. The first N-terminal Kringle domain NK1 consists of two 
globular subunits; the N terminal and the first kringle (K) domain connected by a short 
linker (Lys 122-ASN 127). The N terminal consists of three main elements, a 5 strand 
β-pleated sheet, a 2 strand β-pleated sheet and an α helix region. In contrast the K 
domain consists of 3 disulphide bridges and a 2 strand anti-parallel β-pleated sheet. It is 
thought that binding of the NK1 domain is possibly stabilised by interaction with 
heparin [111, 112]. 10 residues cluster within the NK1 domain, which are known to 
play a role in receptor binding and activation [113]. The second splice site is known as 
the NK2 domain and consists of the N terminal and the first 2 kringle domains. NK2 is 
a c-Met antagonist and is able to bind to the Met receptor and induce cell motility but 
not mitogenesis. Binding of NK2 to c-Met does not facilitate dimerisation of c-Met due 
to NK2 monomeric nature. This is potentially the reason for NK2 c-Met antagonism. 
[110, 114]. 
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1.12 Major signalling pathways downstream of c-Met 
1.12.1 PI3K-Akt axis 
Phosphatidylinositol-3 kinase (PI3K) can bind directly to the phosphorylation sites at 
Y1349 and Y1356 of c-Met. PI3K binds to these two docking sites as it contains two 
SH2 domains however the C-terminal SH2 presents with a higher affinity for binding to 
c-Met.  The N-terminal SH2 domain’s affinity may be affected by the phosphorylation 
status of the C-terminal SH2 domain. Indirect activation of PI3K can also occur through 
binding of Ras. PI3K phosphorylates phosphatidylinositol-4-5-bisphosphate (PIP2) to 
phosphatidylinositol-3-4-5-trisphosphate (PIP3) [115].  Akt binds to PIP3 resulting in 
translocation to the cell membrane where it is phosphorylated by phosphoinositide-
dependent kinase-1 (PDK1) at Thr308. Full activation of Akt requires a second 
phosphorylation at Ser473. Activated Akt is then released into cytosol where it interacts 
with multiple effector proteins [116]. In ovarian cancer treatment of cell lines with c-
Met inhibitor PHA665752 resulted in dephosphorylation of Akt and subsequent 
downregulation of anti-apoptotic proteins XIAP and BCL-XL [117].  
 
1.12.2 MAPK cascades 
c-Met can also activate Ras through the GRB-2-Sos complex.  GRB-2-Sos can interact 
directly or can be associated through SHC adapter proteins to c-Met [96].  GRB-2-Sos 
only requires to Y1356 [99]. This leads to activation of the family of mitogen activated 
protein kinase (MAPK)/extracellular signal regulated (ERK) cascades. HGF increases 
levels of p-ERK in gastric cancer and inhibition of c-Met using inhibitor SU11274 
demonstrated activation of ERK leading to decreased SU11274 induced autophagy 
through interaction with p53 and BCL-2 [118].  
 
1.12.3 STAT3 pathway 
Stat3 associates with phosphorylated c-Met through SH2 domains (Figure 1 - 3). 
Resultant phosphorylation of STAT3 leads to the formation of STAT3 homodimers. 
STAT3 homodimers translocate to the nucleus where they function as transcriptional 
controls [119]. It has been reported that c-Met signal specific control of STAT3 requires 
internalisation of c-Met receptor and trafficking to the peri-nuclear compartment [120]. 
STAT3 can also be activated through Src family kinases and it is these different 
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methods of activation of STAT3 which determine the effects exerted on transcription of 
proteins [121]. 
 
 
Figure 1 - 3 Interaction of STAT3 and c-Met [122].  
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1.13 Regulation of c-Met 
Regulation of c-Met activity is controlled in a number of ways.  It can undergo 
degradation post stimulation with HGF. The receptor is internalised and degraded via an 
ubiquitin-proteosome labelling system. This pathway is dependent on kinase activity of 
the receptor. It has been suggested that activation of the receptor through 
phosphorylation and dimerisation unmasks the ubiquitin recognition sequences [123].  
A dileucine enriched motif has been identified which indicates the presence of a 
selective endocytic assembly for c-Met.  Ambiguity exists over whether endocytic 
internalisation of c-Met results in downregulation of signalling or functions to enhance 
signal transduction. It is probable that both scenarios exist however more research is 
needed to confirm [124].  Ubiquitination of c-Met is mediated by c-Casitas B-
lineage Lymphoma protein (c-CBL) binding on the juxtamembrane domain of the c-Met 
receptor. The c-CBL protein requires an intact tyrosine kinase binding domain and 
phosphorylation at Y1003. In cells which express mutant Y1003, (Figure 1 – 1) c-Met 
may still be internalised, however the receptor is not trafficked into degradation 
pathways [125, 126]. 
 
Phosphatases are biological molecules which dephosphorylate residues therefore 
deactivating them. Phosphatases have been implicated in the negative regulatory 
element of c-Met and the following target the main phosphorylation sites Y1234 and 
Y1235; protein-tyrosine-phosphatase (PTB) 1B as well as T-cell phosphatase (TCPTP). 
PTB-1B is a non-receptor tyrosine phosphatase and possesses a phosphatase catalytic 
domain as well as a proline rich domain. PTB-1B has been shown to interact with 
multiple RTKs. TCPTP is closely related and structurally similar to PTB-1B but possess 
different specificities. PTP-1B and TCPTP both co-localise with c-Met after HGF 
induced activation and dephosphorylate the major autophosphorylation site [127].  
 
Finally, dorsal ruffles are apical protrusions produced in response to growth factors. 
Dorsal ruffles form only transiently in response to growth factor activation and in the 
case of c-Met signalling are enriched in Gab1 (a Met substrate) thereby providing a 
prolonged localised plasma membrane signalling microdomain. Enriched Gab1 dorsal 
ruffle domains enhance c-Met degradation indicating that dorsal ruffles not only create a 
microdomain for downstream signalling but also create a pathway for internalisation of 
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the receptor and targeting for degradation. Data suggests that this method of degradation 
works independently of ubiquitination and occurs when the dorsal ruffle collapses 
causing bulk internalisation and subsequent entry into the canonical degradation 
pathway [128].  
1.14 Role of HGF and c-Met signalling in normal development 
The HGF and c-Met signalling pathway is involved in numerous developmental events. 
HGF was initially identified as a growth factor for hepatocytes playing a role in the 
development and regeneration of the liver [101]. HGF is involved in embryogenesis, 
demonstrated by the embryonic lethality of offspring of homozygous HGF null mice 
from heterozygous parental mice [129].  Abnormality of the placenta in mutant mice 
was seen demonstrating a role for HGF in placenta formation. The placentas displayed 
abnormal labyrinth regions (areas of fine embryonic vessels surrounded by trophoblast 
epithelial cells bathed in maternal blood) with a decreased number of trophoblast cells 
resulting in markedly decreased size of the region. C-Met expression was documented 
on the trophoblast cells suggesting that interaction with HGF is essential for normal 
foetal development. This hypothesis is also supported by the presence of c-Met mRNA 
transcripts in a wide variety of foetal tissue with highest concentrations occurring in the 
liver and spleen [129-131].  In foetal development HGF is also required for the normal 
development of limbs and that of a normal diaphragm [132]. HGF is also known to play 
a role in wound and tissue healing. In response to injury of the liver and kidney the rate 
of pro-HGF conversion to its active form is up-regulated. While conversion rates only 
increase in the injured organs, synthesis of pro-HGF in other tissues increases indicating 
a paracrine method of action for HGF on c-Met, however, wound healing is one of the 
few instances in non-pathogenic states where autocrine signalling and activation can 
occur [108, 133]. HGF also plays a role in normal mammary gland development where 
over-expression results in increased size and number of the ductal end bud (growth 
regulatory control point) as well as hyperplastic branching morphogenesis during 
pubertal development. Throughout mammary gland development a serine protease 
matriptase is known to act as an activator for HGF by cleaving the pro form into its 
biologically active state [134, 135] In normal breast tissue expression of c-Met is 
predominately located in the ductal cells with little expression demonstrated in normal 
stromal cells [136-138]. 
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1.15 c-Met/HGF in cancer  
c-Met/HGF signalling mediates a diverse range of biological events. c-Met/HGF 
activation can occur through a number of mechanisms; over expression, 
paracrine/autocrine loops and amplification/mutation. Tumours of epithelial origin show 
aberrant signalling predominantly through over expression and/or a paracrine 
relationship with HGF [138-140]. Mutations have been detected in papillary renal cell 
carcinomas and head and neck squamous cell carcinomas [98, 141] while tumours of 
haemopoietic origin, neurological tumours, gastric cancers and lung cancer cell lines 
have shown autocrine activation of c-Met [142-144]. In tumour development, 
particularly that of carcinomas, there is often a correlation between the differentiation 
stage of the tumour cells and their ability to invade and metastasise, i.e. a highly 
differentiated tumour cell will show poor invasive characteristics and vice versa. Early 
studies found carcinoma cell lines which were poorly differentiated mediated a much 
stronger response to invasion following stimulation by HGF in comparison to that of 
cell lines with better differentiation and of normal epithelial tissue [145]. This 
observation suggests that HGF and c-Met signalling can be implicated in increased 
tumorigenesis, invasiveness and metastatic ability in human cells. This increase may be 
due to the activation of the uPa proteolysis network resulting in the establishment of a 
proteolytically active cell surface facilitating cell invasion via degradation of the 
extracellular matrix (ECM) [146].  HGF/c-Met signalling significantly increases the 
protein levels of both uPa and its receptor in sarcoma cells [146].   
The c-Met axis is also involved in the development of lymphatic vessels in the 
embryonic stage, during cutaneous tissue repair and during the establishment of 
metastasises. This role has been demonstrated both in vitro and in vivo. HGF 
stimulation of lymphangiogenesis does not require VEGFR-3 signalling unlike that of 
other stimulating factors and facilitates lymphangiogenesis through interaction with 
integrin alpha 9. HGF not only plays a role in formation but also in the function of 
lymphatic vessels as when the c-Met receptor is blocked lymph vessels cannot respond 
via enlargement during inflammatory events [147].  
1.15.1 c-Met/HGF in breast cancer 
Overexpression of c-Met has been documented in numerous clinical studies in breast 
cancer. The main findings of these studies are summarised in Table 1 - 3. The 
expression and phosphorylation of c-Met across the human breast cancer subtypes using 
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microarrays was examined and c-Met was detected to be significantly associated with 
ER and HER2 negativity [148]. Overall, overexpression of c-Met is associated with a 
poorer prognosis for patients. Overexpression levels of c-Met according to the studies 
described in Table 1 - 3 and range from 36 to 100% however this overexpression does 
not seem to be linked to MET amplification in breast cancers. Carracedo et al., carried 
out FISH on 155 ductal infiltrating carcinomas and lobular carcinomas but observed no 
amplification of c-Met [149]. Additionally genome wide screening for focal 
amplifications in 56 TNBC did not show any significant alterations in the copy number 
for the MET locus [150]. MET amplification has been reported in 4.7% (3/63) of 
invasive breast cancer tumours however, study numbers are low and do not achieve any 
statistical significance in survival although associations between high grade histology 
and increased tumour burden were reported [151]. As mentioned above the kinase 
activity of c-Met is activated by phosphorylation. To our knowledge only one study has 
examined levels of phospho-Met in tumour tissue. High levels of phosphorylation were 
seen in 123/257 fine needle aspirates from breast tumours  (47.8%) and this was 
significantly associated with relapse free survival (RFS) and  overall survival (OS) 
however, no significant difference was seen across hormone receptor (HR) positive, 
HER2 or triple-negative subtypes [152].  
Lengyel et al. and Bevigilia et al. both showed increased expression of c-Met in lymph 
nodes and metastatic disease during the progression of disease (Table 1-4) suggesting c-
Met inhibition may be a potential treatment option for metastatic disease [153, 154]. 
Metastatic breast cancer shows high levels of metastases to the bone, with almost 80% 
of metastatic disease developing bone disease [155].  The c-Met axis has been 
implicated in the development of bone metastases through regulation of the β catenin 
pathway [154, 156].  In vivo treatment of xenograft models with c-Met specific inhibitor 
ARQ197, prior to the establishment of bone metastases resulted in reduction of 
metastases in both size and number, and prolonged overall survival of mice. It may be 
important to note the lack of efficacy of ARQ197 in this study in reducing primary 
tumour burden and that of already established metastases [81].The role of c-Met in 
metastases may be mediated through Spry-domain containing SOCs box -1 (SPSB-1). 
In HER2 amplified tumours recurrence and metastases is dependent on up-regulation of 
SPSB-1. HER2 amplified tumours may become HER2 low post treatment with a 
specific HER2 inhibitor e.g. lapatinib. Cells which show HER2 down-regulation show 
an up-regulation of SPSB-1 which enables the cell to avoid apoptosis. c-Met binds to 
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PSB-1 and increased c-Met phosphorylation was observed in HER2 positive cells 
(BT474) following lapatinib treatment. The authors show that SPSB-1 mediated 
inhibition of apoptosis is c-Met dependent [157]. c-Met also mediates inhibition of 
apoptosis through downregulation of p53. In non-small cell lung cancer (NSCLC) cell 
lines treatment with c-Met inhibitor SU-11274 caused an increase in the amount of p53 
protein and subsequent sensitivity to apoptosis induction [158].  
 
High levels of HGF in primary breast tumours have been shown to be a strong predictor 
of recurrence and survival in breast cancer [140, 159, 160].Expression levels are 
variable ranging from 43.6% to 66% [138, 161, 162]. HGF is thought to be primarily 
derived from the stromal cells however; HGF has been detected at significantly higher 
levels in invasive breast carcinomas than in non-invasive areas [160]. HGF mRNA has 
been detected in adipocytes, endothelial cells and stromal fibroblasts which lacked c-
Met mRNA. However, in areas of strong expression of c-Met mRNA high levels of 
HGF mRNA were also detected, suggesting the presence of an autocrine loop [140]. 
Co-expression of c-Met and HGF in breast tumours has been associated with a poorer 
prognosis [153, 161]. In one cohort of Japanese women, 88.8% of samples which 
showed c-Met expression at the leading edge of the tumour showed co-expression of 
HGF in a front accentuation pattern. This front accentuation pattern was associated with 
lymph node involvement, grade and increased KI-67 index [161]. 
Serum levels of HGF are significantly higher in the following instances; ER negativity, 
poorly differentiated tumours, more advanced primary staging, patients with distant 
metastases, and patients with reoccurrence [163, 164].  
In vitro studies demonstrated that HGF confers resistance to apoptosis by certain DNA 
damaging events caused by adriamycin in some cell lines. Thus, it is possible that HGF 
confers resistance to cell death induction by conventional cytotoxic treatments. This 
study included the breast carcinoma cell line MDA-MB-453 and EMT6 mouse 
mammary tumour cells, however, no protection was conferred on a TNBC line 
examined, MDA-MB-231 [165]. 
Huang et al., showed that HGF treatment enhanced lung and liver metastasis in a 
xenograft model of triple negative breast cancer, by inducing expression of the 
chemokine receptor CXCR4 on the tumour cell [166]. 
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Table 1 - 3 Summary of c-Met studies in breast tumours.  
Reference Tissue type Method % Positivity for 
c-Met expression 
Clinical Associations 
Tuck et al.  [140] (IDC) 
DCIS 
ISH, IHC 168/168 (100%) Heterogeneous expression in both benign and malignant 
tissue. Strong positivity at leading edge of tumour 
Lindemann et al. [138] DCIS IHC, IF 39/39 (100%) Differential expression between DCIS lesion and normal 
mammary epithelium 
Significant correlation between tumour grade and high 
expression 
Raghav et al. [152] FNA from invasive 
breast carcinoma 
RPPA 181/257 (70.4%) No significant differences in expression observed 
between subtypes 
High expression significantly associated with decreased 
RFS and OS in  HR  
Carracedo et al.  [149] Invasive breast 
tumours 
FISH, IHC 65/168 (38.7%) Expression was significantly associated with PR 
negativity 
Beviglia et al.  [154] Biopsy specimens 
from human breast 
carcinomas 
IHC 6/6 (100%) Similar levels in adjacent normal tissue and tumour 
tissue. Levels were maintained in metastatic lesions and 
up-regulated in 50% (3/6) 
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Reference Tissue type Method % Positivity for 
c-Met expression 
Clinical Associations 
Edakuni et al.  [161] IDC ISH, IHC 
 
64/88 (72.7%) Co-expression of c-Met and HGF in the leading edge of 
the tumour and associated with decreased OS, high 
tumour grade and high KI-67 index 
Garcia et al. [167][168] TMA from breast 
carcinomas 
IHC 330/916 (36.0%) Overexpression associated with poor survival 
 
Lengyel et al. [153] Breast cancers with 
≥3 positive auxiliary 
nodes 
IHC 29/40 (72.5%) Decrease in DFS 
Higher expression in lymph nodes than primary tumours 
Kang et al.  [162] TMAs from node 
negative breast 
carcinomas 
IHC 165/330 (50%) Overexpression is associated with more aggressive 
tumours 
Cytoplasmic domain stronger predictor of outcome 
Ho-Yen et al. [169] TMAs from primary 
invasive breast 
carcinoma 
IHC 1274 Overexpression is associated with poorer overall 
survival 
Associated with HER2 status 
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1.16  c-Met in TNBC/Basal-like breast cancer 
Through genome wide profiling, c-Met was shown to represent a differential marker in 
the basal-like subtype of breast cancer cell lines. The classification was carried using 
established markers of basal-like breast cancer (BLBC) however, c-Met among other 
RTKs (EGFR, c-Kit) emerged as a new marker shown to be differentially up-regulated 
relative to the luminal subtype [170, 171]. We described earlier the gene expression 
analysis which sub-divided TNBC into 6 subtypes (Table 1 - 2). Only one subtype 
showed elevated gene expression for c-Met. This is the BL2 subtype which also shows 
enriched gene ontologies for EGF, NGF, MET, Wnt/β-catenin, IGF1R signalling, EGFR 
and EPHA2. The authors also showed a high KI-67 index [31]. On tissue microarrays of 
1274 invasive breast cancers, c-Met was significantly associated with BLBC with an 
inverse correlation to tumour size. Given that in general BLBC tumours tend to present 
as larger tumours, the authors postulate that c-Met may therefore be playing a more 
predominant role in TNBC tumours of smaller size [169]. Expression of c-Met has also 
demonstrated trends towards poor survival in two studies in BLBC however, this did 
not reach statistical significance [152, 169]. Another study evaluated c-Met in 
conjunction with loss of PTEN and expression of cytokeratins 5/6. In this study a cohort 
of 97 patients with TNBC disease were evaluated for the above markers using 
immunohistochemistry. Expression of c-Met alone did not achieve statistical 
significance as a prognostic marker of recurrence, however, c-Met was associated with 
T1-2 tumours and tumours of a higher grade in TNBC. c-Met expression also correlated 
significantly with the number of metastatic lymph nodes and with increased risk of 
recurrence and death. Collectively, these markers were associated with an increased risk 
of recurrence and death in patients with TNBC overall. [172]. These studies support the 
hypothesis that c-Met is a useful indicator of poor prognosis specific to BLBC/TNBC, 
however, may not function as a single prognostic indicator in survival studies.  
c-Met has been implicated in the early progression and development of BLBC in a 
number of mouse models [82, 148]. In a study carried out by Ponzo et al. expression of 
c-Met in BLBC correlated with tumours which developed clustered into two types, 
‘solid and mixed phenotype (consisting of papillary, scirrhous, adenosquamous, and 
spindle cell pathologies)’. The mixed pathology tumours showed an enrichment of gene 
ontologies related to WNT and EMT pathway, while solid tumours showed over 
expression of genes related to apoptosis, cell adhesion, and small GTPase signal 
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transduction. Additionally the mixed pathology group of tumours clustered with p53 
mutated tumours and when using hierarchical clustering in 172 human breast cancers 
the mixed pathology tumours show the highest correlation with BLBCs. This MET 
signature was expressed at a significantly higher level in BLBCs [82]. Further strength 
is added to the conjecture that activated c-Met may function as an inducer of basal-like 
tumours through the generation of a mouse model with mutationally activated c-Met to 
induce tumours [148].  Additionally loss of TP53 in combination with the expression of 
a mutationally activated c-Met resulted in increased tumour aggressiveness and 
correlated significantly with hormone receptor negativity as well as poorer prognosis. 
These tumours showed predominantly a spindeloid morphology and when examined 
cluster with the claudin low category of TNBC. Inhibition of c-Met resulted in a marked 
change in morphology and reduced metastatic burden as well as restoring cell-cell 
junctions and rescuing claudin1 expression [173].  
BLBC is suspected to derive from luminal progenitors despite the expression of basal 
markers at later stages. These luminal progenitors have been shown in mouse models to 
express high levels of c-Met. Constitutive activation of c-Met results in a preferential 
differentiation of these progenitors into the basal lineage suggesting a major role for c-
Met signalling in the initial development of BLBC [174]. Additionally, in vitro dramatic 
upregulation of HGF secretion was seen from fibroblasts co-cultured with normal 
mammary epithelial cells representing the atypical ductal hyperplasia stage to replicate 
epithelial-stromal interactions occurring in development of malignant lesions. The 
upregulation of HGF alone was not capable of creating the basal-like phenotype, 
however, in cells representative of the DCIS phenotype, upregulation of expression of 
c-Met was also observed and stimulated changes in cell morphology indicative of a 
more invasive phenotype similar to that of BLBC. These changes were reversed by 
blocking the HGF signal using an antibody, confirming the role of HGF/c-Met in 
development and progression [175].  
This study also confirms the crucial importance of stromal cell interaction in relation to 
c-Met/HGF activity.  Furthermore, Sung et al. also demonstrated downregulation of 
HGF production in a 2D culture model of human mammary fibroblast cells (HMF) 
when compared to a 3D matrix. The HMFs cultured in the 3D model advanced the 
progression of MCF10-DCIS cells to a more invasive phenotype agreeing with the 
results of the study above that HGF secretion by the fibroblasts is important in 
progression from DCIS to IDC [176]. Both of these studies also highlight the role of 
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activated c-Met (primarily through paracrine binding of HGF) in the development and 
progression of BLBC. 
In a cohort of 930 breast carcinomas, high c-Met expression was associated with highly 
invasive malignancies and a negative outcome. Where expression of c-Met was 
observed there was co-expression of other basal markers [168]. 
Finally in a limited cohort of primary and metastatic breast cancers, c-Met expression 
was seen exclusively in basal-like primary tumours with variable expression shown in 
the metastatic sites of these tumours. Within this study only four tumours were 
classified as TNBC/BLBC, however, tumour tissue from a minimum of 6 metastatic 
sites was collected and examined for c-Met. Expression of c-Met in the metastases was 
never lower than the primary tumour but two patients showed higher grade staining in 
some of the metastatic tumours. These sites included pericardium in one patient and 
auxiliary lymph node, omentum and diaphragm in the other [177].  The maintenance of 
staining between primary sites and metastatic sites was also noted in an earlier study, 
however, this also had very limited sample numbers (n=6) [154].  
Greater than 70% of primary BLBC express transcription/translation factor Y-box 
binding protein (YB-1). YB-1 has been found in TNBC cell lines and silencing has been 
shown to decrease cell proliferation. In co-immunopreciptation YB-1 and c-Met were 
found to be associated with YB-1 binding to the MET promotor and stimulating 
transcription. Mutant YB-1 overactive cell lines showed increased c-Met expression and 
silencing of YB-1 or MET resulted in decreased anchorage independent growth [69, 
178].  
 
1.17 Crosstalk with other tyrosine kinases 
Crosstalk between different families of receptors occurs in a number of cancers. c-Met 
communicates directly with a number of  receptors including EGFR, Src HER2, HER3, 
death receptor Fas, Ron, α6β4 integrin, CD44 and semaphoring receptor plexin B1.   
1.17.1 EGFR  
Crosstalk between EGFR and c-Met is probably the best characterised interaction of c-
Met with other receptors. EGFR TKIs have demonstrated efficacy as a treatment option 
in lung and pancreatic cancers but no significant response has been seen in breast 
cancer. In lung cancers with developed resistance to EGFR inhibitors, c-Met 
amplification/HGF activation of c-Met has been implicated as a potential mechanism of 
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resistance [179, 180]. In human breast cancers EGFR over-expression alone is unable to 
cause tumour formation and necessitates an interaction with c-Met [181].  
Communication between c-Met and EGFR can be mediated through the RAS/MAPK 
signalling pathway and c-Met/EGFR interaction can stimulate similar cellular responses 
including growth and motility [182, 183]. EGFR is also capable of stimulating a delayed 
activation of c-Met through c-Src activation. EGF treatment of a NSCLC cell line 
resulted in a biphasic activation of c-Src with peaks in phosphorylation at 2 hours and 8 
hours post treatment corresponding to delayed activation of c-Met via EGFR. Inhibition 
of c-Met with PF2341066 inhibited the phosphorylation of c-Met with no effect on Src 
phosphorylation levels. Conversely inhibition of c-Src via dasatinib or PP2 resulted in a 
decrease in phosphorylation of c-Met, however, had no effect on c-Met 
autophosphorylation [184]. The combination of a c-Met inhibitor (PHA-6657562) and 
EGFR inhibitor (erlotinib) showed synergistic growth inhibition in the TNBC cell line 
MDA-MB-468 [185]. In vitro cell lines treated with the EGFR inhibitor gefitinib 
showed significantly reduced HGF induced motility and cell scattering in a breast 
cancer cell line [186]. Activation of c-Met by stromally derived HGF also contributes to 
the resistance of TNBC cell lines to EGFR inhibitor gefitinib [187]. Direct interaction 
of c-Met and EGFR has been shown and the potential benefits of combined targeting of 
c-Met and EGFR have been shown in numerous preclinical studies in a variety of cancer 
types including breast cancer [181, 188-190].  
1.17.2 Src 
Src family kinases are non-membrane bound tyrosine kinases consisting of nine 
members. Src, Yes, Fyn and FGR belong to the Src A family subtype. Lck, Hck, Blk 
and Lyn belong to Src B family subtype. Frk is in its own subfamily [191]. Pre-clinical 
studies have shown preferential sensitivity to Src inhibition in TNBC than other breast 
cancer subtypes and in head and neck cancers [80, 192-194]. Combined targeting of c-
Met and Src in TNBC cell lines can augment response in cell lines compared to either 
inhibitor alone [195, 196].  
1.17.3 HER2 
Direct interaction of c-Met and HER2 has never been documented, however, HGF 
activation of c-Met has shown the ability to ‘rescue’ gastric, lung and breast cell lines 
from lapatinib induced apoptosis through reactivation of MAPK and PI3K downstream 
signalling [179, 197-199]. Co-expression has been associated with innate resistance to 
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HER2 targeted therapies and synergistic inhibition of cell growth can be achieved by 
dual targeting of c-Met and HER2 in HER2 amplified breast cell lines [199, 200]. 
Additionally, HGF activation of c-Met enhances the invasive malignant phenotype in 
HER2 over-expressing cells [201]. Activation of c-Met has also been suggested to 
contribute to trastuzumab resistance in HER2 over-expressing breast cancer through 
inhibition of p27 induction. A subset of HER2 over-expressing cells also upregulate 
production of c-Met in response to trastuzumab treatment and high copy number 
correlates with poorer outcome [202, 203].  
1.17.4 HER3 
Interaction between c-Met and HER3 has also been recognised as a method of 
resistance to gefitinib in lung cancer. Met amplification stimulates the HER3 dependent 
phosphorylation of the PI3K pathway [179]. 
1.17.5 α6β4 integrin 
α4β6 can form direct complexes with c-Met resulting in enhanced invasiveness in 
carcinoma cells. Upon association tyrosine phosphorylation occurs on the β6 
transmembrane domain stimulating signalling through P13K. FAK is a well-established 
protein kinase involved in integrin mediated cell motility. Downstream FAK is 
activated via c-Met stimulated c-Src. FAK also can interact directly with c-Met when c-
Met is constitutively active or over-expressed [204-206].   
1.17.6 CD44 
HGF induces a time dependent association of c-Met with CD44v10 and regulates HGF 
induced endothelial cell barrier enhancement. Up-regulation of c-Met and CD44 have 
been implicated in tumour cell growth and metastases through prolonged signalling 
from c-Met through MAPK pathways [207, 208].   
1.17.7 HIF1α  
Most solid tumours possess an area of hypoxia where inadequate tissue vasculature 
results in low oxygen levels. The hypoxic environment is involved in mediating a 
number of steps including epithelial-mesenchymal transition and can regulate a number 
of growth factors including HGF. Hypoxia not only increases levels of c-Met RNA in 
tumours but also sensitises tumour cells to HGF stimulation [209].   Hypoxia inducible 
factors (HIFs) mediate transcriptional responses to low oxygen levels. HIF1α is 
stabilised through interaction with ROS1 which in turn leads to increased 
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expression/activation of c-Met in melanoma cells [210].  Nuclear factor kappa-light-
chain-enhancer of activated B cells (NF-κB) has also been implicated in regulating HIF-
1α induced by HGF leading to transactivation, however, in a TNBC cell line this HIF-
1α transactivation was undetectable and HGF caused a temporary downregulation of 
HIF-1α [211].  
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1.18 Preclinical studies on c-Met in TNBC 
Although only a limited number of studies have focused specifically on c-Met/HGF as a 
therapeutic target in basal-like/TNBC, a number of early studies of c-Met/HGF in breast 
cancer included cell lines which we now know to be BLBC/TNBC.  A panel of breast 
cancer cell lines was tested for responsiveness to HGF in invasive and migratory 
properties. The cell lines BT20 and MDA-MB-231 both showed the strongest responses 
to HGF treatment in a dose dependent manner [154]. c-Met has been shown to be 
expressed at higher levels in TNBC cell lines relative to that of other subtypes [185].  
Combinations of protein kinase C α and c-Met inhibitors showed synergism in TNBC 
cell lines [212]. Co-targeting of c-Met with Src inhibitors (dasatinib) showed significant 
decreases in proliferation in cell lines relative to either single agent and no significant 
response was seen in non-TNBC cell lines tested [195] . Cell lines which show 
resistance to EGFR inhibition display constitutive c-Met activation independent of 
HGF. Co-immunoprecipatation experiments demonstrated that this was through a 
physical association between c-Met and EGFR. Src also was associated with EGFR and 
c-Met in these cell lines. Inhibition of c-Src resulted in a decrease in phosphorylation of 
EGFR and reduced proliferation and knockdown of Src resulted in moderate 
sensitisation to the EGFR inhibitor gefitinib. Inhibition of EGFR did not result in a 
decrease in activation of Src suggesting a secondary method. In cells treated with 
gefitinib (an EGFR inhibitor) levels of c-Met phosphorylation increased maintaining 
Src phosphorylation. c-Met activation exerted no effect on levels of EGFR activation 
alone, however, dual inhibition resulted in a decrease in Src phosphorylation and 
proliferation of the cell lines. This indicates activated c-Met results in EGFR inhibitor 
resistance. Further proof of this is the de-sensitisation of sensitive TNBC cell lines to 
EGFR inhibition via the introduction of HGF (recombinant or fibroblast conditioned 
media) to culture. This resulted in a significant decrease in sensitivity to gefitinib in 
proliferation and clonogenic survival assays [181, 187, 213]. 
Radiotherapy is one of the conventional treatments used to treat localised breast 
cancers. When a TNBC cell line (MDA-MB-231) was irradiated with a therapeutic dose 
of ionising radiation (IR), overexpression of c-Met was induced through upregulation of 
MET promoter sequence which increased transcription levels of the protein. Post-
irradiation the cells were treated with a selective c-Met inhibitor which increased 
apoptosis in the cell lines. Furthermore when the cells were treated with a sub-optimal 
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dose of IR in combination with the c-Met inhibitor, apoptosis was significantly 
increased compared to IR alone, both in vitro and in vivo [214]. Treatment with histone 
deacetaylase inhibitor (HDAC) sodium butyrate results in resistance to apoptosis. In 
TNBC cell-line MDA-MB-231 this resistance was mediated via c-Met expression.This 
was confirmed by an increase in the levels of apoptosis in response to sodium butyrate 
post c-Met knockdown. These c-Met expressing resistant cells share similar 
characteristics to cancer stem cells and had a much greater ability to initiate tumour 
formation in  Severe Combined Immunodeficiency (SCID) mice [215]. 
1.19 c-Met as a therapeutic target in TNBC 
 c-Met is a potential druggable target to treat TNBC. The c-Met/HGF inhibitors 
currently in preclinical/clinical development are listed in Table 1 - 4.  In the 
stratification of TNBC into 6 subtypes, c-Met was only associated with the BL2 subtype 
which may impact the success of c-Met inhibition if tested in other subtypes of TNBC 
in clinical trials [31, 169]. Two trials are underway with c-Met inhibitors in TNBC, 
tivantinib in patients with recurrent or metastatic TNBC and cabozantinib in metastatic 
TNBC. Results of a single agent phase II trial of tivantinib in metastatic breast cancer 
showed partial resolution of metastatic lesions and cabozantinib exhibited clinical 
activity in patients regardless of receptor status and prior treatment [216, 217]. Some 
controversy exists over tivantinib and whether it is a true c-Met inhibitor. It was initially 
identified as a non-ATP competitive, selective, c-Met inhibitor with  a Ki of ~ 335nM 
however, Katayama et al. showed that tivantinib in addition to inhibiting c-Met caused 
microtubule disruption and therefore its activity could not be solely attributed to c-Met 
inhibition [218, 219].  
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Table 1 - 4 c-Met/HGF inhibitors and stage of development. 
Compound Mode of Action Phase of Development 
[220] 
Indication [220] 
Rilotumumab  
Amgen Inc. 
HGF monoclonal 
antibody 
Phase III Advanced Gastric and or Gastroeosphageal 
cancer 
AMG458  
Amgen Inc. 
c-Met selective TKI Pre-clinical  
AMG208  
Amgen Inc.  
c-Met selective TKI Phase I Patients with Advanced Solid Tumours 
AMG337 
Amgen Inc.  
 
c-Met selective TKI Phase II MET Amplified Gastric/Oesophageal 
Adenocarcinoma or Other Solid Tumours 
MetMAb 
Genentech Inc. 
c-Met monoclonal 
antibody 
Phase III NSCLC 
Ficlazutumab  
Aveo Pharmaceutical Inc. 
HGF monoclonal 
antibody 
Phase II NSCLC 
MK2461  
Merck Sharp & Dohme 
 
Multi-targeted TKI Phase II Advanced Cancer 
MK-8033  
Merck Sharp & Dohme 
 
c-Met selective TKI Phase I Advanced Solid Tumours 
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Compound Mode of Action Phase of Development 
[220] 
Indication [220] 
INC280 
Novartis Pharmaceuticals 
 
c-Met selective TKI Phase II c-Met dependent advanced solid tumours 
PF-04217903 
Pfizer 
c-Met selective TKI Phase I Advanced Cancer 
BMS817378 
Bristol-Myers Squibb 
Dual c-Met/VEGFR2 
inhibitor 
Pre-clinical n/a 
Cabozantinib 
Exelixis Inc.  
Dual c-Met/VEGFR2 
inhibitor 
Phase III Advanced Medullary Thyroid 
LY2801653  
Eli Lilly & Co 
 
Multi-kinase inhibitor Phase I Advanced Cancer 
PRS-110 
Pieris Ag. Inc. 
c-Met anticalin Pre-clinical n/a 
Foretinib  
GlaxoSmithKline 
Dual c-Met/VEGFR2 
inhibitor 
Phase II Squamous Cell Cancer of the Head and 
Neck 
LY2875358 
Eli Lilly & Co 
 
c-Met monoclonal 
antibody 
Phase II Met Positive Gastric Cancer 
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1.20 Non-selective c-Met small molecule inhibitors 
1.20.1 Crizotinib (PF-2341066) 
PF-2341066, developed by Pfizer, is also an oral, ATP-competitive, small-molecule 
dual inhibitor of c-Met and ALK with IC50 values of 4 nM and 25 nM respectively.  It is 
considered highly selective for the c-Met receptor and was found to be able to select out 
the c-Met receptor in a panel of 120 tyrosine and serine-threonine kinases. It potently 
inhibits c-Met phosphorylation and c-Met–dependent proliferation, migration, or 
invasion of human tumour cells via inhibiting HGF-stimulated or constitutive total 
tyrosine phosphorylation of c-Met. In xenograft mouse models, PF-2341066 displayed 
similar inhibitory activities as those observed in cellular studies. It has also been 
demonstrated that PF-2341066 is less potent against the Y1230C and Y1235D mutant 
variants of c-Met located near the kinase domain activation loop. This indicates that PF-
2341066 activity is dependent on the location of the mutation in the active site [221]. 
There have been numerous clinical trials involving PF-2341066 however, most have 
focused on crizotinib as an ALK inhibitor in NSCLC [220].  
 
1.21 Other non-selective c-Met small molecule inhibitors 
XL880/GSK1363089 is a non-selective small-molecule kinase inhibitor that targets 
members of the HGF and VEGF receptor tyrosine kinase families. However, while the 
main targets are the two families mentioned previously, it exhibits additional inhibitory 
activity toward c-KIT, Flt-3, platelet-derived growth factor receptor (PDGFR) β, and 
Tie-2.  Binding of XL-880 to c-Met and VEGF receptor 2 is characterized by very slow 
dissociation from its target, which is verified using X-ray crystallography data showing 
that the inhibitor is deeply bound in the c-Met receptor active site cleft. It inhibits, in 
cellular models, HGF-induced c-Met phosphorylation and VEGF-induced ERK 
phosphorylation and prevents both HGF-induced responses of tumour cells and 
HGF/VEGF-induced responses of endothelial cells. Although it was optimised for 
inhibition of Met, XL880/ GSK1363089 also displays potency toward Ron, and other 
VEGF receptors [222, 223] 
 
MP470 developed by Supergen is another non-selective kinase inhibitor which 
effectively inhibits PDGFR, c-Kit and c-Met. When compared to the activity of 
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erlotinib or imatinib, MP470 inhibits cell proliferation, induces cell growth arrest and 
promotes apoptosis in prostate LNCaP cancer cells. When combined with erlotinib it 
resulted in the destruction of the HER family/PI3K/Akt pathway with associated tumour 
growth inhibition in an LNCaP mouse xenograft model [224].  
 
GCD265 (Methylgene) is a potent and orally active inhibitor of c-Met, RON, 
VEGFR1/2/3 and TIE-2. A phase I trial with dose escalation is ongoing in patients with 
advanced malignancies.  
 
BMS-777607 (BMS) is another potent and orally bio-available inhibitor of c-Met, RON, 
AXL and TYRO3. It is slightly less active against several other kinases.  
 
MK2461 (Merck) is an orally active inhibitor of c-Met as well as FLT1/3/4, FGFR, 
VEGFR2 and TRKA/B. A phase I trial in advanced patients was recently completed but 
the final results have not been disclosed [222].  
 
AMG 208 is a small-molecule inhibitor of c-Met. It is selective for both c-Met and 
RON. c-Met inhibitor AMG 208 inhibits the ligand-dependent and ligand-independent 
activation of c-Met, inhibiting its tyrosine kinase activity, which may result in cell 
growth inhibition in tumours that over express c-Met [225]. 
 
1.22 PRS110 
Anticalins are engineered lipocalins, endogenous low-molecular weight human proteins 
typically found in blood plasma and other body fluids that naturally bind, store and 
transport a wide spectrum of molecules. PRS110 is an anticalin antagonist of c-Met 
which functions in both ligand dependent and independent systems. It binds specifically 
to c-Met and blocks HGF interaction with the receptor without inducing agonism of the 
receptor a side effect of other bivalent monoclonal antibodies [226, 227]. PRS110 is 
highly selective for c-Met with an IC50 of 3.2 ± 0.4 nM and binds to the extracellular 
domain of c-Met.  Upon bind to c-Met PRS110 is internalised and trafficking to 
endosomal compartments. PRS110 has also shown efficacy in inhibiting in vivo growth 
in a U87-MG and Caki-1 xenograft models [228] . 
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1.23  Monoclonal antibodies in targeting HGF/c-Met 
1.23.1 AMG102 (Rilotumumab) 
AMG102 is a humanised IgG2 directed against HGF and capable of preventing HGF 
binding to c-Met and subsequent c-Met activation [229]. Phase I trials of AMG102 have 
indicated it is well tolerated for the treatment of solid tumours and these encouraging 
results have led to further clinical trials including in conjunction with anti-angiogenesis 
agents (which demonstrated a similar patient tolerance to treatment with the inhibitor 
alone and an acceptable safety profile) [225]. AMG102 has also undergone phase II 
trials in patients with recurrent glioblastoma multiforme [230]. When it was tested in 
combination with temozolomide and docetaxel in U-87 Mg xenografts, the combined 
inhibitory effect on tumour cell growth was significantly increased when compared to 
either agent alone. It is thought that temozolomide and docetaxel work through 
induction of caspase 3/7 activity and this is enhanced through the presence of AMG102 
[231].  Amgen Inc. has recently identified c-Met protein expression as a biomarker to 
response of AMG102 in gastric cancer and are currently pursuing a phase III clinical 
trial in gastric cancer [229, 232].  
 
Onartuzumab (MetMAbTM, Roche) is a recombinant humanised monovalent 
monoclonal antibody which targets the extracellular domain of c-Met The unique 
monovalent design of onartuzumab inhibits HGF binding, while avoiding agonistic 
activity, which has been reported with traditional bivalent antibodies [33, 233]. In a 
phase II trial in NSCLC, patients with c-Met-positive tumours receiving onartuzumab 
plus erlotinib had a significant improvement in progression-free survival and overall 
survival compared to treatment with erlotinib alone [234].   
On the basis of the positive findings in the above study, a phase III trial in confirmed c-
Met-positive NSCLC was launched [234]. However, the phase III trial has recently been 
halted, based on the recommendations of the independent data monitoring committee, 
due to a lack of clinically meaningful efficacy [235]. Onartuzumab is also currently 
being tested in combination with chemotherapy in a phase III trial in patients with 
HER2 negative, c-Met positive gastric cancer [220].  
 
TAK-701 is another humanised monoclonal anti-HGF antibody which binds and 
inhibits HGF/c-Met driven proliferation. Phase I studies carried out have shown it is 
well tolerated and safety and pharmacokinetic profiles are of acceptable levels [236].  
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1.24 Compounds evaluated in TNBC in this thesis 
We evaluated five c-Met inhibitors in this thesis. They included rilotumumab (HGF 
monoclonal antibody), CpdA (a c-Met selective inhibitor) and PRS110 (a c-Met 
selective anticalin) which were all obtained through industry partnerships. Additionally 
we evaluated two non-selective c-Met inhibitors, crizotinib and BMS-777607. 
Crizotinib inhibits both c-Met and ALK although. ALK has been indicated as a 
potential oncogenic driver in TNBC and as such was deemed a target to evaluate in 
addition to c-Met [237]. BMS-777607 was selected for further evaluation due to its dual 
inhibitory effects on RON. c-Met and RON interaction have been documented in a 
number of cancer types including lung, pancreatic and breast [238].  
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1.25 Survival analysis in cancer 
TNBC/BLBC is heterogeneous disease which can by sub-typed into a number of 
distinct tumour types [31, 34]. The confirmed presence of these subtypes and the highly 
proliferative adaptability of TNBC/BLBC affirm the view that meaningful treatment of 
TNBC/BLBC may not be achieved through targeting a single protein. EGFR, for 
example, is overexpressed in TNBC, however, tumours are insensitive to EGFR 
inhibitors. Many publications have suggested the reasoning behind this is interaction 
with other RTKs. For these reasons we examined the 58 known RTK’s and their 
influence on progression and survival. Dr. Stephen Madden analysed the survival curve 
using a database of his own creation BreastMark. BreastMark combines gene 
expression data from 21 DNA microarray experiments and detailed clinical data to 
correlate survival/outcome with gene expression levels [239].  
Survival data in cancer studies focuses on the start time (e.g. treatment with targeted 
agent) to the time of the event of interest. These events include overall survival and 
progression-free survival i.e. time to reoccurrence and it is these events that help to 
monitor the response to certain situations Since survival data is rarely normally 
distributed but skewed consisting of many early events and relatively few late events it 
necessitates a form of statistical analysis known as survival analysis. A key point for 
survival analysis is to define a closing date of follow-up as it is impractical to follow 
every patient infinitely. Another variable in survival analysis is the loss of subjects prior 
to completion of the study i.e. those who withdraw/drop out and those who survive 
beyond closing date. This is known as censoring. Both right and left censoring exists. 
Right censoring involves the estimating the time to occurrence of the event because the 
patient did not experience the event during follow-up. This is the more common 
censoring that occurs in survival data. Left censoring occurs when the time of the event 
is unknown i.e. development of a metastatic lesion diagnosed 3 months post-surgery. 
While the event will be recorded at 3 months, it may have developed at any point in the 
3 month window [240, 241]. Survival data is generally described as two probabilities 
survival [S(t)] and hazard [h(t)].The survival probability, S(t), is the ‘probability that an 
individual survives from the time of origin to a specified future time’. The hazard 
probability, h(t), is the ‘probability that an individual who is under observation at a time 
t has an event at that time’. The survival probability can be estimated using the Kaplan 
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Meier (product limit) Method. The Kaplan Meier survival curve plots the survival 
probability against time [241].  
Gene expression profiling has been used to segregate breast cancer into subtypes [7]. 
Within these subtypes notable differences can be observed in survival analysis. Two 
methods to identify patients within the subtypes include prediction analysis microarrays 
(PAM) and single sample predictors (SSP). In this study we used PAM50, SSP 2003 
and SSP 2006. In order to create the classifiers an ‘intrinsic’ gene list was identified 
which consisted of genes which showed the least variation from successive tumour 
samplings. Profiles (known as centroids) consisting of the average expression for each 
of the genes where then used to predict class of the tumours [8, 242].  While every 
classifier identifies molecular subtypes with similar survival not every patient is reliably 
assigned to the same molecular subtype. In the basal-like subtype however, the greatest 
degree of agreement was shown (κ>0.812 where κ = Cohen’s coefficient) regardless of 
the SSP used [242]. 
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1.26 Study Aims 
The aims of this study were as follows:  
• To investigate the expression of c-Met/HGF expression in TNBC as a potential 
prognostic or predictive biomarker for progression/survival 
• To examine the expression of c-Met in conjunction with EGFR and Src in 
TNBC 
• To pre-clinically evaluate selective and non-selective c-Met/HGF inhibitors in 
TNBC cell lines 
• To pre-clinically evaluate selective c-Met inhibitors in combination with EGFR 
and Src inhibitors 
• To examine the role of c-Met/HGF in TNBC cell line models of  acquired 
resistance  
• To identify novel RTKs implicated in TNBC as potential future targets  
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Chapter 2 
Materials and methods 
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2.1 Cell lines, cell culture and reagents 
Sixteen human breast cancer cell lines were used in this study including nine TNBC 
(BT20, HCC1937, HCC1143, MDA-MB-468, MDA-MB-231, CAL-120, CAL-85-1, 
HDQ-P1 and BT549) two drug resistant variants (231-DasB and MDA-MB-468CR) 
and seven non-TNBC cell lines (SKBR3, MDA-MB-453, BT474, HCC1419, CAMA-1 
and MCF-7). The cell lines, BT20, HCC1937, HCC1143 MDA-MB-231, MDA-MB-
468, HCC1419, BT474, SKBR3, CAMA-1, MCF-7 and T47D were obtained from the 
American Type Culture Collection (ATCC). MDA-MB-453 cell line was obtained from 
the University of California, Los Angeles, USA. CAL-120, CAL-85-1 and HDQ-P1 
were obtained from Leibniz-Institut Deutsche von Mikroorganismem und Zellkulturen 
GmbH (DSMZ). The BT549 cell line was obtained from Dr. Bo Li in University 
College Dublin, Belfield, Dublin 4. The 231-DasB was developed by Dr. Brendan 
Corkery in Dublin City University.  The MDA-MB-468CR was obtained from Dr. 
Ashwag Albukhari in the University of Oxford. The most common mutations observed 
in the panel of TNBC cell lines are described in Table 2 – 1.  The growth conditions for 
each cell line are described in Table 2 – 2. All cell lines were routinely tested for the 
presence of mycoplasma as follows. Cell culture supernatant was collected from each 
cell line a minimum of 3 passages post thawing and 24 hours post media change. The 
supernatant was added to normal rat kidney epithelial cells (NRKs) cultured on glass 
coverslips to 70% confluence in technical duplicate. The supernatent and NRKs were 
incubated for 4 days at 37ºC with 5% CO2. Supernatent and NRK media was removed 
and NRKs were fixed in Carnoy's Fixative (1:3 glacial acetic acid:methanol) for 20 
mins on ice and allowed to airdry. After fixation NRKs were stained with Hoechst 
33258 (Sigma Cat. No. B2883) for 10mins. Each coverslip is washed twice with ultra 
high purity water (UHP) and read on a fluorescent microscope at an excitation 
wavelength of 400nm.  
Drug compounds used in this study are described in Table 2 –3. Compound A (CpdA) 
and rilotumumab were obtained from Amgen Inc. Neratinib and saracatinib were 
purchased from Sequoia Research Products Ltd. PRS110 as well as a negative control 
for PRS110 (TLPC144-PEG40), were obtained from Pieris AG. BMS777607 was 
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purchased from Selleck Chemicals. HGF (294-HG-025) and epidermal growth factor 
(EGF) (236-EG-01M) were purchased from R&D systems Inc. 
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Table 2 -  1 Common genetic alterations in the TNBC cell line panel used in this study (WT- wild type, AMP – amplified and Mut – mutant) 
[243, 244]. 
 BT20 HCC1937 HCC1143 MDA-MB-
468 
MDA-MB-
231 
CAL-120 CAL-85-1 HDQ-P1 BT549 
P53 mutation Mut WT Mut WT Mut Mut Mut WT WT 
EGFR AMP  AMP AMP   AMP   
RAS/RAF 
mutation 
WT WT WT WT KRAS WT WT WT WT 
PI3K mutation WT WT WT WT WT WT WT WT WT 
PTEN status WT Null WT Null WT WT WT WT Null 
BRCA status  Mut        
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Table 2 - 2 Growth media, foetal calf serum (FCS) and supplements for each of the 
cell lines used in this study (TNBC-triple negative breast cancer, UC- unclassified, 
BL1- basal-like 1, BL2- basal-like 2, MSL- mesenchymal stem-like, M- 
mesenchymal [31]) IU-international units, HER2- HER2 amplified. 
Cell line Cell line 
classification 
Media FCS Supplements 
BT20 TNBC (UC) DMEM:HAMS 
F12 
10% None 
HCC1937 TNBC (BL1) RPMI1640 10% None 
HCC1143 TNBC (BL1) RPMI 1640 10% None 
MDA-MB-
468 
TNBC (BL1) RPMI 1640 10% None 
MDA-MB-
231 
TNBC (MSL) RPMI 1640 10% None 
CAL-120 TNBC (M) DMEM 10% None 
CAL-85-1 TNBC (BL2) DMEM 10% 1mM Sodium 
Pyruvate 
2mM L- Glutamine 
HDQ-P1 TNBC (BL2) DMEM 10% None 
BT549 TNBC (M) RRMI 1640 10% 0.023 IU Insulin 
231-DasB TNBC (M) RPMI 1640 10% None 
MDA-MB-
468CR 
TNBC (BL1) DMEM 10% 10 µg Cetuximab 
T47D Luminal RPMI 1640 10% None 
MDA-MB-
453 
HER2 RPMI 1640 10% None 
HCC1419 HER2 RPMI 1640 10% None 
MCF-7 Luminal RPMI 1640 10% None 
SKBR3 HER2 RPMI 1640 10% None 
CAMA-1 Luminal RPMI 1640 10% None 
BT474 HER2 RPMI 1640 10% None 
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Table 2 - 3 Details of targeted therapies used in this study. 
Compound 
(source) 
Class Molecular 
target 
Stock 
solution 
Long-term 
storage 
Short-term 
storage 
Compound A 
(Amgen Inc.) 
Tyrosine 
kinase 
inhibitor 
(TKI) 
c-Met 10 mM 
in DMSO 
-80 ˚C Ambient 
temperature 
for ≤ 7 days 
Rilotumumab 
(Amgen Inc.) 
Monoclonal 
antibody 
(mAb) 
HGF 30 mg/mL -80 ˚C 4-8˚C for ≤ 
7 days 
PRS110 
(Pieris Ag.) 
Anticalin c-Met 7160 
mg/mL 
-20 ˚C 4-8˚C for ≤ 
14 days 
Neratinib 
(Sequoia 
Research 
Products 
Ltd.) 
TKI erbB family 1 mM 
in DMSO 
-20˚C Ambient 
temperature 
for ≤ 7 days 
Saracatinib 
(Sequoia 
Research 
Products 
Ltd.) 
TKI Src/Abl 10 mM 
in DMSO 
-20 ˚C Ambient 
temperature 
for ≤ 7 days 
Dasatinib 
(Sequoia 
Research 
Products 
Ltd.) 
TKI Src, 
BCR/Abl, c-
Kit, 
PDGFRα/β, 
EPH-A/B 
receptors 
1 mM 
in DMSO 
-20 ºC Ambient 
temperature 
for  ≤ 7 days 
BMS 777607 
(Selleck 
Chemicals) 
TKI Met/Axl/Ron 10 mM 
in DMSO 
-80 ºC Ambient 
temperature 
for ≤ 10 
days 
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2.2  Protein extraction/preparation of cell lysates 
Cells were grown in duplicate wells in 6-well plates or in 90 mm cell culture petri 
dishes and whole cell lysates were prepared as follows: cells were washed twice with 
cold phosphate buffered saline solution (PBS) and 150 µL/well or 350 µL/dish 
radioimmunoprecipitation assay buffer  (RIPA) ((Sigma, R0278) 5 mM 
tris(hydroxymethyl)aminomethane-hydrochloric acid (Tris-HCl) pH 7.4, 1% NP-40, 
0.1% SDS, 150 mM NaCl, 1% Triton x-100) containing 1x Protease Inhibitor cocktail 
(PI) (Calbiochem, 539131), 2 mM phenylmethanesulfonylfluoride (PMSF) (Sigma, 
P7626), and 1 mM sodium orthovanadate (NaOv) (Sigma, 6508), was added and cells 
were incubated on ice for 20 minutes. Cells were scraped into lysis buffer. The lysis 
buffer was collected and centrifuged at 16,200 x g for 10 minutes at 4 oC. The pellets 
were discarded and the supernatants collected and stored at -80oC. Protein quantification 
was performed using the BCA (bicinchoninic acid) quantitation kit (Pierce, 23227). 
2.3 Immunoblotting  
Protein (30 or 50 µg) was electrophoretically resolved on 4-12% (Life Technologies 
NP0322BOX) or 7.5% (Lonza 59501) denaturing polyacrylamide gels. The resolved 
proteins were then transferred to nitrocellulose membranes (Invitrogen, IB3010-01) 
using the iBlot transfer system (Invitrogen, IB1001).  Protein transfer was visually 
confirmed using Ponceau S staining (Sigma, P7170). Membranes were blocked with 
skimmed-milk powder (Bio-Rad, 170-6404) in PBS-tween (Sigma, P1379) (0.1%) or 1x 
NET buffer (0.5 M NaCl, 0.05 M EDTA, 0.1 M Tris pH 7.8), and incubated overnight 
at 4 oC with primary antibodies. The blotting conditions for each antibody used in this 
study are described in Table 2 - 4. Proteins were visualised using horse-radish 
peroxidise conjugated (HRP) anti-rabbit or anti-mouse as appropriate and ECL prime 
reagent (GE Healthcare, RPN2232) or Luminol (Fannin Ltd. SC-2048). Membranes 
were washed with 0.1 % PBS-tween or 1x NET buffer 3 times for 10 minutes each, both 
prior to and following incubation with secondary antibodies. Densitometry was 
performed using Epson Perfection Scanner (version 3.03A) on biological triplicate 
immunoblots with ImageJ software (available at 
http://imagej.nih.gov/ij/download.html). Results were normalised using α-tubulin.  
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Table 2 - 4 Details of antibodies and blotting conditions, for all antibodies used in the study; PBS-T = PBS-Tween, CST = Cell Signalling 
Technology.   
Antibody Phospho-site Dilution Blotting conditions Secondary + ve control company Cat no. 
anti-rabbit secondary  1:1000 2.5 % milk / 0.1 % PBS-
T/1x NET 
  Sigma A6154 
anti-mouse secondary  1:1000 2.5 % milk /  0.1 % PBS-
T/1x NET 
  Sigma A6782 
α-tubulin  1:1000 2.5 % milk / 0.1 % PBS-
T/1x NET 
Mouse  Sigma T6199 
anti-c-Met  1:1000 2.5 % milk / 0.1 % PBS-
T/1x NET 
Mouse A549 CST #25H2 
anti-phospho-c-Met Y1234/1235 1:1000 2.5 % milk / 0.1 % PBS-
T/1x NET 
Rabbit A549 +         
50 ng/mL HGF 
CST #3077s 
anti-c-Src  1:1000 2.5 % milk / 0.1 % PBS-
T/1x NET 
Rabbit MCF-7 CST #2108s 
Anti-phospho-Src Y418 1:500 1x NET Rabbit MCF-7 Merck Millipore 05-677 
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2.4 Proliferation assays 
2.4.1 Acid phosphatase 
Cells were seeded into 96-well plates at a density of 3000-5000 cells/well (Table 2 - 5). After 
24 hours, cells were treated with the appropriate media supplemented with 10 % FCS with or 
without serial dilutions of Compound A, AMG102, PRS110, neratinib, saracatinib, dasatinib 
or BMS777607. Proliferation was measured after five days using the acid phosphatase assay. 
For the acid phosphatase assay, media was removed and each well rinsed with PBS, 100 µL 
of acid phosphatase substrate (10 mM p-nitrophenol phosphate (PNP) (Sigma, 1040) in 0.1 M 
sodium acetate (Sigma, S2899), 0.1% triton X-100 (BDH, 9002-93-1), pH 5.5) was then 
added to each well followed by incubation at 37oC for 60 minutes, at which time 50 µL of     
1 M NaOH (Sigma, S5881) was added to each well and the absorbance was read at 405 nm 
with 620 nm as a reference, on Biotek plate reader using KC4 software. Proliferation was 
calculated relative to vehicle/untreated controls. Each assay was carried out in biological 
triplicate.  
 
Table 2 - 5 The number of cells seeded per well in 96 well plate for proliferation assays 
for each TNBC cell line. 
Cell Line Cells seeded/well 
BT20 3000 
HCC1937 3000 
HCC1143 3000 
MDA-MB-468 3000 
MDA-MB-231 3000 
CAL-120 5000 
CAL-85-1 3000 
HDQ-P1 5000 
BT549 3000 
 
2.4.2 Combination assays 
Cells were seeded into 96 well plates as described above in Table 2 - 5. Cells were then 
treated with or without appropriate concentrations of single agents or in combination 
described in Table 2 – 6. Proliferation was measured after five days as described in 2.4.1.  
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Table 2 - 6 Concentrations of drugs used in combination assays. 
 HCC1937 BT20 HCC1143 MDA-
MB-468 
MDA-
MB-231 
CAL-120 CAL-85-1 HDQ-P1 BT549 
Compound A 2 µM 2 µM 2 µM 2 µM 2 µM 2 µM 2 µM 2 µM 2 µM 
AMG102 10 µg/mL 10 µg/mL 10 µg/mL 10 µg/mL 10 µg/mL 10 µg/mL 10 µg/mL 10 µg/mL 10 µg/mL 
PRS110 1 µg/mL 1 µg/mL 1 µg/mL 1 µg/mL 1 µg/mL 1 µg/mL 1 µg/mL 1 µg/mL 1 µg/mL 
Neratinib 0.15 µM 0.17 µM 1.18 µM 0.05 µM 0.4 µM 1.6 µM 4 nM 4 nM 1 µM 
Saracatinib 0.7 µM 1.56 µM 1.21 µM 1.34 µM 0.4 µM 1 µM 0.7 µM 0.3 µM 2 µM 
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2.4.3 HGF/EGF stimulation of proliferation  
Cells were seeded at a density of 2.5 x 104 cells/well in 24-well plates. The cells were 
allowed to attach overnight and then washed 3 times with PBS. Cells were then grown 
for a further 24 hours in serum-free media after which they were treated with either 50 
ng/mL HGF (294-HG-025), 10 nM EGF (236-EG-01M) or combined HGF and EGF 
treatment. Following either 48 or 72 hours of treatment, the media was removed from 
the cells and 100 µL of trypsin was added to each well. Once the cells had detached, 
100 µL of media containing 10 % FCS was added to each well. In a round-bottom 96-
well plate, 100 µL of cell suspension was added to 100 µL of Guava ViaCount reagent 
(Millipore, 4000-041). Cell counts were performed using the Guava EasyCyte ((version 
5.3), (Millipore)) in triplicate and proliferation was calculated relative to serum starved 
controls.  
2.5 Invasion assays 
Invasion assays were performed using the method previously described [245]. 24-well 
invasion inserts (BD Biosciences 734-0036) were coated with 100 µL Matrigel™ (BD 
Biosciences 354234, diluted to 1 µg/µL in serum free DMEM) and left overnight at 4 
°C. The following day, the plates were incubated at 37 °C for one hour. Excess 
Matrigel™ was removed. 5 x 104- 1 x 106 cells in 100 µL medium containing 5 % FCS 
were added to Matrigel™-coated inserts (Table 2 - 7). 500 µL of medium containing 
10% FCS was added to each well beneath the insert. Cells were incubated for 6 hours at 
37 °C before treatment, to allow cells to attach. Following treatment (100 µL 10 % 
foetal calf serum (FCS)-medium or  drug containing (1 µM CpdA, 10 µg/mL PRS110, 1 
µM neratinib  or 1 µM  saracatinib, 100 nM dasatinib), cells were further incubated for 
18 hours. Cells were stained with 0.1 % crystal violet and the number of invading cells 
was estimated by counting 14 fields of view at 200 X magnification. The percentage 
invasion was calculated as follows; average number of cells counted/average number of 
cells in control well x 100. Each assay was performed in biological triplicate. 
 
65 
 
Table 2 - 7 Cells seeded per 100 µL in matrigel coated transwell inserts. 
Cell Line Cells per 100 µL 
BT20 1 x 105 
HCC1937 1 x 105 
HCC1143 1 x 105 
MDA-MB-468 1 x 105 
MDA-MB-231 5 x 104 
CAL-120 1 x 105 
CAL-85-1 1 x 105 
HDQ-P1 1 x 105 
BT549 5 x 104 
 
2.6 Migration assays 
Migration assays were carried out as previously described [246]. Cells were seeded into 
12 well plates and allowed to reach 100% confluence.  At this point media was removed 
and cells were incubated with PBS for 15 mins. PBS was removed and plates were 
marked with a horizontal line through the well on the underside of the plate to create a 
reference point. A scratch was created using a P200 pipette tip perpendicular to the 
horizontal line on the plate. Cells were washed once with PBS.  SFM was added 
with/without drug (1 µM CpdA, 10 µg/mL PRS110, 1 µM neratinib  or 1 µM  
saracatinib) to cells and incubated for up to 48 hrs or until closure of wound occurred. 
Wound closure was examined photographically at 0, 24 and 48 hrs with duplicate 
photos of each well (above and below reference point). The images were analysed using 
Tscratch software (freely available at 
http://www.cselab.ethz.ch/index.php?&option=com_content&view=article&id=363). 
The percentage wound closure at 24/48 hrs was calculated relative to wound area at T0. 
Each assay was performed in biological triplicate. 
2.7 Clonogenic assays 
Cells were seeded at 1000-3000 cells/well in 6 well plate in duplicate and left to attach 
overnight. Media was removed and cells were treated with appropriate concentration of 
drug (Table 2 - 8). Cells were left to form colonies for 10-21 days.  Media was replaced 
on all cells every 7 days following initial treatment. After treatment wells were washed 
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gently with PBS and fixed in cold Methacare (75% v/v methanol, 25% v/v acetic acid) 
for 30 minutes. Methacare fixative was removed and fixed colonies were washed once 
with PBS. The colonies were then stained using 1% Crystal Violet for 30 minutes and 
analysed for colony area and intensity using colony area plug-in in ImageJ software 
(available at http://imagej.nih.gov/ij/download.html). Each assay was performed in 
biological triplicate. 
 
Table 2 - 8 Conditions of cell lines and drug concentrations used in clonogenic 
assays. 
Cell line Cells/well Incubation 
period 
(days) 
Cpd 
A 
(µM) 
PRS110 
(µg/mL) 
neratinib 
(µM) 
Saracatinib 
(µM) 
HCC1937 3000 14 1 1 0.03 0.25 
HCC1143 3000 14 1 1 0.2 0.03 
MDA-
MB-468 
1000 14 1 1 0.02 0.75 
MDA-
MB-231 
500 10 1 1 1.5 0.2 
HDQ-P1 3000 21 1 1 0.001 0.2 
 
2.8 3D growth assays 
96 well plates were coated with 50 µL polyhema (Sigma Aldrich S3932 5 mg/mL in 
96% ethanol) and baked at 50ºC for two days. Plates are stored at room temperature 
(RT) until required, for up to 6 months. Cells were seeded at a density of 1500-3000 
cells/well in 10% FCS with 2-4% Matrigel™ (Table 2 - 9), and incubated overnight at 
37ºC. 30 µL of 10% FCS with/without serial dilutions of CpdA and PRS110 starting at 
10 µM and 10 µg/mL respectively, were added to the wells and incubated at 37 ºC for a 
further 5-7 days. 12 µL of PrestoBlue® Cell Viability reagent (10% of final volume) 
was added to the wells and incubated at 37 ºC for 4-8hrs and fluorescently measured at 
535/590 excitation/emission wavelength on Biotek plate reader using KC4 software. A 
blank consisting of media and 2-4% Matrigel™ as appropriate was used to eliminate 
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background. Percentage viability was calculated relative to untreated control. Each 
assay was performed in biological triplicate.  
Table 2 - 9 Cell line specific conditions used for 3D growth assays 
Cell line Cells/well Matrigel 
concentration 
Days 
incubated 
Presto Blue 
(hrs) 
BT20 1500 2% 7 4 
HCC1937 3000 4%` 5 4 
HCC1143 3000 4% 5 4 
MDA-MB-468 3000 2% 5 4 
MDA-MB-231 3000 4% 5 2 
HDQ-P1 3000 4% 5 8 
BT549 1500 2% 5 6 
 
2.9 Conditioned media 
2.9.1 Collection of conditioned media 
Cell lines were cultured to 70-80% confluence in 90 mm tissue culture petri dishes. 
Cells were washed with PBS three times. Serum free (SFM) media was then added to 
the dishes and cells were cultured for a further 24 or 48 hours. Media was centrifuged at 
900rpm for 5mins to remove debri, collected and stored at -80˚C.  
2.9.2 HGF enzyme linked immunosorbent assay (ELISA)  
Conditioned media was analysed for the presence of HGF using the Human HGF 
Quantikine ELISA kit (DHG00, R&D systems Inc.) as per manufacturer’s instructions. 
The procedure is described briefly below in Figure 2- 1.  
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Figure 2- 1 Schematic diagram of the human HGF Quantikine ELISA procedure. 
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2.9.3 Soluble Met (sMet) ELISA 
Conditioned media was analysed for the presence of sMet using the c-Met (soluble) 
Human Elisa Kit (Invitrogen KHO2031) as per manufacturer's instructions described in 
Figure 2- 2.   
 
Figure 2- 2 Schematic diagram of the c-Met (soluble) human ELISA procedure.  
 
2.10  Magpix® Magnetic Bead assays 
Magnetic bead assays were performed on the Luminex® MagPix ® System (Merck 
Millipore (80-073) using Milliplex Map Phospho Mitogenesis RTK Magnetic Bead 7-
Plex Kit (Merck Millipore 48-672 Mag) and Milliplex Map phospho Human Src Family 
Kinase Magnetic Bead 8-Plex kit (Merck Millipore 48-650Mag). Samples were 
prepared as in 2.2 . Protein (1- 10 µg) was diluted in appropriate volume of assay buffer 
(final volume 25 µL/well) and the assay was performed as per manufacturer's 
instructions as described below in Figure 2- 3.  
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Figure 2- 3  Schematic diagram of the magnetic bead assays. 
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2.11 Immunohistochemistry (IHC)  
Automated immunohistochemistry was performed using the DAKO Autostainer system. 
Antibodies against c-Met, EPHA5 and FGFR3 were used (Santa Cruz SC-161, SC-927, 
SC-123). The c-Met antibody was optimised using renal papillary carcinoma and triple 
negative breast carcinoma slides. EPHA5 and FGFR3 antibodies were optimised using 
triple negative breast carcinoma slides. The breast carcinoma slides are used as positive 
controls for IHC experiments. These slides were also used as negative controls as 
follows; a blocking peptide was added to antibody in a 10:1 (c-Met antibody) or 4:1 
(FGFR3, EPHA5 antibodies) blocking peptide: antibody ratio a minimum of 30 minutes 
prior to staining.  
Antigen retrieval and dewaxing was performed using automated Dako PT Link in 
Target Retrieval Solution pH6 (Dako S1699) for c-Met and pH9 for EPHA5 and 
FGFR3. Slides was placed in Dako PT link at 65 ˚C and heated to 97 ˚C and maintained 
at 97 ˚C for 20 minutes. The slides were cooled to 65 ˚C and removed. After de-
paraffinisation, the slides were placed in the DAKO Autostainer, which performed the 
programmed application of reagents in order as listed in Table 2 - 10 Antibody 
concentrations are described in (Table 2 - 11). Washes were performed, with DAKO 
wash buffer, before and after the application of the each reagent, except in the case of 
the Real HP Block, where a blow step was performed. Slides were subsequently 
dehydrated in grading alcohols 70 %, 90 %, and 100 %, cleared in xylenes (2 x 3 
minutes each) and mounted in Di(nbutyl) Phthalate in Xylene (DPX) (Sigma).   
Tissue microarray (TMA) obtained from St. Vincent’s University Hospital (SVUH) 
slides consisting of four cores from each case with a total of 89 TNBC cases were 
scored by two independent observers and was evaluated as follows [193]. Intensity was 
graded 0 (no staining), 1+ (weak staining) 2+ (moderate staining), 3+ (strong staining), 
% cells staining were graded as 0 (no staining) 1 (0-25% staining), 2 (26-50% staining), 
3 (51-75%) and 4 (> 75%), and cores were marked positive/negative for membrane or 
nuclear staining.  
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Table 2 - 10 Programmed steps for immunostaining procedure for IHC staining 
using DAKO Autostainer system. 
Reagent Time (mins) 
Real HP Block (DAKO) 10 
Antibody 30 
Real EnVision (DAKO) 30 
Real DAB (DAKO) 5 
Haematoxylin 5 
 
Table 2 - 11 Antibody concentrations used in IHC of TMAs. 
Antibody Concentration 
c-Met 1/200 
EPHA5 1/100 
FGFR3 1/100 
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2.12 Quantitative real time-polymerase chain reaction (qRT-PCR) 
2.12.1 RNA extraction 
RNA was extracted using the mirVana™ miRNA Isolation Kit (Ambion, AM1560) and 
carried out according to manufacturer's instructions. Briefly, cells were grown to 70-
80% confluency, trypsinised and centrifuged at 160 x g (900 rpm) for 3 minutes. Cell 
pellets were then washed with PBS centrifuged as before, and placed on ice. Cells were 
lysed in 300 µL of lysis buffer, vortexed and 30 µL of RNA homogenate was added to 
the lysate and incubated on ice for 10 mins. A volume of acid:phenol chloroform equal 
to the volume of lysis buffer was then added, vortexed for 30-60 secs and centrifuged 
for 5 mins at room temperature. The top aqueous layer was then removed (volume 
noted) and 1.25 volumes of room temperature ethanol (100%) was added, the mix was 
added to a filter cartridge, centrifuged for 15 sec at 12400 x g and the flow through was 
discarded. Wash solution 1 was added (700 µL) and centrifuged as before followed by 
two additions of wash solution 2/3 (500 µL) and centrifuged as before with flow 
through discarded each time. The filter cartridge was centrifuged for 1 min to remove 
residual ethanol and placed in a fresh collection tube. Pre-heated (95°C) nuclease free 
water (100 µL) was applied to the filter cartridge and incubated for 1 min at room 
temperature. The filter cartridge was centrifuged at 12400 x g for 20-30 sec to elute 
RNA. RNA extracts were stored at -80°C. The concentration of total RNA in extracted 
samples was determined using the Nano-Drop Spectrophotometer (Thermo Scientific). 
2.12.2  Reverse transcription (RT) 
Stock solutions of 2 µg in 10 µL were made by diluting RNA-extracts with RNase free 
water (Ambion, 9932). Using a high capacity cDNA Reverse Transcription Kit (Applied 
Biosystems, 4368814), a 2X master mix solution was prepared as per Table 2 - 12. For 
each reaction 10 µL of RNA sample and 10 µL of master mix were combined in PCR 
tubes, briefly centrifuged to spin down contents and loaded into the thermo-cycler (G-
STORM) and the reverse transcription run as per Table 2 - 13. The samples were then 
stored at 4 °C until required. A non-target control (NTC) which was prepared without 
the RNA template, and a minus reverse transcriptase control (-RTC) which was 
prepared without the reverse transcriptase enzyme. 
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Table 2 - 12 Components of master mix for RT reaction. 
Component Volume / Reaction (µL) 
10X RT buffer 2.0 
25X dNTP Mix (100 mM) 0.8 
MultiScribe TM Reverse transcriptase 1.0 
RNase-free water 4.2 
10X  RT random primers 2.0 
Total per reaction 10.0 
 
Table 2 - 13 Thermo-cycler steps, indicating the temperature and duration, for 
RT-PCR experiment. 
Step Temperature (°C) Time (minutes) 
1 25 10 
2 37 120 
3 85 5 
4 4 Hold 
2.12.3 Quantitative real-time polymerase chain reaction (qRT-PCR) 
Using cDNA obtained from the RT step, qRT-PCR for the following assays was 
performed; HGF (Applied Biosystems Hs00300159-m1), EPHA5 (Applied Biosystems 
Hs00300724m1), FGFR3 (Applied Biosystems Hs00179829-m1) and ROS1 (Applied 
Biosystems Hs001772288-m1) with GADPH (Applied Biosystems, HS02758991_g1) 
as an endogenous control. Briefly, the cDNA samples were diluted in 30 µL of RNase-
free water (Ambion, 9932) and 1 µL of this stock was added to a 96-well PCR reaction 
plate (Applied Biosystems, 4346906), and combined with 19 µL of assay master mix. 
The assay master mix consisted of 10 µL of Taqman Universal PCR Master Mix 
(Applied Biosystems, 4364340), 8 µL of RNase-free water (Ambion, 9932) and 1 µL of 
the specific assay (primer set), per reaction. The PCR plate was then sealed using 
Optical Adhesive film strips (Applied Biosystems, 4360954). The qrt-PCR reaction was 
performed on the ABI7900HT fast system using Sequence Detection System (SDS) 
automated controller software (version 2.2) (Applied Biosystems). The procedure for 
qRT-PCR was 10 minutes at 95 °C followed by 40 cycles of 15 seconds at 95 °C, and 
then 1 minute at 60 °C. Once complete the cycle threshold (Ct) values were exported to 
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Excel and relative RNA expression levels calculated using the DeltaCt method (∆Ct) 
where ∆Ct was the Ct value of the sample minus the Ct value of the endogenous 
control. The ∆∆Ct values were calculated as the ∆Ct of the test sample minus the ∆Ct of 
the calibration sample. The relative quantity ratios (RQ) of each sample were calculated 
using the equation: 
RQ = 2(-∆∆Ct) = 2∆Cttest-∆Ctcontrol = 2(Ct,X-Ct,R)control-(Ct,X-Ct,R) test[247] 
Where, Ct,X is the cycle threshold of the gene of interest and Ct,R is the cycle threshold 
of the endogenous reference gene. 
2.13 RTK survival analysis 
BreastMark is web based searchable database (available at 
http://glados.ucd.ie/BreastMark/) to allow determination of the association between 
individual genes and disease progression and survival for breast cancer. The underlying 
algorithm combines gene expression data from multiple microarray experiments and 
detailed clinical data to correlate outcome with gene expression levels. This algorithm 
integrates gene expression and survival data from 21 datasets on 10 different microarray 
platforms corresponding to 20,017 gene sequences across 3,519 samples [239]. 
BreastMark was designed by Dr. Stephen Madden (DCU) who carried out the survival 
analysis detailed in this thesis. 
Kaplan Meier curves were generated for each receptor tyrosine kinase (RTK) and 
manually examined. RTKs were selected based on a statistically significant (p <0.05) 
association between disease free or overall survival and gene expression. Groups were 
stratified using the median and 25th and 75th. Each level of stratification was examined. 
For RTKs to be considered for further evaluation we applied a cut off of reaching 
statistical significance in 2/3 breast cancer classifiers used, (PAM50, ssp 2003, ssp 
2006).  
2.14 Ephrin-A4 and FGF9 treatments 
MDA-MB-231, T47D and BT20 cell lines were seeded at a density of 2.5 x104 
cells/well in a 6 well plate and left to attach overnight. After 24 hours media was 
removed and cells washed 3 times with serum free medium. After the final wash, 2 mL 
of SFM was added to each well and incubated overnight. The following day SFM media 
was removed and 10% FCS media or 2% FCS media with/without Ephrin-A4 (1 
µg/mL) or FGF9 (20 ng/mL) with heparan sulphate (2 µg/mL) was added.  The cell 
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lines were allowed proliferate for a further 72 hours and proliferation was measured 
using the acid phosphatase assay described in section 2.4.1.   
2.15 Statistical analysis 
P values were calculated (unless otherwise stated) using the student’s t-test (two tailed 
with unequal variance). Analysis was performed on biological triplicates. P<0.05 was 
considered significant.  
2.15.1 IC50 determination 
IC50 were calculated using dose effect analyser Calcusyn (Version 1.1) and are 
representative of three independent biological experiments.  
2.15.2 Calculation of combination index (CI) values 
For fixed-ratio assays, combination indices (CI) at the ED50 (effective dose of 
combination that inhibits 50% of growth) were determined using the Chou and Talalay 
equation, on CalcuSyn software (Biosoft). The combination index equation is based on 
the multiple drug-effect equation of Chou-Talalay derived from enzyme kinetic models. 
The equation determines only the additive effect rather than synergism or antagonism. 
Synergism is defined as a more than expected additive effect, and antagonism as a less 
than expected additive effect. Determination of synergy/antagonism used in our work 
was based on the recommended descriptions as shown in Table 2 - 14. As recommended 
by Chou et al., the prerequisites for CI calculations included a dose-effect curve, at least 
three data points for each single drug, but any number of points for a combination, and a 
constant combination ratio design [248].  
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Table 2 - 14 Range of combinations index values which determine synergism or 
antagonism in drug combination studies analysed with the Combination Index 
Method 
Range of CI Symbol Description 
<0.10 +++++ Very strong synergism 
0.10-0.30 ++++ Strong synergism 
0.31-0.70 +++ Synergism 
0.71- 0.85 ++ Moderate synergism 
0.86-0.9 + Slight synergism 
0.91- 1.10 ± Nearly additive 
1.11-1.20 _ Slight antagonism 
1.21-1.45 _ _ Moderate antagonism 
1.45-3.30 _ _ _ Antagonism 
3.30- 10.00 _ _ _ _ Strong antagonism 
>10.00 _ _ _ _ _ Very strong antagonism 
 
2.15.3 Statistical calculations for immunohistochemistry 
Fisher’s exact test was used to calculate p values for 2x2 table contingency. Chi-square 
test was used to calculate p values for non-parametric data greater than 2x2. The 
Bonferroni test was used to adjust p values for multiple testing. The Bonferroni test was 
determined as the product of the p value and the number of tests performed on the data 
set.  
2.15.4 Correlation co-efficient calculation 
Correlation co-efficients were calculated using Spearman Rank test with two-tailed P 
value.  
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Chapter 3 
c-Met/HGF expression in TNBC 
79 
 
 
3.1 Introduction 
c-Met and phosphorylated c-Met have been found at higher levels in basal compared to 
luminal cell cancer cell lines [173]. Furthermore, in both breast cancer cell lines and 
breast cancer specimens, overexpression of c-Met was associated with the basal subtype 
[170, 171, 249]. 
 Expression of c-Met corresponds significantly with the development of basal mammary 
tumours in mice and high levels of c-Met and p-Met are expressed across all breast 
cancer subtypes [82, 148, 152]. Two studies have shown that expression of c-Met in 
mice induced basal-like breast carcinomas [148, 159]. c-Met overexpression has been 
associated decreased survival and poor outcomes [250]. 
HGF is the only known ligand for c-Met and is present mainly in stromal cells such as 
adipocytes, endothelial cells and fibroblasts [185]. The most likely mechanism of c-Met 
activation in breast cancer is via HGF acting in a paracrine manner to activate c-Met.  
Increased levels of HGF in primary breast tumours have been shown to be a strong 
predictor of a shortened recurrence-free interval and decreased survival [103, 140, 169].  
While specific molecular targets are available for HER2 and ER positive subtypes, no 
target has as yet been proven for the TNBC/basal-like subtype. We investigated the 
potential role of the c-Met/HGF axis as a target by examining expression in both TNBC 
cell lines and in tumour samples. 
3.2 c-Met expression in TNBC 
3.2.1 c-Met, phosphorylated Met and soluble Met in TNBC cell lines 
We assessed a panel of triple negative breast cancer cell lines for the expression and 
phosphorylation of c-Met by western blotting (Figure 3 -  1). Total c-Met was detected 
in all nine of the cell lines tested. CAL-85-1 and MDA-MB-231 showed the highest 
levels of total c-Met and c-Met expression was significantly associated with TNBC cell 
lines. p-Met (Y1234/Y1235) was detectable in 4/9 cell lines (BT20, HCC1937, 
HCC1143 and CAL-85-1). Three of the cell lines positive for p-Met are the Basal A 
subtype (BT20, HCC1937, HCC1143), however the CAL-85-1 cell line basal subtype is 
unknown. This suggests an association between Basal A subtype and activation of c-
Met however this does not achieve statistical significance (p=0.4). According to the 
Lehman subtypes [31], of the four showing activation of p-Met, 2 are BL-1 subtype 
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(HCC1937, HCC1143), the CAL-85-1 are BL-2 subtype and the BT20 are unclassified. 
This again suggests an association with the BL subtype. The CAL-85-1 cell line has the 
highest level of p-Met however, when related to total Met levels the HCC1937 have the 
highest level of phosphorylation of c-Met. In a panel of non-TNBC cell lines consisting 
of both ER positive and HER2 positive cell lines, we see low levels of expression of c-
Met in only 3/7 cell lines with no detectable levels of p-Met (Figure 3 -  1). Using a 
magnetic bead assay for seven phosphorylated RTKs we examined the levels of 
phosphorylation in the panel of TNBC cell lines. The phosphorylated RTKs included 
are p-Met (pan-Tyr), p-EGFR (pan-Tyr), p-HER2 (pan-Tyr), p-IGF1R (pan-Tyr), p-IR 
(pan-Tyr), p-HER3 (pan-Tyr) and p-HER4 (pan Tyr). The levels of p-Met are similar 
across the panel of cell lines, in contrast to the western blot of Y1234/Y1235 (Figure 3 - 
2 ). Levels of p-EGFR varied significantly across the panel of cell with MDA-MB-468 
and HDQ-P1 showing the highest levels of p-EGFR (Figure 3 - 2). This assay was also 
used to assess phosphorylation in powdered tumour samples discussed in Section 3.2.2.  
Soluble Met (sMet) is a soluble cleaved form of the extracellular domain of mature c-
Met. It is easily measurable in serum and plasma and cell culture supernatant. We 
measured sMet in conditioned media from the panel of TNBC cell lines. The CAL-85-1 
cell line showed the highest level of sMet (77.1 ± 3.5 ng/mL). The BT549 showed the 
lowest level of sMet with 6.9 ± 2.9 ng/mL sMet. No significant correlation between c-
Met levels, phosphorylation of c-Met and sMet levels was observed (p= 0.6 and 0.5 
respectively) Figure 3 -  3. 
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Figure 3 -  1 Western Blot analysis of c-Met and p-Met (Y1234/Y1235) in a panel of a) TNBC cell lines and b) TNBC cell lines. α-tubulin 
was used as a loading control c) Densitometric analysis of western blots of total c-Met normalised to α-tubulin. d) p-Met levels initially 
normalised to α-tubulin and then normalised to values described in c). Error bars represent the standard deviation of triplicate 
independent experiments. 
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Figure 3 - 2 Levels of phosphorylated RTKs in 10 µg protein as determined by 
Magpix® magnetic bead assays. Error bars are standard error of biological 
duplicates.  
83 
 
 
0
10
20
30
40
50
60
70
80
90
so
lu
b
le
 c
-M
e
t 
(n
g
/
m
l)
a)
b)
 
Figure 3 -  3 a) Levels of sMet measured by ELISA in panel of TNBC cell lines. b) 
XY scatter plot of sMet levels vs. c-Met (LHS) and p-Met (RHS) as calculated in 
Figure 3 - 1. Error bars are indicative of independent biological triplicates. 
3.2.2 c-Met and phosphorylated Met expression in TNBC tumour samples 
We examined 89 cases of TNBC and 100 non-TNBC for expression of c-Met. 83 and 
93 cases respectively were suitable for evaluation. However 20 and 26 cases of those 
were missing at least one core per case due to lack of tumour tissue/lifting of cores. 
Staining for c-Met was graded according to % positivity (0-10%, 11-25%, 26%-50%, 
51-75% and >75%) and intensity (neg, 1+ weak, 2+ moderate and 3+ strong). 
Representative images are shown in Figure 3 - 1. The patient characteristics are 
described in Table 3 - 1. The patients were predominantly older (>50) with ductal 
histology. The TNBC were mainly advanced grade (grade 3 (85% TNBC vs 25% non-
TNBC) as expected. Size, lymph node and LVI status showed no significant differences 
between the TNBC and non-TNBC (Table 3 - 1) [193]. Median follow up for the 
patients in this study was 39 months.  
The staining observed for c-Met was granular cytoplasmic staining. Weak nuclear 
staining in <10% of cells was observed in a single case in both the TNBC and non-
TNBC TMAs. No specific membrane staining was present. 44/83 (53.0%) and 25/93 
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(26.8%) showed positive staining for c-Met in TNBC and non-TNBC cases 
respectively. There was a significant association between c-Met expression and TNBC 
subtype (p=0.004) (Table 3 - 2). No significant association was seen between any 
patient prognostic indicators (age, grade, histological subtype, size, lymph node status 
(LN), lymphovascular invasion (LVI)) and c-Met expression in this cohort of patients in 
the TNBC or non TNBC tumours when stained for c-Met (Table 3 – 3, Table 3 – 4, 
Table 3 -5, Table 3 - 6). For survival studies c-Met was dichotomised into high/low 
groups using 50% (median) positive staining as a cut-off point. No significant 
association with recurrence or survival was noted between the two groups (p= 0.95 and 
p= 0.52, HR = 1.03, 1.43 respectively) (Figure 3 - 2).  
EGFR, c-Met and c-Src crosstalk are well documented in the literature [181, 185, 195, 
251, 252]. Previous work by Dr. Siun Walsh (UCD) involved the staining of the TNBC 
tumours for EGFR, total c-Src and phospho-Src (p-Src, Y418). Using these results we 
examined whether co-positivity of c-Met and these proteins is significantly associated 
with patient prognostic indicators and recurrence/survival in this cohort of patients.  
Only six of the TNBC tumours showed EGFR positivity, 3 of these tumours showed 
dual positive staining for EGFR and c-Met. All three tumours were in patients over 50 
years of age with ductal carcinomas and negative for LVI invasion. Two of the patients 
had tumours >2cm with lymph node invasion (Table 3 - 7). 
 Using a cut-off of 50%, 15/18 (83.3%) of c-Met positive TNBC cases showed specific 
staining for both c-Met and total Src. No significant association was seen with any of 
the patient prognostic indicators (Table 3 - 8). No significant differences in recurrence 
or survival were observed for c-Met positivity combined with c-Src (p= 0.84, 0.25 HR = 
0.89 and 0.55 respectively) (Figure 3 - 3).  
Of the 18 tumours positive for c-Src and c-Met, 7 (38.8 %) showed positive staining for 
phospho Src (Y418) using a cut-off of > 50%. One other patient showed positive 
staining for p-Src without positive total Src staining. No significant association between 
co-positivity and prognostic indicators was seen (Table 3 - 9). Kaplan Meier curves of 
tumours with high p-Src and high c-Met expression showed no significant differences 
between the groups in either recurrence or survival (p= 0.74, 0.59 HR = 0.79 and 0.64 
respectively) (Figure 3 - 4). 
Finally we compared the percentage of KI-67 positively stained cells with the 
percentage positivity of c-Met in the TNBC cohort of patients. Scores were grouped 
into five groups (1-10%,11-25%, 26-50%, 50-75% and > 75%) and given an arbitrary 
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value of 1-5 (where 1= 1-10% and 5= >75%) based on the % positive cells for c-Met or 
KI-67. Scores were given a 0 value for no specific staining. Using the Chi Square test c-
Met and KI-67 showed a weak association trending toward statistical significance with 
p = 0.051 indicating that higher c-Met percentage positivity is associated with a higher 
KI-67 percentage positivity. 
We assessed the phosphorylation of 9 tumours using powdered tumour lysates which 
included three paired adjacent normal tissues. In 8/9 tumours we detected 
phosphorylation of c-Met and in 2/3 paired samples, p-Met was higher in the normal 
tissue than the tumour tissue. c-Met seems to have the lowest levels of phosphorylation 
of all the RTKs with the insulin receptor demonstrating higher levels than the others 
(Figure 3 - 5). 
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Figure 3 - 1 Representative Images of c-Met IHC staining. c-Met positive control 
(TNBC) (LHS) , c-Met negative control (Ab + blocking peptide) (RHS) 
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Table 3 - 1 Patient and tumour characteristics in TNBC and non-TNBC TMAs. 
  Triple negative Non-triple negative 
 n % N % 
Patient age at diagnosis 
< 50  35 39.3 23 23 
> 50 
 
 54 60.7 77 77 
Grade 
Grade 1/2  12 13.5 61 61 
Grade 3  76 85.4 25 25 
Unknown 
 
 0 0.0 14 14 
Histological subtype 
Ductal  83 93.3 70 69 
Lobular  5 5.6 26 24 
Other   0 0.0 1 1 
Unknown 
 
 1 1.1 3 3 
Size 
<2cm  48 53.9 51 51 
>2cm  39 43.8 49 49 
Unknown 
 
 2 2.2 0 0 
LN Status 
Negative  50 56.2 56 56 
Positive  37 41.6 40 40 
Unknown 
 
 2 2.2 3 3 
LVI 
Negative  44 49.4 37 37 
Positive  44 49.4 60 60 
Unknown  1 1.1 3 3 
 
Table 3 - 2 c-Met positivity in TNBC and non-TNBC tumour samples. P value was 
calculated using Fishers Exact Test and adjusted using Bonferroni Correction. 
 Pos Neg P value P adj 
TNBC 44 39   
Non-TNBC 25 68 0.0006 0.0042 
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Table 3 - 3 Cytoplasmic c-Met positivity in TNBC TMA and patient prognostic 
indicators. P values were calculated using Chi square test. 
 Neg 0-10% 10-25% 26-50% 51-75% >75% P 
Patient age at diagnosis 
< 50 15 2 4 2 6 1  
> 50 24 2 6 8 11 2 0.8973 
 
Grade 
Grade1/2 3 1 1 0 1 1  
Grade 3 37 3 11 9 14 2 0.4452 
Unknown 
 
0 0 0 1 0 0  
Histological subtype 
Ductal 38 4 11 10 12 3  
Lobular 1 0 0 0 3 0 0.0985 
Other  
 
0 0 1 0 0 0  
Size 
<2cm 20 1 6 3 9 2  
>2cm 19 3 5 7 6 1 0.6008 
Unknown 
 
0 0 0 1 0 0  
LN Status 
Negative 16 1 7 4 9 2  
Positive 23 3 4 6 6 1 0.5178 
Unknown 
 
0 0 0 1 0 0  
LVI 
Negative 17 1 6 6 11 3  
Positive 22 3 5 4 4 0 0.2011 
Unknown 0 0 0 1 0 0  
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Table 3 - 4 Cytoplasmic c-Met intensity in TNBC TMA and patient prognostic 
indicators. P values were calculated using Chi square test. 
 Neg 1+ 2+ 3+ P value 
Patient age at diagnosis 
< 50 15 12 4 0  
> 50 
 
24 14 13 1 0.4767 
Grade 
Grade ½ 3 3 1 0 0.875 
Grade 3 36 22 16 1  
Unknown 
 
0 1 0 0  
Histological subtype 
Ductal 38 24 15 1 0.5163 
Lobular 1 1 2 0  
Other  
 
0 1 0 0  
Size 
<2cm 20 13 6 0 0.5036 
>2cm 19 12 11 1  
Unknown 
 
0 1 0 0  
LN Status 
Negative 16 14 7 0 0.4959 
Positive 23 11 10 1  
Unknown 
 
0 1 0 0  
LVI 
Negative 17 17 10 0 0.2352 
Positive 22 8 7 1  
Unknown 0 1 0 0  
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Table 3 - 5 Cytoplasmic c-Met positivity in non-TNBC TMA and patient 
prognostic indicators. P values were calculated using Chi square test.  
 Neg 0-10% 10-25% >50% P value 
Patient age at diagnosis 
< 50 19 2 0 0  
> 50 49 12 9 2 0.181 
 
Grade      
Grade 1/2 40 8 7 2  
Grade 3 17 3 2 0 0.8415 
Unknown 11 3 0 0  
 
Histological subtype 
Ductal 48 10 7 1  
Lobular 17 3 2 0 0.9314 
Other  1 0 0 1  
Unknown 2 1 0 0  
 
Size 
<2cm 31 6 5 2  
>2cm 37 8 4  0.4462 
 
LN Status 
Negative 37 7 5 2  
Positive 29 6 4 0 0.6626 
Unknown 2 1 0 0  
 
LVI 
Negative 25 2 4 2  
Positive 41 11 5 0 0.0994 
Unknown 2 1 0 0  
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Table 3 - 6 Cytoplasmic c-Met intensity in non-TNBC TMA and patient prognostic 
indicators. P values were calculated using Chi square test. 
 0 1+ 2+ P value 
Patient age at diagnosis 
< 50 19 2 1  
> 50 49 16 6 0.2725 
 
Grade     
Grade 1/2 40 11 6  
Grade 3 17 4 1 0.6739 
Unknown 11 3 0  
 
Histological subtype 
Ductal 48 13 5  
Lobular 17 4 1 0.8659 
Other  1 0 1  
Unknown 2 1 0  
 
Size 
<2cm 31 7 5  
>2cm 37 11 2 0.3346 
 
LN Status 
Negative 37 10 3  
Positive 29 8 3 0.9599 
Unknown 2 1 0  
 
LVI 
Negative 25 5 3  
Positive 41 11 5 0.8841 
Unknown 2 1   
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a)
b)
 
Figure 3 - 2 Kaplan Meier curve based on a) 5 year recurrence of TNBC patients 
divided into c-Met high (red) and c-Met low (black) groups b) 5 year survival of 
TNBC patients divided into c-Met high (red) and c-Met low (black) groups, where 
high/low = >50/<50 % of positively stained cells in tumour (n=83). 
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Table 3 - 7 TNBC tumours positive for both EGFR and c-Met as determined by 
immunohistochemistry.  
Age  Grade Subtype Size LN 
Statu
s 
LVI 5 year 
recurrenc
e 
5 year 
survival 
>50 2 Ductal <2cm - - No Yes 
>50 3 Ductal >2cm + - Yes Yes 
>50 3 Ductal >2cm + - No Yes 
 
Table 3 - 8 Tumours samples positive for c-Met and Total c-Src in TNBC tumours. 
P values were calculated using Chi Square test and adjusted using Bonferroni 
Correction. 
Column1 Positive P value 
Patient Age at Diagnosis  
< 50 6/24  
> 50 
 
9/42 0.7764 
Grade    
Grade 1/2 3/8  
Grade 3 
 
12/58 0.4184 
Histological Subtype   
Ductal 14/63  
Lobular 1/2 0.4684 
Unknown 0/1  
 
Size   
<2cm 9/31  
>2cm 6/33 0.5679 
Unknown 
 
0/2  
LN Status   
Negative 10/35  
Positive 5/29 0.5639 
Unknown 
 
0/2  
LVI Status   
Negative 10/31  
Positive 5/31 0.2543 
Unknown 0/1  
 
94 
 
Table 3 - 9 Tumours samples positive for c-Met and phospho-Src (Y418) in TNBC 
tumours. P values were calculated using Fishers Exact Test.  
 Positive/negative P value 
Patient age at diagnosis   
< 50 3/27  
> 50 5/46 1.0 
 
Grade     
Grade 1/2 3/8  
Grade 3 6/65 0.0725 
 
Histological subtype 
 
Ductal 7/70  
Lobular 1/2 0.2741 
Other  0/1  
 
Size     
<2cm 6/34  
>2cm 2/37 0.2633 
Unknown 0/2  
 
LN Status  
Negative 5/40  
Positive 3/31 1.0 
Unknown 0/2  
 
LVI  
Negative 4/37  
Positive 4/35 1.0 
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a)
b)
 
Figure 3 - 3 Kaplan Meier curve based on a) 5 year recurrence and b) 5 year 
survival of TNBC patients divided into c-Met high/low and c-Src high low, where 
c-Met high/low = >50/<50 % of positively stained cells in tumour and c-Src 
high/low = >50%/<50% of positively stained cells in tumour (n=81).  
96 
 
a)
b)
 
Figure 3 - 4 Kaplan Meier curve based on a) 5 year recurrence and b) 5 year 
survival of TNBC patients divided into c-Met high/low and p-Src high low, where 
c-Met high/low = >50/<50 % of positively stained cells in tumour and p-Src 
high/low = >50%/<50% of positively stained cells in tumour (n=81).  
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Figure 3 - 5 Levels of phosphorylated a) c-Met and b) phosphorylated RTKs in 10 
µg protein from powdered tumour (blue) and normal (red) samples as determined 
by Magpix® magnetic bead assays. Samples were tested in single replicates.  
 
3.3 Role of HGF in TNBC  
3.3.1 HGF expression in TNBC cell lines 
We examined TNBC cell lines for HGF expression using two methods, a HGF ELISA 
to detect the mature molecule in conditioned media, and qRT-PCR to detect HGF 
mRNA. U87-MG-luc2 glioma cell line was used as a positive control for both 
experiments. Two cell lines (p-Met positive HCC1937 and p-Met negative MDA-MB-
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231) were assayed for secretion of HGF into 6 mL conditioned medium. No HGF was 
detectable in either cell line (Table 3 – 10). A calibration curve was generated using the 
log absorbance of a set of standards provided with the ELISA ranging from 0.125 to 8 
ng/mL (Figure 3 - 6). Using qRT-PCR we determined mRNA expression levels of HGF 
in 13 TNBC cell lines. No HGF mRNA was detected in any of the TNBC cell lines, 
whereas HGF mRNA was detected at high levels in U87-MG-luc2 cells, with a Ct value 
of 18.58 compared to >40 for the TNBC cell lines (Figure 3 – 10).  
 
 
Figure 3 - 6  Calibration curve of ELISA plotting log absorbance vs. log HGF 
concentration. 
 
 
Table 3 - 10 Concentrations of positive controls and samples tested for HGF by 
ELISA. *ND - Not detected 
Sample Absorbance Concentration (ng/mL) 
U87-MG-Luc2 0.261 0.91 
HCC 1937 0.089 ND* 
MDA-MB-231 0.071 ND* 
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Figure 3 - 7 Amplification plot for HGF mRNA in TNBC cell lines and U-87-MG-
luc2 glioma cell line (shown in green) showing reaction vs cycle number.  
3.3.2 HGF stimulation of proliferation 
Expression and phosphorylation of c-Met has been shown in both TNBC cell lines and 
TNBC tumours however no HGF was detected. We treated five cell lines (2 positive for 
phosphorylation and 3 negative) with saturating concentrations of HGF (50 ng/mL) and 
EGF (10 nM) to stimulate growth. HGF treatment caused a significant increase in 
proliferation in 2/5 cell lines, HCC1937 and BT20 (p= 0.026 and 0.049 respectively).  
EGF treatment caused a significant increase in proliferation in HCC1937 (p = 0.007).  
No significant increase was seen in response to combination treatment with both HGF 
and EGF (Figure 3 - 8).  
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Figure 3 - 8 Proliferation assay showing % growth relative to serum free control 
48 hrs post treatment with HGF (50 ng/mL), EGF (10 nM) alone or in 
combination.  
3.4 Summary 
c-Met expression was detected in all nine TNBC cell lines tested and phosphorylation 
(Y1234/Y1235) was detectable in 4/9 cell lines in contrast to non-TNBC cell lines 
where total c-Met was detectable in 3/7 cell lines with no detectable levels of 
phosphorylation. Examination of pan-Tyr phosphorylation of six RTKs in the panel of 
TNBC did not reveal significant differences between the cell lines. Soluble Met was 
detectable in all TNBC cell lines with CAL-85-1 cells showing the highest levels. There 
was no significant correlation between the expression of c-Met or p-Met and levels of 
sMet. c-Met was detected more frequently in TNBC than non-TNBC tumours with 
44/83 (53.0%) of TNBC tumours positive for c-Met. However no significant association 
was seen between expression and patient prognostic indicators. No significant 
association between c-Met expression and recurrence or survival was seen. Expression 
of c-Met was examined in conjunction EGFR, c-Src and activated c-Src. Levels of 
EGFR positive tumours were too low for statistical analysis but 3/6 tumours positive for 
EGFR also show c-Met expression. 83.3% of c-Met expressers also show expression of 
total Src with 38.8% of these patients showing phosphorylation of c-Src at Y418. No 
significant association between co-expression of c-Met, Src and phospho-Src and the 
prognostic indicators was determined.   
In nine TN tumours assessed for phosphorylation, 8/9 tumours show phosphorylation of 
c-Met however, phosphorylation of c-Met was detected at higher levels in 2/3 normal 
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tissues with paired samples. Interestingly, the insulin receptor showed notably higher 
levels of phosphorylation than other receptors in all of the tumours tested.  
HGF is undetectable in the TNBC cells however the presence of HGF stimulates the 
growth of 2/5 cell lines tested from the TNBC cell line panel.   
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Chapter 4 
Preclinical evaluation of CpdA and rilotumumab in 
TNBC cell lines 
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4.1 Introduction 
TNBC currently lacks a validated molecular target for treatment and is managed via 
cytotoxic chemotherapies (anthracycline and taxane based). c-Met has been implicated 
in the development of basal-like/TNBC breast cancer and is frequently over expressed 
in these tumours, however c-Met signalling has not been extensively evaluated as a 
target for treating TNBC [152, 161, 162, 167-169, 185]. We evaluated a c-Met selective 
inhibitor (CpdA) and a HGF monoclonal antibody (rilotumumab) in TNBC cell lines. 
Kim et al. have recently reported that PHA-665752 (selective c-Met inhibitor) inhibits 
growth in 6 of nine TNBC cell lines, additionally c-Met has been implicated in 
resistance to EGFR TKIs in NSCLC mediated by interaction and activation of Src 
[180]. An enhancement of response to EGFR inhibitors via c-Src inhibition has been 
observed previously in two breast cancer cell lines (HER2 positive and TNBC) [213]. 
We evaluated the combination of c-Met and HGF inhibition, and c-Met and EGFR/Src 
inhibition using the pan-erbB inhibitor neratinib and Src inhibitor saracatinib. Neratinib 
is currently in phase II clinical trials in combination with temsirolomous in metastatic 
HER2 positive or TNBC. Saracatinib is currently in phase II trials for recurrent 
osteosarcoma [220]. A trial of saracatinib in metastatic hormone receptor negative 
breast cancer was discontinued due to lack of efficacy as a single agent [253].  
4.2 Sensitivity of TNBC cell lines in 2D growth assays 
4.2.1 Proliferation assays 
CpdA inhibited 2D growth in all of the TNBC cell lines tested. In only six of nine cell 
lines an IC50 value was achieved when tested with CpdA at concentrations up to 10 µM. 
MDA-MB-231 was the most sensitive cell line with an IC50 of 2.5 ± 0.3 µM (Figure 4 - 
1). Rilotumumab did not significantly inhibit the growth of any of the TNBC cell lines. 
Maximum growth inhibition achieved at 10µg/mL was approximately 8.2 ± 1.9% in the 
HCC1143 cell line (Figure 4 - 2).  The TNBC cell lines all showed sensitivity to 
neratinib. CAL-85-1 and HDQ-P1 were the most sensitive cell lines with IC50 < 100 
nM. The BT549 cell line were the least sensitive with an IC50 of 6.6 ± 0.5 µM (Figure 4 
- 3). An IC50 was achieved in seven of nine TNBC cell lines when treated with 
saracatinib at concentrations up to 10 µM. The HDQ-P1 cell line displayed the most 
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sensitivity with an IC50 of 0.3 ± 0.1 µM. The least sensitive cell line was BT20 which 
had an IC50 of 1.7 ± 0.3 µM (Figure 4 – 4). The IC50 for each cell line is described in 
Table 4 - 1.  
The combination of CpdA and rilotumumab at fixed concentrations of 2 µM and 10 
µg/mL respectively, resulted in significantly decreased growth in 3/8 cell lines; 
HCC1937, MDA-MB-231 and MDA-MB-468 (p= 0.02, p= 0.03, p= 0.009 relative to 
CpdA as single agent respectively as shown in Figure 4 - 5. Combinations of CpdA (2 
µM) and neratinib (IC50 concentrations-Table 4 - 1) resulted in significantly decreased 
growth in the MDA-MB-468 cell line only (p = 0.003 relative to neratinib effect) 
compared to Cpd A and neratinib as single agents respectively) (Figure 4 - 6). 
Combinations of Cpd A (2 µM) and saracatinib (IC50 concentrations-Table 4 - 1) 
resulted in significantly decreased growth in four of nine cell lines, HCC1937, MDA-
MB-468, MDA-MB-231 and HDQ-P1 (p=0.023 p= 0.003, p= 0.00033, p= 0.0003 
relative to saracatinib effect (Figure 4 - 7).  
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Table 4 - 1 Sensitivity of TNBC cell lines to CpdA, neratinib and saracatinib in 2D 
proliferation assays. IC50 is the concentration required to inhibit growth by 50%. 
% growth at 10 µg/mL is relative to untreated vehicle control ± standard deviation 
of independent biological triplicates. UC-unclassified, BL1/2- basal-like 1/2, M-
mesenchymal, MSL-mesenchymal stem-like. 
Cell Line TNBC 
subtype 
IC50 (µM) 
CpdA 
%Growth 
at  10 µM 
CpdA 
IC50 (µM) 
neratinib 
IC50 (µM) 
saracatinib 
BT20 UC >10 73.7 ± 4.9 0.4 ± 0.04 1.7 ± 0.2 
HCC1937 BL1 4.1 ± 0.5 11.4 ± 1.8 0.2 ± 0.02 0.8 ± 0.1 
HCC1143 BL1 >10 89.9 ± 8.5 0.6 ± 0.09 1.1 ± 0.2 
MDA-MB-
468 
BL1 3.1 ± 0.4 11.6 ± 1.8 0.05 ± 0.01 1.3 ± 0.3 
MDA-MB-
231 
MSL 2.5 ± 0.3 9.0 ± 2.2 2.8 ± 0.2 0.5 ± 0.1 
CAL-120 M 3.8 ± 0.3 37.4 ± 9.5 1.6 ± 0.2 >10 
CAL-85-1 BL2 >10 86.2 ± 3.8 <0.03 0.7 ± 0.1 
HDQ-P1 BL2 5.1 ± 0.4 36.7 ± 3.6 <0.03 0.3 ± 0.05 
BT549 M >10 41. 3 ± 4.3 6.6 ± 0.5 >10 
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Figure 4 - 1 Proliferation assays of TNBC cell lines treated with CpdA at serially 
decreasing concentrations from 10 µM relative to vehicle control in 2D 
proliferation. Error bars represent the standard deviation of three independent 
biological triplicates.   
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Figure 4 - 2 Proliferation assays in TNBC cell lines treated with 10 µg/mL 
rilotumumab. % growth is relative to untreated control. Error bars represent the 
standard deviation of triplicate independent experiments.  
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Figure 4 - 3  Proliferation assays in TNBC cells treated with neratinib at serially 
decreasing concentrations from 10 µM. Error bars represent standard deviations 
of triplicate independent experiments.  
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Figure 4 - 4 Proliferation assays in TNBC cells treated with saracatinib at serially 
decreasing concentrations from 10 µM. Error bars represent standard deviations 
of triplicate independent experiments. 
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Figure 4 - 5 % growth relative to untreated control of cell lines of rilotumumab 
(AMG102-10 µg/mL) and CpdA (2 µM) Error bars represent the standard 
deviation of triplicate independent experiments.* = p<0.05, ** = p< 0.01 relative to 
CpdA as single agent 
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Figure 4 - 6  Proliferation assays in TNBC cells treated with CpdA (2 µM) and 
neratinib at respective IC50 concentrations. Error bars represent the standard 
deviation of triplicate independent experiments.  ** = p<0.01 relative to CpdA as a 
single agent. 
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Figure 4 - 7 Proliferation assays in TNBC cells treated with CpdA (2 µM) and 
saracatinib at respective IC50 concentrations. Error bars represent the standard 
deviation of triplicate independent experiments.  * = p<0.05, **= p<0.01 and ***= 
p<0.001 relative to CpdA as a single agent.  
4.2.2 Clonogenic Assays 
2D clonogenic assays or colony formation assays are in vitro cell survival assays which 
measure a single cells ability to reproduce. Classically they have been used to measure 
response to IR however they may be additionally used to evaluate cytotoxic agents as 
we present here. Commonly the clonogenic assays are manually counted and colony 
forming efficacy calculated based on the number of colonies and number of cells 
seeded. Only a limited number of cells should possess the ability to form colonies. The 
data presented in this thesis uses % area covered and average intensity of the colonies as 
a measurement as determined by the automated software Image J (see Section 2.7). 
We assessed five cell lines for response to CpdA, neratinib and saracatinib using 
clonogenic assays. Representative Images are shown in Figure 4 – 8.   Four of the cell 
lines (HCC1937, HCC1143, MDA-MB-468, and HDQ-P1) showed significant 
reduction in % area covered (p= 0.006, 0.007, 0.02 and 0.03 respectively relative to 
untreated controls) following treatment with 1 µM CpdA for 14 or 21 days. HCC1143 
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and HDQ-P1 also showed a significant reduction in average intensity of colonies (p= 
0.03 and 0.008 respectively relative to untreated control) indicating a reduction in cell 
number in the individual colonies (Figure 4 - 9). HCC1937 were the most sensitive cell 
line with an 80.3 ± 9.7 % reduction in area covered.  
Three of the five cell lines; HCC1937, HCC1143 and MDA-MB-231 tested showed a 
statistically significant decrease (p = 0.02, 0.002 and 0.001 respectively) in % area 
covered following neratinib treatment. MDA-MB-231 was the most sensitive cell line 
with an 85. 4 ± 5.5 % reduction in area covered relative to the untreated control. The 
HCC1143 and MDA-MB-231 cell lines also showed a statistically significant (p= 0.005 
and 0.003 respectively) decrease in average intensity of colonies. The HCC1937 
showed a slight decrease however this was not significant and the HDQ-P1 (p=0.04) 
cell which did not show a decrease in % area covered showed a decrease in average 
intensity of the colonies measured (Figure 4 - 10).  Combination of treatment with 
CpdA and neratinib showed no significant change in % area covered or in colony 
intensity in any of the cell lines tested (Figure 4 - 11).  
Four of the five cell lines (HCC1937, HCC1143 MDA-MB-468 and MDA-MB-231) 
tested showed a statistically significant decrease (p= 0.002, 0.02, 0.02 and 0.0006 
respectively) in % area covered following saracatinib treatment. The cell line HDQ-P1 
showed a decrease in % area covered however failed to reach significance with p-value 
of 0.06. HCC1143 was the most sensitive cell line with an 80.8 ± 0.1 % reduction in 
area covered relative to the untreated control. All of the cell lines tested also showed a 
statistically significant decrease in average intensity of colonies except the HCC1937 
(Figure 4 - 12).  Combined treatment with CpdA and saracatinib showed no significant 
change in % area covered or in colony intensity in any of the cell lines tested.  However 
MDA-MB-231 shows a decrease in % area covered which is approaching significance 
(p=0.06) (Figure 4 - 13). 
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Figure 4 - 8 Representative images of clonogenic assays untreated or treatment as 
described. Cells were fixed with methacare fixative and stained with 1% Crystal 
Violet. Images are representative of triplicate experiments.  
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Figure 4 - 9 a) Clonogenic assays showing % area covered by colonies relative to 
untreated control 14-21 days post treatment with 1 µM CpdA and b) average 
intensity of colonies analysed after 14/21 days post treatment. Error bars represent 
the standard deviations of triplicate independent experiments. *= p<0.05, **= 
p<0.01 of CpdA compared to control values. 
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Figure 4 - 10 Clonogenic assays showing % area covered by colonies relative to 
untreated control 14-21 days post treatment with respective concentrations of 
neratinib and b) average intensity of colonies analysed after 14/21 days post 
treatment. Error bars represent the standard deviation of triplicate independent 
experiments. *= p<0.05, **= p<0.01 of neratinib treated values compared to 
control values.  
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Figure 4 - 11 Clonogenic assays showing % area covered by colonies treated with 
CpdA and neratinib or in combination b) average intensity of colonies analysed 
after 14/21 days post treatment. Error bars represent the standard deviations of 
triplicate independent experiments.  
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Figure 4 - 12 Clonogenic assays showing a) % area covered by colonies relative to 
untreated control 14-21 days post treatment with respective concentrations of 
neratinib and b) average intensity of colonies analysed after 14/21 days post 
treatment. Error bars represent the standard deviations of triplicate independent 
experiments * = p<0.05, **=p<0.01, *** = p<0.001of saracatinib treated values 
compared to control values. 
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Figure 4 - 13 Clonogenic assays showing % area covered by colonies treated with 
CpdA and neratinib and in combination b) average intensity of colonies analysed 
after 14/21 days post treatment. Error bars represent the standard deviations of 
triplicate independent experiments.
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4.3 Sensitivity to CpdA in 3D growth assays 
BT20, HCC1937, HCC1143, MDA-MB-468, MDA-MB-231, HDQ-P1 and BT549 cell 
lines all showed the ability to form colonies when culture in 3D environment with 
matrigel as the support matrix. CAL-85-1 was the only cell line tested which did not 
form colonies and lysis of >90% of cells seeded occurred within 5 days. Representative 
images of colonies formed are shown with and without treatment of CpdA (10 µM) after 
5/7 days growth (Figure 4 - 14). MDA-MB-468 and MDA-MB-231 were the most 
sensitive cell lines to CpdA in 3D assays. MDA-MB-468 showed a statistically 
significant 30.1 ± 10.6 % reduction in cell viability (p= 0.01) followed by MDA-MB-
231 showing statistically significant 11.8 ± 0.5 % reduction (p=0.01) (Figure 4 - 15) at 
10 µM. Overall the nine cell lines showed limited response in 3D culture to CpdA and 
were less sensitive to inhibition by CpdA than 2D cell culture (Table 4 – 2).  
 
Figure 4 - 14 3D colonies formed after 5/7 days growth in 2-4% matrigel 
with/without CpdA treatment (10 µM). 
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Figure 4 - 15 % viability of cells after 5/7 day treatments with serially decreasing 
concentrations of CpdA from 10 µM. Error bars represent standard deviations of 
triplicate independent experiments.  
 
Table 4 - 2 Comparison of growth in 2D v 3D growth assays at 10 µM CpdA ± 
standard deviations which represent triplicate independent experiments.  
Cell Line % growth @ 10 µM-2D % growth @  10 µM-3D 
BT20 73.7 ± 4.9 107.2 ± 5.6 
HCC1937 11.4 ± 1.9 98.5 ± 5.8 
HCC1143 89.9 ± 8.5 103.6 ± 8.6 
MDA-MB-468 11.6 ± 1.9 89.3 ± 10.6 
MDA-MB-231 9.0 ± 2.2 70.9 ± 0.6 
HDQ-P1 36.7 ± 3.6 88.5 ± 10.9 
BT549 41.3 ± 4.3 93.2 ± 9.7 
 
4.4 Sensitivity of TNBC in invasion assays 
 We conducted invasion assays on our panel of TNBC cell lines. Representative images 
of cell invading after 24hrs are shown in Figure 4 – 16. MDA-MB-231 show the highest 
level of invasion with 190 ± 3 cells invading per 1000 cells seeded. BT20, HCC1937, 
HCC1143, CAL-85-1 and BT549 all show moderate levels of invasion and MDA-MB-
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468, CAL-120 and HDQ-P1 show the lowest levels of invasion with 40 ± 2, 30 ± 2 and 
10 ± 1 cells invading per 1000 cell seeded (Figure 4 - 17). None of the cell lines tested 
showed a significant response in invasion post treatment with 1 µM CpdA (Table 4 – 3, 
Figure 4 – 18). None of the cell lines tested showed a significant response to neratinib 
post treatment with 1 µM neratinib (Table 4 – 3). The addition of neratinib did not 
enhance the cell lines response to CpdA (Figure 4 - 19). Similarly to neratinib, 
saracatinib showed no significant effect on the invasion of TNBC cell lines and no 
significant increase in response to CpdA was noted in the combination (Table 4 – 3, 
Figure 4 – 20).  
 
BT20 HCC1937 HCC1143
MDA-MB-468 MDA-MB-231 CAL-120
CAL-85-1 HDQ-P1 BT549
 
Figure 4 - 16 Representative images of invading cells (through 1 mg/mL matrigel) 
of nine TNBC cell lines after 24hrs. 
 
 
121 
 
 
Figure 4 - 17 No. of invading cells relative to number of cells seeded (1x 105 or 5 x 
104) of TNBC cell lines. Error bars represent standard deviations of independent 
triplicate experiments. 
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Table 4 - 3 shows the % invasion post treatment with 1 µM CpdA relative to 
untreated control  
Cell lines Subtype No of cells 
invading/1000 
cells seeded 
%  
invasion @ 
1 µM 
CpdA 
% invasion 
@ 1 µM 
neratinib 
%  
Invasion @ 
1 µM 
saracatinib 
BT20 UC 81.6 ± 18.8 88.8 ± 23.2 87.4 ± 9.3 88.0 ± 11.0 
HCC1937 BL-1 93.8 ± 21.8 91.5 ± 11.9 88.3 ± 15.3 102.9 ± 8.8 
HCC1143 BL-1 116.3 ± 6.4 94.2 ± 5.5 93.3 ± 6.9 101.2 ± 7.4 
MDA-
MB-468 
BL-1 35.6 ± 2.2 114.7 ± 6.2 108.3 ± 10.5 91.9 ± 21.6 
MDA-
MB-231 
MSL 185.9 ± 4.0 105.5 ± 2.1 84.2 ± 16.4 104.9 ± 19.4 
CAL-120 M 32.1 ± 2.7 92.5 ± 12.3 97.8 ± 9.9 97.9 ± 5.3 
CAL-85-1 BL-2 106.5 ± 19.9 93.6 ± 18.6 88.4 ± 15.6 76.9 ± 17.0 
HDQ-P1 BL-2 15.0 ± 1.7 96.3 ± 11.4 94.5 ± 9.9 108.3 ± 10.5 
BT549 M 98.0 ± 8.3 91.8 ± 8.5 87.4 ± 11.3 88.0 ± 21.6 
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Figure 4 - 18  Invasion assays of TNBC cell lines treated with 1 µM CpdA. Error 
bars represent standard deviation of triplicate independent experiments. 
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Figure 4 - 19  Invasion assays of TNBC cell lines with CpdA and neratinib at fixed 
concentrations of 1 µM respectively. Error bars represent standard deviation of 
triplicate independent experiments. 
124 
 
 
0
20
40
60
80
100
120
140
%
 I
n
v
a
d
in
g
 c
e
ll
s 
re
la
ti
v
e
 t
o
 c
o
n
tr
o
l
CpdA
saracatinib
CpdA + saracatinib
 
Figure 4 - 20 Invasion assays of TNBC cell lines with CpdA and saracatinib, or the 
combination at fixed concentrations of 1 µM respectively. Error bars represent 
standard deviation of triplicate independent experiments. 
 
4.5 Sensitivity to CpdA in migration assays 
We assessed the effect of HGF on the levels of migration in MDA-MB-468. HGF 
stimulated a significant increase in migration after 48 hrs (p=0.02) however had no 
significant effect at 24 hrs. Representative images of wound scratches at T0, T24 and 
T48 are shown in Figure 4 - 21. Rilotumumab and CpdA both inhibited the migration 
stimulated by HGF (p= 0.008 and 0.004 respectively) however did not significantly 
decrease migration below untreated control levels (Figure 4 - 22). We examined 
whether CpdA could inhibit basal levels of migration at 24 and 48 hrs in 5 cell lines 
(HCC1937, HCC1143, MDA-MB-231 and HDQ-P1 and whether the response to CpdA 
could be enhanced by combination with neratinib and saracatinib. The MDA-MB-231 
and HDQ-P1 were not suitable for evaluation at 48 hrs. The cell lines show varying 
basal levels of migration with the MDA-MB-231 showing the highest level of migration 
with 96.4 ± 3.8 % wound closure after 24 hrs. MDA-MB-468 showed the lowest level 
of migration with 16.4 ± 2.9 % after 24 hrs. No significant response was seen to CpdA 
treatment at 24 or 48 hrs in any of the cell lines tested (Figure 4 - 24). No significant 
reduction was seen after 24 or 48 hrs in response to neratinib treatment at 1 µM and no 
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enhancement was observed with combined CpdA and neratinib treatment (Figure 4 - 
25). Similarly to neratinib, no significant response was seen to saracatinib as a single 
agent at either 24 or 48 hrs and no enhancement of response was observed for CpdA 
when used in combination with saracatinib (Figure 4 - 26).  
HCC1937
T0 T24 T48
HCC1143
MDA-MB-468
MDA-MB-231
HDQ-P1
 
Figure 4 - 21 Wound scratch photographs of control wells taken at T0, T24 and 
T48 where applicable.  
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Figure 4 - 22 MDA-MB-468 levels of migration relative to T0 and T24 and T48 hrs. 
Cells were treated with HGF (50 µg/mL), Rilotumumab (10 µg/mL) and CpdA (1 
µM). Error bars represent the standard deviation of triplicate independent 
experiments. * = p<0.05, **= p<0.01 relative to HGF treated values 
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Figure 4 - 23 Basal migration levels of five TNBC cell lines as determined by 
wound scratch assays after 24hrs migration. Error bars represent standard 
deviations of triplicate independent experiments.  
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Figure 4 - 24 Migration levels relative to T0 of five TNBC cells lines treated 
with/without CpdA (1 µM) for a) 24hrs and b) 48 hrs. Errors bars represent 
standard deviations of independent triplicate experiments. 
129 
 
0
20
40
60
80
100
120
HCC1937 HCC1143 MDA-MB-468 MDA-MB-231
%
 m
ig
ra
ti
o
n
 r
e
la
ti
v
e
 t
o
 T
0
T24
Control
Neratinib
0
20
40
60
80
100
120
HCC1937 HCC1143 MDA-MB-468
%
 m
ig
ra
ti
o
n
 r
e
la
ti
v
e
 t
o
 T
0
T48
Control
Neratinib
0
20
40
60
80
100
120
HCC1937 HCC1143 MDA-MB-468 MDA-MB-231
%
 m
ig
ra
ti
o
n
 r
e
la
ti
v
e
 t
o
 T
0
T24
Control
CpdA
Neratinib
CpdA+Neratinib
0
20
40
60
80
100
120
HCC1937 HCC1143 MDA-MB-468
%
 m
ig
ra
ti
o
n
 r
e
la
ti
v
e
 t
o
 T
0
T48
Control
CpdA
Neratinib
CpdA+Neratinib
a)
b)
 
Figure 4 - 25 Migration levels relative to T0 of four TNBC cells lines treated 
with/without a) neratinib (1 µM) for 24 hrs (LHS) and 48 hrs(RHS) and b) 
migration levels relative to T0 with/without treatment of CpdA (1 µM), neratinib 
(1 µM) or in combination. Errors bars represent standard deviations of 
independent triplicate experiments.  
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Figure 4 - 26 Migration levels relative to T0 of five TNBC cells lines treated 
with/without a) saracatinib (1 µM) for 24 hrs (LHS) and 48 hrs(RHS) and b) 
migration levels relative to T0 with/without treatment of CpdA (1 µM), saracatinib 
(1µM) or in combination. Errors bars represent standard deviations of 
independent triplicate experiments. 
4.6 Summary 
CpdA achieved greater than 50% growth inhibition at concentrations less than 10 µM in 
six of nine cell lines tested. MDA-MB-231 was the most sensitive. Combinations of 
CpdA and rilotumumab resulted in significantly decreased growth in three cell lines, 
HCC1937, MDA-MB-468 and MDA-MB-231. Neratinib only enhanced response to 
CpdA in one EGFR amplified cell line MDA-MB-468. Saracatinib also enhanced 
response to CpdA in 2D proliferation assays in four cell lines, HCC1937, MDA-MB-
468, MDA-MB-231 and HDQ-P1. 
Clonogenic assays showed much higher sensitivities to 1 µM CpdA than 2D assays. 
Four of five cell lines tested showed a response including one which did not 
demonstrate any response in 2D assays. The addition of neratinib or saracatinb in this 
case did not enhance sensitivity to CpdA in any of the cell lines.   
Two cell lines showed sensitivity to CpdA treatment in 3D assays. MDA-MB-231 and 
MDA-MB-468 were the most sensitive in agreement with the 2D assays. 
131 
 
Invasion assays showed no significant response to treatment with any inhibitors. MDA-
MB-231 was the most invasive cell line and HDQ-P1 was the least invasive.  
In migration assays, CpdA and rilotumumab have the ability to inhibit HGF induced 
migration however show no significant effect on basal levels of migration.  
In summary c-Met inhibition showed limited anti-cancer actively in the panel of TNBC 
cell lines (Table 4 – 4). Having combined treatment with neratinib or sarcatinib 
enhanced response is seen in a small number of cell lines (Table 4 – 5).  
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Table 4 - 4 Summary of responses to TNBC in 2D proliferation, clonogenic, 3D, 
invasion and migration assays. 
Cell Line Sub-
type 
2D IC50 Clonogenic 
% 
inhibition 
@ 1 µM 
3D % 
inhibition 
@ 10 µM 
Invasion % 
inhibition 
at 1 µM 
Migration 
% 
inhibition 
at 1 µM 
BT20 UC >10 NT 107.2 ± 5.6 88.8 ± 23.2 NT 
HCC1937 BL1 4.1 ± 0.5 69.2 ± 9.4 98.5 ± 5.8 91.5 ± 11.9 72.6 ± 4.1 
HCC1143 BL1 >10 46.3 ± 3.4 103.6 ± 8.6 94.2 ± 5.5 60.7 ± 7.9 
MDA-
MB-468 
BL1 3.1 ± 0.4 57.9 ± 5.5 89.3 ± 10.6 114.7 ± 6.2 83.6 ± 2.9 
MDA-
MB-231 
MSL 2.5 ± 0.3 20.7 ± 9.6 70.9 ± 0.6 105.5 ± 2.1 3.6 ± 3.83 
CAL-120 M 3.8 ± 0.3 NT NT 92.5 ± 12.3 NT 
CAL-85-1 BL2 >10 NT NT 93.6 ± 18.6 NT 
HDQ-P1 BL2 5.1 ± 0.4 18.11 ± 2.8 88.5 ± 10.9 96.3 ± 11.4 63.0 ± 10.4 
BT549 M >10 NT 93.2 ± 9.7 91.8 ± 8.5 NT 
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Table 4 - 5 Cell lines which show enhanced response to combination. UK - 
Unknown 
Cell Line Sub-
type 
Basal 
A/B 
2D growth Key 
features 
HCC1937 BL-1 A CpdA + 
rilotumumab 
CpdA + 
saracatinib 
BRCA 
PI3K WT 
PTEN+ 
P53 mutated 
MDA-MDA-
231 
MSL B CpdA + 
rilotumumab 
CpdA + 
saracatinib 
PI3K WT 
PTEN+ P53 
mutated 
MDA-MB-468 BL-1 A CpdA + 
rilotumumab 
CpdA + neratinib 
CpdA+ 
saracatinib 
PI3K WT 
PTEN null 
EGFR 
amplified 
P53 mutated 
HDQ-P1 BL-2 UK CpdA+ 
Sarcatinib 
P53 mutated 
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Chapter 5 
Preclinical Evaluation of PRS110 in TNBC Cell Lines 
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5.1 Introduction 
PRS110 is a monovalent antagonist of c-Met in pre-clinical development by Pieris Ag. 
PRS110 is unique in its structure which is named an anticalin. The anticalins are 
engineered from endogenous lipocalins [228]. The lipocalins are a family of proteins 
which transport small hydrophobic molecules and are involved in inflammation and 
detoxification processes. PRS110 essentially functions as a monoclonal antibody 
binding to the extracellular portion of c-Met, however lacks the large fragment 
crystallisable (Fc) domain of monoclonal antibodies which are known to stimulate 
activation of receptors through cross linking and may function as a potential resistance 
mechanisms in monoclonal antibody therapies [254]. Anticalin molecules are suggested 
to overcome this. Additionally PRS110 is capable of blocking both ligand dependent 
and ligand-independent mechanisms of activation of c-Met. Several other monoclonal 
antibodies against c-Met are in development, the most promising of which was 
onartuzumab [233] . After initial success in Phase I and II trials in NSCLC, a Phase III 
trial was launched. This trial evaluated the role of onartuzumab in combination with 
erlotinib; however it was halted early due to lack of meaningful activity of the 
combination [220].  
5.2 Sensitivity of TNBC cell lines to PRS110 in 2D proliferation assays 
5.2.1 2D Proliferation Assays 
PRS110 had no observable effect as a single agent on the proliferation of any of the 9 
TNBC cell lines tested, using serially diluted concentrations from 10 µg/mL (Figure 5 - 
1). The CAL-85-1 cell line while not significant (p=0.477) showed the greatest decrease 
with 14.4 ± 10.3 % inhibition of growth. To confirm activity and efficacy of PRS110 we 
tested the ovarian cancer cell line EBC-1 as a positive control. PRS110 had an IC50 of 
1.1 ±0.08 µg/mL in the EBC-1 cell line (Figure 5 - 1). We then tested whether PRS110 
at 10µg/mL could enhance response of neratinib and saracatinib at their respective IC50 
concentrations (see Table 4 - 1). No significant increase in response relative to the 
single agents of neratinib or saracatinib was observed (Figure 5 - 2). 
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Figure 5 - 1 Proliferation assays of TNBC cell lines treated with PRS110 at serially 
decreasing concentrations from 10 µg/mL relative to vehicle control in 2D 
proliferation. Error bars represent the standard deviations of triplicate 
independent experiments.   
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Figure 5 - 2 Proliferation assays in TNBC cells treated with PRS110 (10 µg/mL) 
and a) neratinib and b) saracatinib. Error bars represent the standard deviation of 
triplicate independent experiments.  
5.2.2 Clonogenic assays 
Additionally we tested the cell lines using the 2D clonogenic assay as described in 
Chapter 4. Briefly, clonogenic assays measure a cells ability to self-propagate 
a
b
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indefinitely by forming colonies from single cells. This assay is supposed to artificially 
represent this hallmark of cancer cells. We treated five cell lines (minimum 1 selected 
from each subtype of TNBC available to us) with 10 µg/mL PRS110. Representative 
Images are shown in Figure 5 – 3.   HCC1937, HCC1143 and MDA-MB-231 cell lines 
all showed a significant reduction in the percentage area covered following treatment 
with PRS110 (p= 0.002, 0.01 and 0.02 respectively). HCC1143 was the most sensitive 
cell line with 56.4 ± 5.3 % reduction in area covered relative to untreated control. The 
HCC1143 was also the only cell to show a significant reduction in intensity of colonies 
relative to an untreated control (p=0.02) (Figure 5 - 4). I have previously described the 
response to neratinib and saracatinib in clonogenic assays in chapter 4. Briefly, 
HCC1937, HCC1143 and MDA-MB-231 tested showed a statistically significant 
decrease (p = 0.02, 0.02 and 0.001 respectively) in the percentage area cover with 
neratinib treatment. The HCC1143 and MDA-MB-231 cell lines also showed a 
statistically significant (p= 0.05 and 0.003 respectively) decrease in average intensity of 
colonies. Similarly, HCC1937, HCC1143 and MDA-MB-231 showed a statistically 
significant decrease (p= 0.002, 0.02 and 0.0006 respectively) in percentage area cover 
with saracatinib treatment and every cell line except HCC1937 showed a statistically 
significant decrease in colony intensity. Combining PRS110 and neratinib resulted in a 
significant decrease in percentage intensity and average intensity (p= 0.02 and 0.03 
respectively) in MDA-MB-468 cells (Figure 5 - 5). The combination of PRS110 and 
saracatinib resulted in no significant increase in response to PRS110 alone either 
percentage area covered or in intensity of colonies although the MDA-MB-231 showed 
a trend towards decreased colony formation with the combination (Figure 5 - 6).  
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Figure 5 - 3 Representative images of colonies from clonogenic assays untreated or 
with PRS110, neratinib or saracatinib as single agents or with PRS110 in 
combination neratinib or saracatinib.
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Figure 5 - 4 Clonogenic assays showing % area covered by colonies relative to 
untreated control 14-21 days post treatment with a) 10 µg/mL PRS110 and b) 
average intensity of colonies analysed after 14/21 days post treatment. *= p < 0.05, 
**= p<0.01 Error bars represent the standard deviations of triplicate independent 
experiments.  
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Figure 5 - 5 Clonogenic assays showing % area covered by colonies treated with 
PRS110 and neratinib in combination b) average intensity of colonies analysed 
after 14/21 days post treatment at 10 µg/mL PRS110 and IC20 concentrations as 
determined by 2D proliferation assays in 5.2.1. *= p< 0.05. Error bars represent 
the standard deviation of independent triplicate experiments.  
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Figure 5 - 6 Clonogenic assays showing % area covered by colonies treated with 
PRS110 and saracatinib in combination b) average intensity of colonies analysed 
after 14/21 days post treatment at 10 µg/mL PRS110 and IC20 concentrations as 
determined by 2D proliferation assays in 5.2.1. Error bars represent the standard 
deviation of independent triplicate experiments. 
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5.3 Sensitivity to PRS110 in 3D assays 
We tested our panel of cell lines for sensitivity to PRS110 using a 3D matrigel based 
assay and viability was determined using PrestoBlue® reagent. The cell lines were 
tested in a similar experimental set up as that of the 2D acid phosphatase assays. The 
cells were seeded and drugged the following day with serially decreasing concentrations 
of PRS110 from 10 µg/mL. Representative images of colonies are displayed  in Figure 5 
– 7 . No significant response was seen to treatment at the highest concentration (10 
µg/mL) as described in Figure 5 – 8. When compared to 2D assays no significant 
difference is observed between the 2D and 3D proliferation assays. (Table 5 - 1).It is of 
note however that at lowest concentrations tested, PRS110 demonstrated an agonistic 
effect on three of the seven cell lines tested, the highest increase being the MDA-MB-
231 with a % viability of 125.4 ± 8.9 when treated with 0.16 µg/mL PRS110 (Figure 5 - 
8).  
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Figure 5 - 7 3D colonies formed after 5/7 days growth in 2-4% matrigel 
with/without PRS110 treatment (10 µg/mL). 
 
145 
 
0
20
40
60
80
100
120
140
160
0 2 4 6 8 10
%
 v
ia
b
il
it
y
 r
e
la
ti
v
e
 t
o
 u
n
tr
e
a
te
d
 c
o
n
tr
o
l
PRS110 (μg/ml)
BT20
HCC1937
HCC1143
MDA-MB-231
MDA-MB-468
HDQ-P1
BT549
 
Figure 5 - 8 Percentage viability of cells in colony formation assay after 5/7 day 
treatments with serially decreasing concentrations of PRS110 from 10 µg/mL. 
Error bars represent standard deviations of independent triplicate experiments.  
 
Table 5 - 1 Comparison of growth in 2D v 3D growth assays at 10 µg/mL PRS110 ± 
standard deviations which represent independent triplicate experiments. 
Cell Line % growth @ 10 µg/mL-
2D 
% growth @  10 µg/mL-
3D 
BT20 102.7 ± 6.1 107.2 ± 5.6 
HCC1937 96.4 ± 4.2 98.5 ± 6.2 
HCC1143 102.9 ± 3.4 107.2 ± 3.8 
MDA-MB-231 99.4 ± 0.7 89.3 ± 0.8 
MDA-MB-468 98.8 ± 2.3 96.5 ± 6.3 
HDQ-P1 99.1 ± 1.5 101.2 ± 5.7 
BT549 99.0 ± 2.1 103.4 ± 2.1 
 
5.4 Sensitivity to PRS110 in invasion assays 
Coinciding with the 2D and 3D proliferation assays no significant response was seen to 
single agent treatment with 10 µg/mL PRS110 (Table 5 - 2, Figure 5 - 9). For 
representative images of invasion assays see Chapter 4. No significant enhancement of 
response to PRS110 was seen with the combination of neratinib or saracatinib however 
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the combination of PRS110 and neratinib in CAL-85-1 cells showed a non-significant 
decrease in invasion (Figure 5 - 10).  
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Figure 5 - 9 Sensitivity of TNBC cell lines to PRS110, in invasion assays, at a fixed 
concentration of 10 µg/mL. Error bars represent standard deviation of three 
independent biological replicates.  
 
Table 5 - 2 shows the % invasion post treatment with 10 µg/mL PRS110 relative to 
untreated control.  
Cell Line % Invasion 
BT20 114.1 ± 11.4 
HCC1937 105.0 ± 18.8 
HCC1143 85.2 ± 8.8 
MDA-MB-468 106.7 ± 8.5 
MDA-MB-231 100.8 ± 4.7 
CAL-120 90.2 ± 0.4 
CAL-85-1 77.8 ± 18.2 
HDQ-P1 124.8 ± 11.4 
BT549 98.4 ± 8.5 
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Figure 5 - 10 Sensitivity of TNBC cell lines in invasion assays a) treated with 
PRS110 and neratinib in combination at 1 µM and b) with PRS110 and saracatinib 
in combinations at 1 µM. Error bars represent standard deviation of triplicate 
independent experiments. 
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5.5 RTK signalling post PRS110 and neratinib treatment 
PRS110 has showed a limited response in each of the assays tested in all of the TNBC 
cell lines. The CAL-85-1 cell line showed the best response, showing the highest level 
of inhibition in 2D proliferation assays and invasion assays. Additionally the 
combination of the PRS110 and neratinib in CAL-85-1 cell line resulted in a 
significantly decreased level of invasion. For these reasons we chose the CAL-85-1 cell 
line for further evaluation. To investigate the interaction of PRS110 in TNBC cells with 
neratinib, we used a multiplex magnetic bead assay to examine the phosphorylation of 
seven commonly expressed RTKs in TNBC. The CAL-85-1 cell line was treated with 
0.625 µg/mL of PRS110 and 5 nM of neratinib as either single agents or in combination 
for 6 hrs prior to protein extraction. PRS110 decreased phosphorylation of c-Met by 
71.6 ± 19.8%. Neratinib also decreased phosphorylation of EGFR and HER2 as 
expected however interestingly it also significantly reduced phosphorylation of c-Met. 
No other RTK showed significant changes in phosphorylation and the combination of 
PRS110 and neratinib did not significantly reduce phosphorylation compared to either 
agent alone (Figure 5 -11). 
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Figure 5 - 11 Phosphorylation levels of seven RTKS as determined via multiplex 
magnetic bead assays on CAL-85-1 cell line treated with PRS110 and neratinib, as 
single agents or in combination. Net MFI is median fluorescence intensity. Error 
bars represent the standard deviations of triplicate independent experiments.  
 
5.6 Combined inhibition of c-Met with ALK, Axl and RON 
BMS777607 is a small molecule TKI for c-Met, Axl, Ron and Tyro3 with IC50 of 3.9 
nM, 1.1 nM, 1.8 nM and 4.3 nM respectively. Axl has been implicated in TNBC 
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through interaction with EGFR stimulating diverse downstream signalling pathways not 
activated by EGFR alone. Although not as thoroughly investigated it has been shown 
that Axl associates with c-Met in a similar fashion and may therefore activate c-Met 
independently of HGF which may not be targetable by extracellular inhibitors such as 
PRS110. RON is a family member of RTKs of which c-Met is the prototypic member. 
RON and c-Met share approximately 60% sequence homology and are thought to signal 
in similar fashions. Because of this duplicity it has been suggested that dual inhibition 
of c-Met and RON may be advantageous. We also dually inhibited c-Met and ALK 
using the small molecule inhibitor crizotinib. Crizotinib targets c-Met and ALK with 
IC50 of 11 and 24 nM respectively [255]. The M subtype of TNBC has shown 
upregulation of ALK pathway suggesting that a subset of patients may benefit from dual 
inhibition. We tested our panel of TNBC cell lines for sensitivity to BMS777607 and 
tested four cell lines for sensitivity to crizotinib.  
5.6.1 BMS777607 
Only two the cell lines tested with BMS777607 showed a percentage inhibition above 
50%. These were BT20 and BT549, reached greater than 50% inhibition at 10 µM. The 
HCC1937 and the HDQ-P1 also showed a moderate inhibition of growth (33.8 ± 4.5 % 
and 34.6 ± 5.3% respectively) and while the other cell lines did not show any sensitivity 
(Figure 5 - 12).   
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Figure 5 - 12 Sensitivity of TNBC cell lines to BMS777607 at serially decreasing 
concentrations from 10 µM. Error bars represent standard deviations in of 
independent biological triplicates.  
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5.7 Crizotinib 
We initially tested crizotinib in four cell lines, BT20, HCC1143, MDA-MB-231 and 
MDA-MB-468. Only the HCC1143 showed modest effect to crizotinib. Due to the lack 
of efficacy of crizotinib in the TNBC cell lines it was not tested in remainder of the 
panel (Figure 5 - 13).  
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Figure 5 - 13 Sensitivity of four TNBC cell lines to crizotinib at serially decreasing 
concentrations from 10 µM. Error bars are indicative of independent biological 
replicates  
 
5.8 Summary 
PRS110 showed very little effect in proliferation assays despite varying levels of 
activation of c-Met in the TNBC cell lines. To confirm the activity of PRS110 in our 
experimental setup we tested an ovarian cancer cell line EBC-1 which we knew to be 
sensitive to c-Met inhibition. The EBC-1 cell line was tested at identical concentrations 
to the TNBC cell lines and showed a high level of sensitivity with 78.8 ± 2.9 % PRS110 
has the ability to inhibit both ligand dependent and ligand independent activation. 
Ligand independent activation typically occurs through activation of adjacent RTKs by 
their respective ligands, the most likely candidate being EGFR, additionally the 
literature suggests a ligand independent mechanism of activation through a positive 
feedback loop involving c-Src. Based on these assumption we tested the combination of 
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EGFR inhibitor neratinib and c-Src inhibitor saracatinib. The combinations yielded no 
significant enhancement of response in proliferation assays. 
Interestingly despite a lack of response to the acid phosphatase assays, 3 of 5 cell lines 
tested show significant inhibition of clonogenic growth in response to PRS110. This 
was accompanied by a significant decrease in intensity for two of these cell lines 
suggestive of a reduction in the number of cells per colony. Combining PRS110 with 
neratinib and saracatinib did not enhance the effects of PRS110. Anchorage independent 
growth, invasion and migration were also tested but no significant sensitivity was 
observed in majority of the cell lines. The CAL-85-1 cell lines showed some sensitivity 
in both proliferation and invasion assays, although the effects did not achieve statistical 
significance. In invasion assays the combination of PRS110 and neratinib showed a 
trend towards significance with a p value of 0.07 in the CAL-85-1 cell line.  
Unfortunately, the CAL-85-1 did not form colonies in either 3D anchorage independent 
growth and the no. of colonies formed in clonogenic assays was too low to be 
interpreted accurately in response to treatment so we could not interpret results from 
these assays. We examined phosphorylation levels of seven RTKs in the CAL-85-1 
treated with PRS110 and neratinib. This once again confirmed the efficacy of PRS110 
which caused a reduction in p-Met levels. Interestingly neratinib not only caused a 
decrease in the HER family members as well as a marked reduction in c-Met.  
Finally despite disappointing results from c-Met inhibition as a single agent and in 
combination with EGFR and c-Src we tried inhibitors which combine inhibition of other 
RTKs implicated in TNBC and prospective candidates suggested from the literature. 
BMS777607 only caused inhibition above 50% in two cell lines while crizotinib 
showed no response in four cell lines tested. Due to this lack of response to crizotinib 
we found it redundant to continue to test the rest of the panel.  
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Chapter 6 
c-Met inhibition in a dasatinib resistant TNBC cell line 
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6.1 Introduction 
Dasatinib is a multi-targeted tyrosine kinase inhibitor whose targets include BCR/Abl 
and Src family kinases. Pre-clinical work by Finn et al.  suggested that basal-like breast 
cancer cell lines show higher sensitivity to dasatinib than luminal cell lines and suggest 
dasatinib as a potential targeted treatment for TNBC [192]. However, as a single agent 
in phase 2 clinical trials, dasatinib, showed limited efficacy in unselected TNBC and is 
currently being tested in combination with chemotherapeutics and additional targeted 
therapies [220, 256]. Previous work by Dr. Brendan Corkery in our laboratory led to the 
development and characterisation of a dasatinib resistant variant of the MDA-MB-231 
cell line designated 231-DasB. The cell line was developed by constant exposure to 
incrementally increasing concentrations of dasatinib, from 200 nM to 500 nM over a 
period of 13 weeks. The 231-DasB cells show constitutive activation of c-Src even in 
the presence of dasatinib. Given the direct links between c-Src and c-Met we examined 
whether c-Met could potentially play a role in acquired resistance to dasatinib in TNBC.  
6.2 Phosphorylated Src in MDA-MB-231 and 231-DasB cell lines 
231-DasB and parental MDA-MB-231 were treated with 100 nM Dasatinib for 6 hours. 
MDA-MB-231 cells show a significant reduction in levels of p-Src compared to 231-
DasB cells (p=0.0004) in agreement with results previously presented by Dr. Brendan 
Corkery (Figure 6 - 1). The 231-DasB cells show constitutive activation of p-Src 
(Y418) even in the presence of dasatinib. 231-Das B cells show limited response to 
dasatinib at concentrations up to 10 µM, whereas the dasatinib IC50 is 0.005 ± 0.0004 
µM in MDA-MB-231. The Src family kinases consist of 9 family members with high 
conservation between family members at Y418. We examined phosphorylation of seven 
of these proteins using magnetic multiplex. In agreement with the western blots the 
MDA-MB-231 showed a significant reduction in p-Src. p-FYN, p-YES and p-LYN also 
show reductions (although not statistically significant) in phosphorylation after 
treatment with dasatinib.  In the 231-DasB, treatment with dasatinib resulted in no 
decrease in phosphorylation of any of the Src proteins examined (Figure 6 - 2).  
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Figure 6 - 1a) Western blotting of MDA-MB-231 and 231-DasB treated with 
100nM Dasatinib (D) for 6hrs b) Densitometry analysis of immunoblots of MDA-
MB-231 and 231-DasB treated with 100nM Dasatinib. c) Dose response curves of 
MDA-MB-231 and 231-DasB treated with serially decreased concentrations of 
dasatinib from 10 µM. Error bars represent the standard deviations of 
independent biological triplicates. ***= p< 0.001  
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Figure 6 - 2 Phosphorylation of Src family kinases as determined by multiplex 
bead assay in MDA-MB-231 and 231-DasB cell lines with and without 6hr 
dasatinib treatment (100 nM). Error bars represent the standard deviations of 
triplicate independent experiments except for SRC values for MDA-MB-231, 
which is standard error of two independent experiments.  
 
6.3 c-Met in 231-DasB cell line 
Constitutive phosphorylation of the Src family kinases (SFKs) in the 231-DasB cell line 
was observed as described above. Increased activation of RTKs up-stream of SFKs may 
contribute to this activation. The phosphorylation status of five candidate RTKs (c-Met, 
EGFR, HER2, IGFIR, and IR was examined. c-Met (panTYR) was the only RTK to 
show any alteration in phosphorylation in the 231-DasB cells. 231-DasB cells show 
significantly higher levels of p-Met (p= 0.004) compared to the MDA-MB-231 (Figure 
6 – 3). 
Given the increased activation of p-Met in the 231-DasB cell line we hypothesised this 
may lead to an increased sensitivity to c-Met inhibition. 231-DasB is more sensitive to 
CpdA with an IC50 of 2.1 ± 0.1 µM compared to the MDA-MB-231 cells where CpdA 
has an IC50 of 3.5 ± 0.2 µM.  The combination of CpdA and dasatinib resulted in 
significantly decreased growth in the MDA-MB-231 (p=0.02), however no significant 
effect of the combination was observed in 231-DasB cells. In a fixed ratio combination 
CpdA and Dasatinib show synergism with a combination index (CI) value of 0.8 ± 1.3 
(Figure 6 – 4). Dr. Brendan Corkery previously described how 231-DasB showed no 
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significant response to dasatinib compared to MDA-MB-231 in invasion assays. We 
confirmed this result and examined the effect of CpdA and the combination of CpdA 
and dasatinib in MDA-MB-231 and 231-DasB. No significant response was seen to 
CpdA however the combination resulted in significantly (p=0.002) decreased invasion 
in the MDA-MB-231 cell line. No significant response was observed in the 231-DasB 
cell line (Figure 6 - 5). We examined the phosphorylation of the SFKs after treatment 
with CpdA. No significant change is observed in the parental MDA-MB-231 in 
response to treatment, however six of the eight p-SFKs show a significant reduction in 
phosphorylation in 231-DasB. FYN, YES, LCK, LYN, FGR and BLK all show 
significant reductions in phosphorylation (p= 0.02, 0.02, 0.009, 0.003 and 0.02) in 
response to CpdA treatment (5 µM) (Figure 6 – 6).  
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Figure 6 - 3 Phosphorylation of four RTKs in the MDA-MB-231 and 231-DasB cell 
lines. Error bars are standard deviations of independent biological triplicates. 
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Figure 6 - 4 a) MDA-MB-231 and 231-DasB dose response curves with serially 
decreasing concentrations of CpdA from 5 µM. b) Fixed concentration 
proliferation assays at 50 nM dasatinib and 2.5 µM in MDA-MB-231 and 231-
DasB cell lines. c) Fixed ratio combination of serially decreasing concentrations of 
dasatinib (from 100 nM) and CpdA (from 5 µM) in MDA-MB-231 cell line * = p< 
0.05 Error bars represent the standard deviation of independent biological 
experiments.  
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Figure 6 - 5 Representative images of invasion assays on top either untreated or 
with dasatinib (100 nM) or CpdA (5 µM) as described. % invasion relative to 
untreated control is shown below. ** = p < 0.01 Error bars represent the standard 
deviations of triplicate independent experiments.  
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Figure 6 - 6 Phosphorylation of SFKs in MDA-MB-231 and 231-DasB in response 
to dasatinib 100 nM treatment and CpdA (5 µM) where NET MFI is net median 
fluorescence intensity. * = p<0.05, ** = p< 0.01 Error bars represent the standard 
deviations of triplicate independent experiments. 
6.4 c-Met in MDA-MB-468 cetuximab resistant cell line MDA-MB-468CR 
To examine whether the increased sensitivity to c-Met inhibition was potentially a 
common consequence of resistance in triple negative breast cancer, we obtained the 
MDA-MB-468CR and the parental MDA-MB-468 cell from the laboratory of Dr. 
Anthony Kong, University of Oxford. The MDA-MB-468CR cell line was developed 
by chronic exposure to cetuximab. At 100 µg/mL, the parental MDA-MB-468 showed a 
significant reduction in growth with 45.7 ± 4.2% growth inhibition compared to 0.1 ± 
4.8% in the MDA-MB-468CR cell line (Figure 6 – 7). The MDA-MB-468Cr showed a 
higher sensitivity to CpdA with IC50 of 2.1 ± 0.2 µM compared to 3.0 ± 0.3 µM in the 
MDA-MB-468 parental. Combination assays of CpdA and cetuximab showed a modest 
but not statistically significant (p=0.18) decrease in the MDA-MB-468 cell line with 
10.7 ± 6.2% decrease in growth compared CpdA as a single agent. The MDA-MB-
468CR cell line also showed a decrease in the combination with 4.1 ± 2.1 % decrease in 
growth in the combination. The combination of cetuximab and CpdA in a fixed ratio 
combination in MDA-MB-468 parental cell line resulted in a synergistic combination 
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Figure 6 – 7 MDA-MB-468 and MDA-MB-468CR proliferation after 5 day 
treatment with 100 µg/mL cetuximab.  
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Figure 6 - 8 a) Dose response curves of MDA-MB-468 and MDA-MB-468CR 
treated with CpdA at serially decreasing concentrations from 10 µM b) fixed 
concentration combination of Cetuximab and CpdA in MDA-MB-468 and MDA-
MB-468CR cell lines. c) Fixed ratio combinations of cetuximab MDA-MB-468 and 
MDA-MB-468CR. 
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6.5 Summary 
231-DasB cells are resistant to dasatinib up to 10 µM and show constitutive Src 
phosphorylation. No significant inhibition of phosphorylation of the SFK members 
tested was observed. 231-DasB cells show increased p-Met and sensitivity to CpdA. 
Treatment with CpdA in 231-DasB cells results in significantly decreased 
phosphorylation of FYN, YES, LCK, LYN, FGR and BLK in contrast to the parental 
cell line. Combinations of CpdA and dasatinib in MDA-MB-231 results in synergistic 
activity of the compounds on proliferation, whereas the combination does not show 
activity in 231-DasB. Similarly in invasion assays the combination in MDA-MB-231 
significantly reduces invasion greater than either agent alone, with no significant effect 
in 231-DasB cell line. The MDA-MB-468CR cell line behaves in a similar fashion with 
greater sensitivity to CpdA than the parental cell line and the combination in the 
parental cell line results in a synergistic reduction in proliferation in the parental cell 
line but not in the resistant variant.  
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Chapter 7 
Novel receptor tyrosine kinases associated with TNBC 
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7.1 Introduction 
Receptor tyrosine kinases (RTKs) are a large family of proteins involved in cell to cell 
signalling eliciting responses in growth, differentiation, adhesion, cell motility and 
death. Of the 90 tyrosine kinases identified 58 have been classified as receptor type. 
These 58 receptors can be sub-divided into 20 families [62]. A number of families of 
RTKs have been implicated in the development of many cancers including HER and 
IGFR families through over-expression, amplification and/or aberrant signalling of the 
RTKs [257]. This has led to the development of many target specific drugs in the form 
of monoclonal antibodies (mAbs) and small molecule inhibitors. Using an algorithm 
which combines gene expression data from 21 DNA microarray experiments and 
detailed clinical data to correlate outcome with gene expression levels we correlated the 
expression of each of the 58 RTKs (as described in Appendix 1) in the basal-like 
subtype (defined using 3 sets of classifiers (PAM50, ssp2003 and ssp2006)) in relation 
to the parameters disease free survival (DFS) and overall survival (OS).  
Levels of RTK expression were subdivided into 3 groups; the high expression group 
consisting of those patients present in 75th percentile and above, the median group and 
the low group consisting of expression levels in the 25th percentile and below. The 
creation of the algorithm and survival analysis was carried out by Dr. Stephen Madden 
(DCU). Using a significance cut-off of p<0.05 in a minimum of 2/3 sets of classifiers 
we identified RTKs which may play a role in the development/progression of basal-like 
breast cancer.  
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7.2 RTKs associated with poor prognosis 
7.2.1 Overview of RTKs implicated in basal-like/TNBC 
Using the three cut-offs described above, median expression, greater than the 75th 
percentile referred to as the 'high' cut-off and less than the 25th percentile referred to as 
the 'low' cut-off, six RTKs were implicated in a poor prognosis; FGFR1, FGFR3, 
VEGFR1, PDGFRβ, ROS, TIE1 and EPHA5 (Table 7 - 1). 
Table 7 - 1 RTKs associated with poor prognosis 
RTK DFS OS 
FGFR1 High + low  
FGFR3  Median 
VEGFR1  High 
PDGFRβ High + Median High + Median 
TIE1  Median 
EPHA5 Median Median 
ROS1 Median  
7.2.2 FGFR1 
Using the 25th percentile (i.e. low cut-off group) for stratification, high expression of 
FGFR1 was associated with significantly decreased DFS using PAM50, ssp2003 and 
ssp2006 (p-value =0.004, 0.039 and 0.022) with hazard ratios of 1.67, 1.46 and 1.44 
respectively (Figure 7 - 1). When stratified using the high group FGFR1 was also 
associated with a significantly decreased DFS in PAM50, ssp2003 and ssp2006 (p= 
0.008, 0.009 and 0.009) with hazard ratios of 1.58, 1.53 and 1.58 respectively (Figure 7 
- 2).  
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Figure 7 - 1 Kaplan Meier survival curves based on a) PAM50 classifier n= 376 
high/low expression b) ssp 2003 n= 349 high/low expression c) ssp 2006 n= 456 
high/low expression classifier demonstrating significant decrease in DFS with high 
expression of FGFR1.  
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Figure 7 - 2 Kaplan Meier survival curves based on a) PAM50 classifier (n = 376) 
b) ssp 2003 classifier n= 349 and c) ssp2006 n= 456 demonstrating significant 
decrease in DFS with high expression of FGFR1. 
 
7.2.3 FGFR3 
High expression of FGFR3, using the median cut-off was associated with significantly 
decreased OS in PAM50 and ssp2006 (p-value = 0.041 and 0.013) with hazard ratios of 
1.579 and 1.67 respectively (Figure 7 - 3).  
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Figure 7 - 3 Kaplan Meier survival curve based on a) PAM50 classifier (n= 211) b) 
ssp 2006 classifier (n=250) demonstrating significant decrease in OS with high 
expression of FGFR3.  
 
7.2.4 VEGFR1 
High expression of VEGFR1, using the high group as a cut-off, was associated with 
significantly decreased OS using PAM50, ssp 2003 and ssp2006 (p-value = 0.015, 
0.008 and 0.006) with hazard ratios of 1.85, 1.97 and 1.86 respectively (Figure 7 - 4). 
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Figure 7 - 4 Kaplan Meier survival curve based on a) PAM50 classifier (n=179) b) 
ssp 2003 classifier (n=176) c) ssp 2003 classifier (n=211) demonstrating significant 
decrease in OS with high expression of VEGFR1. 
 
7.2.5 PDGFRβ 
Based on stratification using the 75th percentile, high expression of PDGFRβ was 
associated with significantly decreased DFS using PAM50, ssp 2003 and ssp 2006 (p-
value = 0.00005, 0.001 and 0.005) with hazard ratios of 2.07, 1.87, and 1.80 
respectively (Figure 7 - 5). Using the median for stratification, high expression of 
PDGFRβ was also associated with significantly decreased DFS using PAM50, ssp 2003 
and ssp 2006 (p-value = 0.001, 0.032 and 0.001) with hazard ratios of 1.66, 1.45 and 
1.59 respectively (Figure 7 - 6). Finally high expression of PDGFRβ using the median 
cut-off was associated with significantly decreased OS using PAM50, ssp 2003 and ssp 
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2006 (p-value = 0.005, 0.013 and 0.005) with hazard ratios of 2.17, 2.47 and 2.04 
respectively (Figure 7 - 7). 
 
Figure 7 - 5 Kaplan Meier survival curves based on a) PAM50 classifier (n= 387) b) 
ssp 2003 classifier (n=361) c) ssp 2006 classifier (n=465) demonstrating significant 
decrease in DFS with high expression of PDGFRβ. 
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Figure 7 - 6 Kaplan Meier survival curves based on a) PAM50 classifier (n=387) b) 
ssp 2003 classifier (n=361) c) ssp 2006 classifier (n=465) demonstrating significant 
decrease in DFS with high expression of PDGFRβ.  
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Figure 7 - 7 Kaplan Meier survival curve based on a) PAM50 classifier (n=211) b) 
ssp 2003 classifier (n=129) c) ssp 2006 classifier demonstrating significant decrease 
in OS with high expression of PDGFRβ. 
 
7.2.6 TIE1 
High expression of TIE1 using the median cut-off, was associated with significantly 
decreased OS in PAM50, ssp 2003 and ssp 2006 (p-value = 0.013, 0.013 and 0.008) 
with hazard ratios of 1.73, 1.76 and 1.72 respectively (Figure 7 - 8). 
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Figure 7 - 8 Kaplan Meier survival curves based on a) PAM50 classifier (n=211) b) 
ssp 2003 classifier (n=199) high/low expression c) ssp 2003 classifier (n=250) 
high/low expression demonstrating significant decrease in OS with high expression 
of TIE1. 
 
7.2.7 EPHA5 
EPHA5 was associated with a significantly decreased DFS in PAM50, ssp2003 and 
ssp2006 (p-value =0.0003, 0.020 and 0.001) with hazard ratios of 1.87, 1.59 and 1.44 
respectively (Figure 7 - 9), using the median point for stratification. EPHA5 was 
additionally associated with significantly decreased OS using the median point in 
PAM50, ssp 2003 and ssp 2006 (p-value = 0.042, 0.011 and 0.007) with hazard ratios of 
1.77, 2.41 and 1.98 respectively (Figure 7 - 10). 
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Figure 7 - 9 Kaplan Meier survival curve based on a) PAM50 classifier (n=312) b) 
ssp 2003 classifier (n=321) c) ssp 2006 classifier (n=413) demonstrating significant 
decrease in DFS with high expression of EPHA5. 
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Figure 7 - 10 Kaplan Meier survival curve based on a) PAM50 classifier (n=312) b) 
ssp 2003 classifier n= 321 c) ssp 2006 classifier (n=413) demonstrating significant 
decrease in DFS with high expression of EPHA5. 
 
7.2.8 ROS1 
ROS1 was associated with significantly decreased DFS in ssp2003 and ssp2006 (p-
value =0.047 and 0.015) with hazard ratios of 1.42 and 1.41 respectively, using the 
median point for stratification (Figure 7 - 11). 
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Figure 7 - 11 Kaplan Meier survival curve based on a) ssp 2003 classifier (n=368) 
b) ssp 2006 classifier (n=476) classifier demonstrating significant decrease in DFS 
with high expression of ROS1. 
 
7.3 Selection of RTKs for further study 
We selected 3 RTKs for further evaluation following a literature survey of the novelty 
of the proteins in breast cancer and their function. FGFR1 is well established in the 
development and progression of breast cancer and amplification has been observed in 
approximately 10% of all breast carcinomas [258]. VEGFR1 PDGFRβ and TIE1 are 
implicated in angiogenic processes. This would suggest that anti-angiogenic therapies 
may be of benefit in TNBC however clinical trials with bevacizumab have proved 
disappointing despite initial success [259]. The FDA has withdrawn its' approval of 
bevacizumab as a treatment for metastatic breast cancer due to no significant increase in 
survival post treatment. For these reasons, we selected EPHA5, FGFR3 and ROS1 for 
further evaluation. Combining the expression of these RTKs, using the median point of 
FGFR3, expression results in an increased hazard ratio of 3.08 (p=0.0008) in overall 
survival compared to the individual survival curves. The combination does not seem to 
have an effect on DFS relative to the individual RTKs with a hazard ratio of 1.55 
(p=0.06) (Figure 7 - 12).   
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Figure 7 - 12 Kaplan Meier survival curve based on a) ssp 2006 classifier (n=422) 
b) ssp 2006 classifier (n=271) demonstrating significant decrease in OS with high 
expression of FGFR3, EPHA5 and ROS1 . 
 
7.4 QRT-PCR in TNBC cell lines and tumour samples 
We used qRT-PCR to determine mRNA expression in TNBC cell lines and a small 
number of tumour samples. We examined thirteen triple negative cell lines for mRNA 
expression of ROS1, EPHA5 and FGFR3 compared to an immortalised normal breast 
cell line MCF10a. RNA from 7/13 cell lines and MCF10a cell line was obtained from 
Mr. Bo Li, Conway Institute, UCD. ROS1 showed decreased mRNA expression in all 
TNBC cell lines relative to MCF10a, EPHA5 showed higher expression in 6/13 TNBC 
cell lines and FGFR3 showed higher expression 10/13 cell lines (Table 7 - 2).   
We analysed RNA extracted from breast tumours from 7 patients for expression of 
FGFR3 and EPHA5 (including 3 paired tumours). The CT values were compared 
against the pooled CT values of 3 normal adjacent tissue samples (Table 7 - 3). EPHA5 
was undetectable in all 7 tissue samples. FGFR3 expression was  higher in 5/7 cases (or 
8/10 individual specimens).  The CT values for FGFR3 in both the cell lines and tumour 
samples were relatively high suggesting that it may be a low abundance mRNA.  
179 
 
Table 7 - 2 Results from qRT-PCR analysis of RNA from TNBC cell lines showing 
the Ct values and fold change relative to MCF10a. UD = Undetected 
  ROS1 EPHA5 FGFR3 
Cell Line CT 
value 
Fold 
Change 
CT 
value 
Fold 
Change 
CT 
Value 
Fold 
Change 
MCF10a 23.7 33.8 35.9 
BT20 32.5 -540.7 UD 28.1 186.6 
HCC1143 33.00 -214.6 33.6 3.4 30.6 116.6 
MDA-MB-
468 26.2 -2.5 UD 34.5 6.0 
HCC38 32.5 -129.4 UD 39.3 -3.1 
CAL-85-1 36.3 -3323.9 UD UD 
HDQ-P1 32.6 -249.3 34.3 1.4 31.6 37.9 
BT549 31.8 -194.8 31.6 6.8 31.6 28.9 
HCC70 31.4 -145.3 UD 32.8 12.1 
HCC1187 31.8 -64.9 UD 34.2 14.1 
MDA-MB-
231 37.2 -3358.9 33.1 5.8 31.9 51.8 
CAL120 37.5 -8102.5 28.6 64.4 31.8 31.5 
CAL51 UD UD UD 38.2 1.7 
MDA-MB-
436 33.2 -1281.7 35.8 7.1 35.4 -1.2 
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Table 7 - 3 Results from QRT-PCR analysis of RNA from TNBC powdered 
tumour samples showing the Ct values and expression values relative to normal 
adjacent tissue. UD= undetected 
  EPHA5 FGFR3 
Tumour CT value CT Value Fold Change 
161T A1 UD UD 
151T A1 UD UD 
151T A2 UD UD 
159T A1 UD UD 
204T A1 UD 36.7 5.5 
204T A2 UD 34.5 1.6 
171T A1 UD UD 
223T A1 UD 35.6 2.6 
223T A2 UD 33.3 1.5 
154T A2 UD UD 
 
7.5 Ephrin-A4 and FGF9 effect on proliferation  
We examined whether ligands of FGFR3 and EPHA5 could potentially stimulate 
growth in TNBC cell lines through activation of their respective receptors.  We selected 
two cell lines (BT20 and MDA-MB-231) on the basis of the mRNA relative levels (see 
Table 7 - 2) and treated with appropriate concentrations as suggested by the literature. 
Both FGFR3 and EPHA5 bind multiple ligands. We chose ephrin-A4 based on survival 
data generated from BreastMark of the ephrin ligands. Ephrin-A4 was the only ephrin to 
show any significant effect on DFS ( p= 0.005, 0.0006 and 0.018) with hazard ratios of 
1.47,1.52 and 1.40 in each of the classifiers using the median point for separation into 
high and low expressers (Figure 7 - 13). No significant effect was observed in OS 
however the combination of EPHA5 and ephrin-A4 using the median point for 
stratification in ssp2006 showed a significant effect on DFS (p=0.046) and OS (p= 
0.016) with hazard ratios of 1.37 and 1.93 respectively (Figure 7 - 14).  
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No significant effect on growth was observed after 72 hrs in the BT20 treated with 
FGF9 or MDA-MB-231 treated with Ephrin-A4 however the MDA-MB-231 showed a 
trend towards increased growth with a p value of 0.059 (Figure 7 - 15)  
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Figure 7 - 13 Kaplan Meier survival curve based on a) PAM50 classifier (n=293) b) 
ssp 2003 classifier (n=273) c) ssp 2006 classifier demonstrating significant decrease 
in DFS with high expression of ephrin-A4 (n=323). 
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Figure 7 - 14 Kaplan Meier survival curve based on a) ssp2006 classifier b) ssp 
2006 classifier demonstrating significant decrease in OS with high expression of 
EPHA5 and ephrin-A4.  
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Figure 7 - 15 Proliferation assay in a) BT20 cell line treated with 100 ng/mL FGF9 
for 72hrs b) MDA-MB-231 cell line treated with 2 µg/mL Ephrin-A4 for 72hrs. 
7.6 Protein expression of EPHA5 and FGFR3 in TNBC 
We have shown above that EPHA5 and FGFR3 mRNA levels are higher in TNBC cell 
lines and tumour samples than normal breast.  We examined whether EPHA5 and 
FGFR3 protein was expressed in TNBC tumour samples using two monoclonal 
antibodies against FGFR3 and EPHA5 in formalin fixed paraffin embedded tumour 
samples in tissue-microarray format (TMA). The TMA consisted of 89 TNBC tumours 
selected randomly from St. Vincent's University Hospital Database.  
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7.6.1 TNBC tumour samples 
Little literature or guidelines exist for the immunohistochemical staining of FGFR3 or 
EPHA5. We assessed the staining using an intensity and % positivity scoring system. 
Briefly a negative score was recorded in the absence of specific staining within the 
tumour, tumours with positive staining were scored as 1+ (weak intensity), 2+ 
(moderate intensity) and 3+ (strong intensity) and % positivity was divided as follows; 
1-10%, 11-25%, 26-50%, 50-75% and >75% of cells stained.  
7.6.2 Patient characteristics  
Of the 89 tumours, 80 were suitable for examination due to lack of tumour tissue/lifting 
of cores. The patient characteristics are described in Table 7 - 4. The patients are 
predominantly older (61% >50years) with Grade 3 (85%) tumours < 2cm (54%). The 
majority of the tumours were ductal (93%) and negative for lymph node spread (56%).  
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Table 7 - 4 Patient characteristics of TNBC patients analysed (n=89) 
 
Patient age at diagnosis                                                         n                          % 
 
Age   
< 50 35 39 
> 50 
 
54 61 
Grade 
Grade 1/2 13 15 
Grade 3 
 
76 85.0 
Histological subtype 
Ductal 83 93 
Lobular 5 5.6 
Other  0 0 
Unknown 1 1 
 
Size 
<2cm 48 54 
>2cm 40 44 
Unknown 1 1 
 
LN Status 
Negative 50 56 
Positive 38 43 
Unknown 1 1 
 
LVI 
Negative 44 50 
Positive 44 50 
Unknown 1 1 
 
 
7.6.3 FGFR3 and EPHA5 expression in TNBC patients 
TMAs containing 89 TNBC tumours were obtained from St. Vincent's University 
Hospital and stained for FGFR3 and EPHA5. For staining 80 and 81 tumours were 
suitable for analysis in FGFR3 and EPHA5 stained sections respectively. The samples 
were unsuitable due to lack of tumour tissue or lifting of cores from slides. Each patient 
sample consisted of four cores/case however it must be noted that 25 of the 80 (for 
FGFR3) and 37 of the 81 (for EPHA5) cases analysed were either missing at least one 
core or no tumour tissue remained within one or more of the cores. This is due to the 
lack of material left on the TMA blocks after numerous cuttings. 
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For FGFR3 staining we observed cytoplasmic and nuclear staining in 66% and 43% of 
tumours respectively. Representative images of the staining observed are shown in 
Figure 7 - 16. No significant association is seen with any of the prognostic indicators 
with % positivity or intensity in the tumours positive for cytoplasmic FGFR3 (Table 7 – 
5, Table 7 – 6). A significant association with was seen with nuclear staining and 
histological subtype in both % positivity and intensity (p= 0.0453 and <0.0001) 
however after adjusting the p value for multiple testing using the Bonferroni Correction 
Method, the association between % positivity and histological subtype no longer 
achieved significance levels (p= 0.2718) (Table 7 – 7, Table 7 – 8). There is a 
statistically significant association between intensity of nuclear FGFR3 staining and 
histological subtype (p <0.0006). For survival curves any positive staining either 
cytoplasmic or nuclear was given a score of one. When we examined five year 
recurrence and 5 year survival between the FGFR3 positive and FGFR3 negative groups 
no significant difference was observed between the groups (Figure 7 - 18).  
For EPHA5 staining we observed both cytoplasmic (43%) and membrane staining 
(17%). Focal nuclear staining was also noted in 6 of 81 cases examined. Representative 
images of staining observed can been seen in Figure 7 - 17. No significant association is 
seen with any of the prognostic indicators with % positivity or intensity in the tumours 
positive for cytoplasmic EPHA5 (Table 7 – 9, Table 7 – 10). There is a significant 
association between membrane staining and age with both levels of positivity and 
intensity (adj p= 0.0126 and 0.0204) (Table 7 – 11, Table 7 – 12). Similarly to FGFR3, 
tumours were given a score of one for the presence of specific staining in survival 
studies. The resultant survival curves generated for EPHA5 positive and negative 
tumours show no significant differences in either 5 year recurrence or survival (Figure 7 
- 19) 
Finally we compared the cases which stained positive for both FGFR3 and EPHA5. 
Any positive staining of either marker was recorded as a positive tumour. No significant 
association was seen between co-staining of FGFR3 and EPHA5 and the patient 
prognostic indicators (Table 7 – 13). Additionally co-positivity of FGFR3 and EPHA5 
did not have a significant effect on either 5 year recurrence or 5 year survival (Figure 7 - 
20). 
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Figure 7 - 16 Representative Pictures of FGFR3 with a) TNBC positive control 
(LHS) and TNBC with blocking peptide (RHS) b) weak cytoplasmic staining in 50-
75% of cells (RHS) and moderate cytoplasmic staining in >75% cells and c) weak 
nuclear staining in <10% cells (RHS) and moderate nuclear staining >10% of cells. 
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Figure 7 - 17 Representative Pictures of EPHA5 with a) TNBC positive control 
(LHS) and TNBC with blocking peptide (RHS) b) weak cytoplasmic staining in 25-
50% of cells (RHS) and moderate cytoplasmic staining in 10-25% cells and c) 
moderate membrane staining in <10% cells (RHS) and strong membrane staining 
in >10% cells. 
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Table 7 - 5 Cytoplasmic FGFR3 positivity and patient prognostic indicators. P 
values were calculated using Chi square test 
 Neg 0-10% 10-25% 26-50% 51-75% >75% P value 
Patient age at diagnosis 
< 50 10 0 3 6 9 1  
> 50 
 
17 2 9 11 9 3 0.6234 
Grade 
Grade1/2 3 1 3 0 3 1  
Grade 3 
 
24 1 9 17 15 3 0.2022 
Histological subtype 
Ductal 24 2 11 16 19 3  
Lobular 2 0 1 0 0 1 0.3139 
Unknown 
 
1 0 0 0 0 0  
Size 
<2cm 12 2 7 5 12 1  
>2cm 15 0 4 11 7 3 0.1732 
Unknown 
 
0 0 1 0 0 0  
LN Status 
Negative 16 0 3 8 8 2  
Positive 11 2 8 8 11 2 0.3716 
Unknown 
 
0 0 1 0 0 0  
LVI 
Negative 19 2 7 6 7 3  
Positive 8 0 5 9 12 1 0.1159 
Unknown 0 0 0 1 0 0  
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Table 7 - 6 Cytoplasmic FGFR3 intensity and patient prognostic indicators. P 
values were calculated using Chi Square test.  No tumour had a score of greater 
than 2+ (i.e. 3+) 
Cytoplasmic Neg 1+ 2+ P value 
Patient age at diagnosis    
< 50 10 8 12  
> 50 
 
17 23 10 0.1034 
Grade     
Grade 1/2 3 5 3  
Grade 3 24 25 19 0.8319 
Unknown 
 
0 1 0  
Histological subtype    
Ductal 24 29 22  
Lobular 2 2 0 0.4336 
Unknown 
 
1 0 0  
Size     
<2cm 12 13 15  
>2cm 15 17 7 0.1523 
Unknown 
 
0 1 0  
LN Status     
Negative 16 17 9  
Positive 11 13 13 0.3911 
Unknown 
 
0 1 0  
LVI     
Negative 19 19 11  
Positive 8 11 11 0.4399 
Unknown 0 1 0  
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Table 7 - 7 Nuclear FGFR3 positivity and patient prognostic indicators. P values 
were calculated using Chi Square test. Adjusted P values are calculated using 
Bonferroni Calculation 
 Neg 0-10% >10% p value adj P 
Patient age at diagnosis    
< 50 17 9 2    
> 50 
 
29 18 5 0.9663   
Grade       
Grade 1/2 6 3 2    
Grade 3 40 23 5 0.9431   
Unknown 
 
0 1 0    
Histological subtype    
Ductal 45 24 5    
Lobular 0 3 2 0.0453 0.2718  
Unknown 
 
1 0 0    
Size       
<2cm 24 13 2    
>2cm 22 13 5 0.6552   
Unknown 
 
0 1 0    
LN Status       
Negative 20 12 5    
Positive 26 14 2 0.5346   
Unknown 
 
0 1 0    
LVI       
Negative 25 12 4    
Positive 20 15 3 0.6652   
Unknown 1 0 0    
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Table 7 - 8 Nuclear FGFR3 intensity and patient prognostic indicators. P values 
were calculated using Chi Square test. Adjusted P values are calculated using 
Bonferroni Calculation. 
 Neg 1+ 2+ 3+ p value adj P 
Patient age at diagnosis      
< 50 17 6 7 0   
> 50 
 
29 11 8 1 0.8414  
Grade       
Grade 1/2 6 2 2 0   
Grade 3 40 14 13 1 0.9849  
Unknown 
 
0 1 0 0   
Histological subtype 
Ductal 45 14 15 0   
Lobular 0 3 0 1 <0.0001 <0.0006 
Unknown 
 
1 0 0 0   
Size       
<2cm 24 9 7 0   
>2cm 22 7 8 1 0.7064  
Unknown 
 
0 1 0 0   
LN Status       
Negative 20 9 7 1   
Positive 26 7 8 0 0.5619  
Unknown 
 
0 1 0 0   
LVI       
Negative 25 8 8 1   
Positive 20 9 7 0 0.7939  
Unknown 1 0 0 0   
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a)
b)
 
Figure 7 - 18 Kaplan Meier analysis of TNBC tumours with high (red) and low 
(black)  expression for FGFR3 staining by immunohistochemistry in relation to a) 
months to recurrence b) five year survival. 
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Table 7 - 9 Cytoplasmic EPHA5 positivity and patient prognostic indicators. P 
values are calculated using Chi Square Test. 
 Neg 0-10% 10-25% 26-50% 51-75% >75% P 
Patient age at diagnosis 
< 50 18 1 4 3 3 2 0.3738 
> 50 
 
28 3 1 8 8 2  
Grade 
Grade1/2 7 0 0 3 1 0 0.5365 
Grade 3 38 4 5 8 10 4  
Unknown 
 
1 0 0 0 0 0  
Histological subtype 
Ductal 44 3 5 10 10 4 0.3749 
Lobular 1 1 0 1 1 0  
Unknown 
 
1 0 0 0 0 0  
Size 
<2cm 24 1 3 3 5 3 0.4514 
>2cm 21 3 2 8 6 1  
Unknown 
 
1 0 0 0 0 0  
LN Status 
Negative 26 2 0 5 6 0 0.0691 
Positive 19 2 5 6 5 4  
Unknown 
 
1 0 0 0 0 0  
LVI 
Negative 29 2 0 6 7 2 0.1519 
Positive 16 2 5 5 4 2  
Unknown 1 0 0 0 0 0  
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Table 7 - 10 Cytoplasmic EPHA5 intensity and patient prognostic indicators. P 
values are calculated using Chi Square Test. 
 0 1+ 2+ 3+ P 
Patient age at diagnosis 
< 50 18 10 2 1  
> 50 
 
28 20 2 0 0.5379 
Grade      
Grade 1/2 7 3 1 0  
Grade 3 38 27 3 1 0.7854 
Unknown 
 
1 0 0 0  
Histological subtype 
Ductal 44 28 3 1  
Lobular 1 2 1 0 0.2282 
Unknown 
 
1 0 0 0  
Size 
<2cm 24 12 3 0  
>2cm 21 18 1 1 0.3405 
Unknown 
 
1 0 0 0  
LN Status 
Negative 26 14 1 1  
Positive 19 16 3 0 0.3871 
Unknown 
 
1 0 0 0  
LVI 
Negative 29 15 2 1  
Positive 16 15 2 0 0.4977 
Unknown 1 0 0 0  
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Table 7 - 11 Membrane EPHA5 positivity and patient prognostic indicators. P 
values were calculated using Chi Square test. Adj P was calculated using the 
Bonferroni Method. 
 Neg <10% >10% P adj P 
Patient age at diagnosis 
< 50 20 8 3   
> 50 
 
47 3 0 0.0021 0.0126 
Grade 
Grade 1/2 10 1 0   
Grade 3 56 10 3 0.674  
Unknown 
 
1     
Histological subtype 
Ductal 62 10 4   
Lobular 3 1 0 0.7341  
Unknown 
 
1 0 0   
Size 
<2cm 31 7 1   
>2cm 35 4 2 0.5105  
Unknown 
 
1 0 0   
LN Status 
Negative 34 7 1   
Positive 32 4 2 0.6021  
Unknown 
 
1 0 0   
LVI 
Negative 40 6 1   
Positive 26 5 2 0.5509  
Unknown 1 0 0   
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Table 7 - 12 Membrane EPHA5 intensity and patient prognostic indicators. P 
values were calculated using Chi Square test. Adj P was calculated using the 
Bonferroni Method. 
 Neg 1+ 2+ 3+ P adj P 
Patient age at diagnosis 
< 50 20 3 5 3   
> 50 
 
47 0 3 0 0.0034 0.0204 
Grade       
Grade 1/2 10 0 1 0   
Grade 3 56 3 7 3 0.7828  
Unknown 
 
1 0 0 0   
Histological subtype      
Ductal 62 3 8 3   
Lobular 3 0 1 0 0.7907  
Unknown 
 
1 0 0 0   
Size       
<2cm 31 3 4 1   
>2cm 35 0 4 2 0.3172  
Unknown 
 
1 0 0 0   
LN Status       
Negative 34 2 3 2   
Positive 32 1 5 1 0.7583  
Unknown 
 
1 0 0 0   
LVI       
Negative 40 1 3 2   
Positive 24 2 5 1 0.4331  
Unknown 3 0 0 0   
 
199 
 
a)
b)
 
Figure 7 - 19 Kaplan Meier analysis of TNBC tumours with high (red) and low 
(black)  expression of EPHA5 staining by immunohistochemistry in relation to a) 
months to recurrence b) five year survival. 
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Table 7 - 13 Co-positivity for FGFR3 and EPHA5 and patient prognostic 
indicators. P values were calculated using Fishers Exact Test.  
 Neg Pos P 
Patient age at diagnosis 
< 50 14 16  
> 50 
 
30 20 0.2579 
Grade 
Grade 1/2 7 4  
Grade 3 36 32 0.7457 
Unknown 
 
1 0  
Histological subtype 
Ductal 42 33  
Lobular 1 3 0.3257 
Unknown 
 
1 0  
Size 
<2cm 21 17  
>2cm 22 19 1 
Unknown 
 
1 0  
LN Status 
Negative 28 19  
Positive 15 17 0.3578 
Unknown 
 
1 0  
LVI 
Negative 25 16  
Positive 18 20 0.2631 
Unknown 1 0  
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a)
b)
 
Figure 7 - 20 Kaplan Meier analysis of TNBC tumours with high (red) and low 
(black) expression of FGFR3 and EPHA5 by immunohistochemistry in relation to 
a) months to recurrence b) five year survival. 
 
7.7 Summary 
The RTKs associated with decreased DFS included EPHA5, FGFR1 and PDGFRβ.  
EPHA5 was significant in 3 classifiers. FGFR1 was significant using both the 75th and 
25th percentile for stratification in 2/3 and 3/3 classifiers respectively. PDGFRβ was 
significant at the 75th and median percentile in 3 classifiers. RET was significant in 2/3 
classifiers. Of the 58 RTKs examined in the Basal-like subtype expression of EPHA5, 
FGFR3, VEGFR1, PDGFRβ and TIE1 showed significance associated with decreased 
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OS. EPHA5, VEGFR1, PDGFRβ and TIE1 were significant in all 3 classifiers and 
FGFR3 was significant in 2/3.  
After selection of RTKs for follow-up, mRNA expression of FGFR3 was upregulated in 
10/13 TNBC cells lines relative to a normal immortalised breast epithelial cell line. 
EPHA5 mRNA was significantly up-regulated in 6/13 cell lines. Ligands of FGFR3 and 
EPHA5 also had no significant effect on the growth on the BT20 and MDA-MB-231 
cell lines respectively.  
FGFR3 also showed mRNA upregulation in 5/7 tumour samples relative to pooled 
adjacent normal tissue. EPHA5 mRNA was not detectable in the TN tumours tested.  
Using immunohistochemistry we detected the mature proteins of FGFR3 and EPHA5 in 
TNBC tumour tissue. In agreement with the RNA results FGFR3 was detected in the 
majority of TNBC tumours. FGFR3 was localised to the cytoplasm and nucleus with 
positive staining in 66% and 43% respectively. FGFR3 nuclear staining was 
significantly associated with histological subtype with an adj p value of <0.0006. 
Cytoplasmic and membrane EPHA5 were detected in 43% and 17% of TNBC tumours. 
Membrane staining of EPHA5 was significantly associated with age (adj p= 0.0126 and 
0.0204). Neither protein had a significant effect on 5 year recurrence or 5 year survival 
in this cohort of patients.  
The combined expression of FGFR3 and EPHA5 has no significant association with the 
patient prognostic indicators, or 5 year recurrence and 5 year survival examined in this 
study.   
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Chapter 8 
Discussion 
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8.1 Introduction 
Triple negative breast cancer (TNBC) represents approximately 15% of all breast 
cancers. It is a subtype of a heterogeneous disease which not only carries a poorer 
prognosis than other subtypes, but patients are significantly younger, with more 
advanced disease when diagnosed [16]. TBNC is defined as tumours lacking expression 
of ER, PR and without over-expression of HER2, rendering current targeted therapies 
(e.g. tamoxifen and trastuzumab) redundant. Although c-Met expression has been 
associated with TNBC and been implicated in the development of BL tumours in mouse 
models, it has not been extensively evaluated as a therapeutic target for TNBC [81]. 
Crosstalk between EGFR and c-Met mediated through Src has been reported in 
numerous cancer types [251, 260, 261]. This cross-talk between c-Met, EGFR and Src 
has been implicated in cancer progression and drug resistance in TNBC. Therefore we 
examined c-Met expression in TNBC cell lines and tumour samples, and tested c-Met 
inhibition alone and in combination with EGFR and Src inhibition in TNBC cell lines. 
8.2 c-Met/HGF expression in TNBC 
8.2.1 Tumour samples 
Reports of c-Met expression levels in breast tumour samples have varied widely ranging 
from 36 -100% positivity [138, 140, 149, 152-154, 161, 162]. In our cohort was c-Met 
expression was detected in 44% of TNBC compared to 26% of non-TNBC.  The 
varying levels of positivity reported may stem from different methods of detection and 
differing cut-off points for determination of positivity. Tuck et al. determined 100% 
positivity with ISH and an immunoperoxidase technique [140]. Raghav et al. 
demonstrated 100% positivity of both total Met and p-Met in the triple negative subtype 
using a RPPA technique which involved snap freezing of fine needle aspirates [152].  
Despite being a membrane bound protein no membrane staining was observed in our 
study. Specificity of the antibody was confirmed using a blocking peptide. It may have 
been beneficial to test the tumour samples with the companion diagnostic antibody 
(Ventana) currently used in conjunction with c-Met monoclonal antibody MetMab.  
Membrane staining has been noted in cases of DCIS on the apical cell membrane and 
was also demonstrated in breast carcinomas tested using the same antibody and similar 
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conditions [138, 154]. In a large cohort of Korean women, the staining identified via 
immunohistochemistry was predominately membrane staining with only weak 
cytoplasmic staining [185].The antibody used in the study described above was the  
companion diagnostic for MetMab mentioned above and is targeted at a C-terminal site 
in the c-Met protein. Cytoplasmic staining has been observed in multiple studies but 
only three report cytoplasmic staining separately [153, 161, 162, 167, 168]. 
Cytoplasmic c-Met has shown a significant association with HER2 expression and 
tumour metastases in node negative breast cancer patients [153, 168]. Contradicting 
results exist for the evaluation of membrane staining and cytoplasmic staining. Lengyel 
et al. states that cytoplasmic staining for c-Met can be used as a prognostic indicator; 
however the combination of c-Met membrane and cytoplasmic staining is the strongest 
prognostic indicator for survival over either staining pattern alone in this study. Kang et 
al. noted that antibodies targeting intracellular c-Met were significantly more prognostic 
than those directed against extracellular c-Met, suggesting that the cytoplasmic c-Met 
tail may play a more significant role in breast cancer progression than the extracellular 
domain [162]. Discordance between c-Met antibodies of the C- and N- terminal has also 
been reported previously in a separate study in gastric cancer [232]. Potentially 
discordance between C- and N- terminal antibodies may be due to sMet described 
below in Section 8.5 
 
Over-expression of c-Met was not significantly associated with overall survival in our 
study.  High over-expression of both c-Met and HGF has been previously associated 
with poorer overall survival in breast cancer [152, 153, 161]. Two studies have also 
examined expression of c-Met in primary breast tumours and lymph nodes. Both these 
studies conclude that c-Met expression is higher in lymph node metastases than primary 
tumours and this correlates with poor survival outcome.  Both also note highly 
heterogeneous patterns of expression which may be related to higher intensity noted in 
leading edge of the tumour in DCIS and in breast carcinomas [140, 153, 154, 161]. In 
studies where the data is available, tumours with higher expression of c-Met relative to 
adjacent normal tissue tend to have a poorer prognosis than those with similar staining 
patterns. This is a limitation of using the TMA format as we did not have sufficient 
representation of normal tissue in cores to compare expression in tumour and normal 
tissue. The TMA format also does not allow examination of specific staining at the 
leading edge of the tumour. 
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While expression of the total protein has proved to be an invaluable marker for certain 
disease types e.g. HER2 overexpression significantly associates with decreased survival 
and is a biomarker for sensitivity to trastuzumab in breast cancer, expression of certain 
total proteins e.g. EGFR in NSCLC does not show any prognostic significance. A 
theory evolved that more important information could be derived from the activation 
state of the protein and not expression alone. The advent of phospho-specific antibodies 
in the 1980s allowed people to examine phosphorylation in FFPE, however the results 
were discordant. Using EGFR as an example, EGFR and p-EGFR were examined in a 
cohort of glioma patients. Despite high EGFR expression, p-EGFR was only observed 
in 1/3 of tumours and had no prognostic significance [262]. Additionally in a breast 
cancer cohort 54% of patients showed phosphorylation of EGFR with no association 
between prognostic indicators or survival. Interestingly here p-EGFR did not have an 
association with the EGFR expression [263].  
 
The lack of prognostic significance of examining phospho-proteins in FFPE may be 
related to the stability of the phosphorylation group. Fixation and embedding is a 
relatively slow process allowing the continued action of endogenous phosphatases 
[264]. For phospho-proteins in tissue the preferential method seems to be snap freezing 
of tissue [152]. High p-Met has been associated with recurrence in breast cancer [249]. 
We had access to fresh frozen tissue from nine patients with 3 paired normal adjacent 
tissue samples and assessed phosphorylation using a magnetic bead multiplex assay. In 
8/9 (88.8%) of the tumours we measured detectable levels of c-Met phosphorylation. 
Where paired samples were available, higher levels of phosphorylated c-Met were 
detected in the tumour tissue compared to the normal adjacent tissue in 2 of the 3 
(66.6%) matched pairs. We do not currently have survival data for these patients; 
however given the high incidence of phosphorylation in this small sample set it would 
be interesting to expand this analysis to a larger cohort of patients with associated 
survival data to determine the prognostic significance of phospho-Met levels in TNBC. . 
The multiplex ELISA format is attractive as it facilitates analysis of multiple RTKs in 
relatively small quantities of tumour tissue. 
 
We observed a significant association between the TNBC subtype and c-Met expression 
in our cohort of patients. This is in agreement with previous studies. A previous study of 
168 tumours by immunohistochemistry found that c-Met expression correlated with the 
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absence of PR [149]. c-Met has also been independently associated with BL status, 
defined by ER/PR/HER2 negativity and positive for either CK 5/6, CK14 or EGFR 
[169]. In a study of Korean woman, c-Met significantly associated with ER and PR 
negativity, larger tumour size, and positive lymph nodes [169].  
 
We found no significant association between c-Met expression and other prognostic 
indicators. Previous studies have demonstrated associations between clinico-
pathological variables including grade, node negativity and smaller tumour size 
however these studies examine expression in general breast cancer and not specifically 
TNBC. [138, 149, 161, 167, 169]. 
  
We noted a weak association between c-Met expression levels and KI-67 percentage 
positivity (p= 0.051). KI-67 is a proliferation marker and has been shown to be an 
independent prognostic indicator for DFS in invasive breast cancers and high KI-67 
indices are seen more frequently in TNBC [265, 266]. KI-67 has previously been linked 
with c-Met expression in hepatocellular, gastric carcinomas and NSCLC [267-269]. 
8.2.2  c-Met/HGF expression in TNBC cell lines 
In our panel of TNBC cell lines both expression levels and activation of Met were 
higher in TNBC than in non-TNBC. This has been reported in panels of mixed breast 
cancer subtypes previously including 5 TNBC, 4 ER positive and 3 HER2 amplified 
[154, 185]. However to our knowledge this is the first study to report expression of c-
Met in a panel of 9 TNBC cell lines. All nine TNBC cell lines showed expression of 
total c-Met and four (BT20, HCC1937, HCC1143 and CAL-85-1) showed 
phosphorylation at the activation site Y1234/Y1235. Pan-phosphorylation was also 
detected in all nine TNBC cell lines using magnetic bead assays. As HGF is a known 
ligand of c-Met, we examined HGF expression using a human HGF ELISA and qRT-
PCR; based on the lack of detectable HGF protein or mRNA we can conclude that the 
cell lines do not produce endogenous HGF. Given the low incidence of c-Met 
amplification in TNBC we can assume that activation could be occurring through two 
potential mechanisms; ligand dependent through bovine HGF or ligand independently 
through receptor cross talk and feedback loops. The amino acid sequences in bovine 
HGF and bovine c-Met show an average of 87% consensus to the human HGF and c-
Met sequences therefore, it is probable that bovine HGF is capable of inducing 
activation of human c-Met however no information exists on the binding affinity or 
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strength of activation induced [270]. Another potential mechanism of activation is 
through cross-talk with EGFR and Src. This is discussed fully below; however EGFR 
can activate c-Met through Src causing constitutive activation. It is most likely a 
combination of both of these mechanisms which results in activation of c-Met in the 
TNBC cell lines.  
8.2.3 HGF in TNBC 
As described above we were unable to detect mature human HGF in CM via ELISA in 
two TNBC cell lines (HCC1937 and MDA-MB-231) and no HGF mRNA was detected 
in 13 TNBC cell lines tested which indicates that the cancer cells do not produce 
autocrine HGF. The relationship between HGF and its role in breast cancer has been 
examined in both cell lines and tumour samples which support our results. Co-culture of 
fibroblasts and an immortalised normal breast cell line demonstrated that fibroblasts are 
exclusively responsible for HGF production [175]. Two non-TNBC cell lines (MCF-7 
and ZR-75-1) assessed for HGF production in conditioned media were also negative for 
HGF [271].  
High HGF levels in breast cancer tissue extracts has been shown to be a prognostic 
indicator associated with recurrence and survival. These studies do not take into account 
the location of the HGF or if the HGF is produced by malignant cells or produced by 
normal cells such as fibroblasts or endothelial cells [159, 160, 271]. Co-expression of c-
Met and HGF mRNA has been seen in breast carcinoma cells but with most intense 
regions of HGF staining at the leading edge of the tumour [140].  The authors suggest 
this may be indicative of an autocrine loop however it may be as a result of 
internalisation from surrounding stroma explaining the gradient of expression [175].  
The results presented in this thesis in conjunction with the literature, present a scenario 
where the ideal assessment of c-Met/HGF axis in vivo would require the determination 
of c-Met/HGF expression and activation ideally in snap frozen tumour samples and 
adjacent normal tissue in a large cohort of TNBC patients.  
Many studies show that the addition of HGF stimulates proliferation, invasion and 
migration in 2D cell culture models; however only two of five TNBC cell lines tested 
(BT20 and HCC1937) showed increased growth in response to a saturating 
concentration of recombinant huHGF. Additionally we observed a HGF mediated 
increase in migration in the MDA-MB-468 which was blocked using c-Met inhibitor 
CpdA. CpdA however had no effect on basal levels of migration. The addition of 
exogenous HGF may mimic the production of HGF by stromal cells in a tumour and 
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thus may reflect the in vivo situation more closely. However, the concentrations of HGF 
used should reflect the concentrations that are present in the tumour microenvironment, 
rather than high saturating concentrations which may produce false positive results. 
Measurement of HGF levels in fresh frozen TN tumour specimens would be required to 
accurately determine the appropriate concentrations to use. 
8.3 c-Met and EGFR 
Reported EGFR expression levels in breast cancer range from 18% to 60% [69]}}. The 
frequency of EGFR expression is significantly higher in TNBC and correlates adversely 
with chemosensitivity [20, 272, 273]. TNBC is inherently insensitive to EGFR 
inhibition and a mechanism suggested for this resistance is through interaction with c-
Met through c-Src. c-Met expression significantly correlates with EGFR expression in 
breast cancer [169].   
Only six tumours in our TNBC TMA were positive for EGFR. Of these six, three 
showed co-expression of EGFR and c-Met. All patients who showed co-expression 
were >50 years of age. A significant association between EGFR and age at diagnosis 
has been previously reported i.e. older patients have significantly lower levels of 
intratumoral EGFR [70]. 
8.4  c-Met and Src 
Src is the most widely characterised member of a family of non-receptor tyrosine 
kinases known as the Src family. Src can be activated either by cytoplasmic proteins or 
through ligand dependent activation of cell surface receptors e.g. HGF binding to c-Met 
[96, 274].  
 
In our cohort of patients 15/44 (34.1%) showed co-expression for c-Met and Src. Of 
those that showed co-expression of c-Met and Src, 7/15 (53.3%) also had detectable 
phospho-Src (Y418). No significant association between co-expression and clinico-
pathological indicators was observed. However co-expression of c-Met and total Src 
and higher grade showed a trend towards significance with a p value of 0.07. Tumour 
grade is prognostically significant and is used to assess patients who do not show 
axillary lymph node involvement [275].  No significant association between DFS and 
OS was seen in this small cohort. Both membrane and cytoplasmic Src are detected at 
significantly higher levels in TNBC making it an attractive target for TNBC [193]. 
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However, one study reported that in patients with ER positive/HER2 negative 
phosphorylated cytoplasmic Src was associated with increased disease-free survival 
indicating Src inhibition may require a predictive biomarker to determine which patients 
will respond well to inhibition and those in which it may have a detrimental effect [193, 
194, 276, 277].  
8.5 sMet and its potential role in TNBC as a biomarker or predictor of response 
sMet is a truncated extracellular portion of the mature c-Met molecule which is cleaved 
from the cell membrane by metalloproteinases ADAM 10/17 or induced by HGF 
binding [278, 279]. Shedding induced by HGF is a proteolytic process reliant on 
signalling through protein kinase C (PKC) [278-280]. Our results demonstrate that all of 
the TNBC cell lines release detectable sMet into conditioned media at varying levels. 
The CAL-85-1 cell line showed the highest levels of sMet release and while no 
significant correlation was determined between Met levels and sMet in conditioned 
media from the TNBC cell lines, CAL-85-1 also show the highest detectable levels of 
total Met by western blotting. No significant correlation was seen between sMet levels 
and response to c-Met inhibitors (using IC50 values). Homo- and hetero-dimerisation of 
c-Met is crucial in c-Met signalling. Soluble receptors (sMet included) retain their 
ability to bind to membrane bound receptors however soluble receptors do not elicit a 
propagating signal due to lack of intracellular domain and may  function as decoy 
receptors similarly to the mechanism of action of monoclonal antibodies e.g. anti-APO-
1 as described in Section 1.6.2. sMet has been investigated in a small number of cancers 
as a potential biomarker and as it is expressed in all of the TNBC cell lines, it could 
potentially be used as a diagnostic biomarker or as a biomarker to monitor disease 
progression. Two studies examined sMet in serum and both found a negative correlation 
between levels of sMet and disease stage/burden in the individuals. These studies were 
carried out on multiple myeloma and gastric cancer and levels appear to be lower in 
disease states and drop as the disease progresses. The study on multiple myeloma did 
not find a significant difference in sMet levels despite a 3 ng/mL deficit in healthy 
individuals (similar reduction observed in gastric cancer) between the two groups 
however this is potentially due to low numbers within the study (n= 49/16 
cancer/normal samples) in comparison to the gastric cancer study (n = 290/290 
cancer/normal samples) [281, 282]. In contrast, in bladder cancer sMet levels in urine 
211 
 
were significantly higher than control groups, however no significant correlation was 
observed between sMet levels and stage of disease [283].  
8.6 Cell line sensitivity to inhibitors of c-Met, HGF, EGFR and Src in TNBC cell 
lines 
8.6.1 Characterisation of TNBC cell lines 
We characterised the TNBC cell lines using three experimental approaches; invasion, 
migration and 3D colony formation. MDA-MB-231 were the most invasive cell line 
while HDQ-P1, CAL-120 and MDA-MB-468 showed the lowest levels of invasion. No 
association was observed between TNBC subtypes and invasion status. MDA-MB-231 
have been characterised as a highly invasive cell line in the literature and therefore 
served as a positive control for our invasion experiments. Due to lack of response to c-
Met inhibition in the invasion assays we assessed only a limited selection of the cell 
lines in migration assays. Again, MDA-MB-231 displaed the highest migration (fully 
closing the ‘wound’ within 24 hrs). MDA-MB-468 showed the lowest level of 
migration. The HCC1937 and HCC1143 also showed concordance between the invasion 
assays with moderate levels of migration. A discrepancy was seen within the HDQ-P1, 
which show moderate levels of migration compared to low levels of invasion. This may 
be due to the assay format. Cells are placed in serum free medium for the duration of the 
migration assay to minimise artificial positive results occurring due to continued 
proliferation. The HDQ-P1 is exquisitely sensitive to serum starvation, meaning the 
assays could not be interpreted at the 48 hr timepoint. The sensitivity may have resulted 
in a falsely elevated migration rate due to the presence of debris. This would suggest 
that the HDQ-P1 cells are not suitable for analysis by this method and it may be more 
appropriate to use a Boyden chamber approach.  
Throughout the literature a number of TNBC cell lines have demonstrated the ability to 
form 3D colonies using a variety of techniques. These include BT20, HCC1937, MDA-
MB-231, MDA-MB-468 and BT549 [284-287]. In addition to the previous studies, we 
have shown that the HCC1143 and HDQ-P1 produce colonies in 3D assays.  Where 
available, images of colonies from published studies showed similar morphology to 
those determined in our experiments.  
8.6.2 Subtypes of TNBC in the cell lines 
Lehmann et al. identified 6 subtypes within TNBC cell lines and tumour samples, two 
of which were enriched in gene expression for growth factors. The BL-2 subtype is 
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enriched in growth factor gene expression including c-Met, EGF, NGF Wnt and IGF1R 
pathways [31]. Our panel of TNBC cell lines consisted of 3 BL-1 (HCC1937, 
HCC1143, MDA-MB-468), 2 BL-2 (CAL-85-1 and HDQ-P1), 2- M (CAL-120 and 
BT549) and 1 MSL (MDA-MB-231) cell lines. Burstein et al. recently identified gene 
signatures which subtyped TNBC into four groups; LAR and MSL which overlap with 
the Lehmann subtypes, and basal-like immunoactivated (BLIA) and basal-like immune-
suppressed (BLIS) groups which consist of a mixture of the other four Lehmann 
subtypes [34]. The authors of this study did not apply their gene signatures to TNBC 
cell lines so we cannot interpret whether these subtypes impact responsiveness to the 
inhibitors we have tested, however we can look at the subtypes established by Lehmann 
et.al.  
 
c-Met inhibitor responsiveness did not correlate with Lehmann subtype (BL-2 shows 
enrichment for c-Met), however responses to the other inhibitors were more 
characteristic of the subtypes, e.g. the IC50 of neratinib was significantly lower in the 
two BL2 cell lines (CAL-85-1 and HDQ-P1) than the other TNBC cell lines. MDA-
MB-468 is also sensitive to neratinib and BL1 cell line. However the MDA-MB-468 
cells are EGFR amplified and showed high levels of p-EGFR according to magnetic 
bead analysis, which may explain the neratinib sensitivity. MDA-MB-231, which 
belongs to the MSL subtype, was the most sensitive cell line to Src inhibition using both 
saracatinib and dasatinib [31, 80, 192]. In contrast, the cell lines which belong to the M 
subtype (CAL-120 and BT549) showed no response to saracatinib at concentrations up 
to 10 µM and decreased sensitivity to dasatinib when compared with MSL cell lines 
[31]. Dasatinib is a much more potent inhibitor of Src with an IC50 of 0.8 nM versus an 
IC50 of 2.7 nM for saracatinib [192, 288]. The subtypes share many gene ontologies 
however the major difference is the enrichment in MSL for growth factor related genes 
including inositol phosphate metabolism, EGFR, PDGF, calcium signalling, G-protein 
coupled receptor, and ERK1/2 signalling as well as ABC transporter and adipocytokine 
signalling.  
8.7 2D Proliferation Assays 
In proliferation assays we saw mixed responses to CpdA and limited responses to 
PRS110. The MDA-MB-231 and MDA-MB-468 cells showed the greatest response in 
2D proliferation (IC50 2.5 ± 0.3 and 3.1 ± 0.4 µM respectively), and in 3D assays with 
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11.8 ±0.5 % and 30.1 ± 10.6% reduction in cell viability after 5 days treatment with 10 
µM CpdA. Sensitivity to PHA-665752, a c-Met selective inhibitor in a panel of TNBC 
differs dramatically to our results. Five TNBC and the HER2 over-expressing HCC1954 
(which the authors Kim, Yu Jin et al. classified as TNBC in this study) were evaluated. 
BT20 and BT549 showed the highest level of sensitivity to PHA-665752, and MDA-
MB-231 and MDA-MB-468 were the least sensitive cell lines [185]. In response to 
CpdA, BT20 and BT549 showed no significant reduction in proliferation. CpdA is a 
proprietary agent provided from Amgen Inc. We did not possess information on the 
pharmacokinetics of CpdA or the c-Met kinase IC50. The IC50 of CpdA in the TNBC 
cell lines are relatively high in concentration and we did not have information as to 
whether this is reflective of pure c-Met inhibition or if CpdA may inhibit other kinases 
at concentrations greater than 2 µM. As discussed in Section 8.6.2 the panel of TNBC 
cell lines did not show a correlation with the Lehmann subtypes nor did we see a 
correlation between activation of c-Met (via western blotting) and response to CpdA. 
From the literature we classified the basal subtype, the PI3K or the PTEN status of the 
cell lines used in relation to prediction of response to CpdA. No correlation can be seen 
between the IC50 and with PI3k status, PTEN status or basal subtype indicating these 
have no effect on response (Table 8 - 1).  
 
We also tested two non-selective c-Met inhibitors, BMS-777607 (inhibits c-Met, Axl, 
Ron and Tyro3) and crizotinib (inhibits c-Met and ALK). Only two cell lines of eight 
tested with BMS-777607 achieved greater than 50% growth inhibition (BT20 and 
BT549). HCC1937 and HDQ-P1 achieved moderate inhibition of growth at 10 µM 
BMS-777607.  The IC50 of BMS-777607 for c-Met is 3.9 nM so it seems unlikely with 
no effect at lower concentrations that the inhibition of growth observed is due solely to 
c-Met inhibition. BMS-777607 has been implicated in the induction of breast cancer 
cell polyploidy which decreased sensitivity to chemotherapy agents [289, 290].  
Crizotinib, the ALK inhibitor, was tested in four cell lines however none achieved 
greater than 50% growth inhibition. HCC1143 showed the highest level of sensitivity 
with 27.6 ± 8.9% inhibition at 0.3 µM. ALK expression has been noted in 25% of 
TNBC and is associated with M and MSL subtypes [31, 237].  
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Considering all of the inhibitor results presented, it seems that TNBC cells are not 
inherently sensitive to c-Met inhibition and clinical trials of c-Met inhibitors alone 
would not be recommended for TNBC, on this in vitro analysis. 
 
Table 8 - 1 Basal subtype, PI3K and PTEN status of TNBC cell lines [244, 291-293] 
UK = unknown 
Cell Line IC50 Basal A/B PI3K status PTEN Status 
BT20 >10 A Mutated Positive 
HCC1937 4.1 ± 0.5 A WT Positive 
HCC1143 >10 A WT Positive 
MDA-MB-468 3.1 ± 0.4 A WT PTEN null 
MDA-MB-231 2.5 ± 0.3 B WT Positive 
CAL-120 3.8 ± 0.3 UK WT WT 
CAL-85-1 >10 UK WT WT 
HDQ-P1 5.1 ± 0.4 UK WT WT 
BT549 >10 B WT PTEN null 
 
8.8 Dual Inhibition of c-Met  
8.8.1 c-Met receptor (CpdA) and ligand (rilotumumab) 
We found increased growth inhibition in three cell lines (HCC1937, MDA-MB-468 and 
MDA-MB-231) when we targeted both the c-Met receptor via small molecule (CpdA) 
and its ligand HGF via rilotumumab. Dual targeting of the receptor c-Met and ligand 
HGF has not been previously tested. No response to rilotumumab was seen in the cell 
lines as a single agent which makes the enhancement of response intriguing. CpdA 
inhibits both ligand dependent and independent methods of activation of c-Met by 
binding intracellularly, however it would seem that some HGF dependent signalling 
through c-Met is occurring in the presence of CpdA. We do not know the exact 
mechanism of action or the specific binding site of CpdA. Potentially, CpdA may be 
unable bind the activated receptor due to the structural changes upon HGF binding or if 
CpdA is an ATP competitive molecule, it may be unable to outcompete ATP in a 
receptor with bound HGF. 
There is an overlap of the cell lines which showed enhancement of response to CpdA in 
combinations with rilotumumab and saracatinib. Four cell lines (described below in 
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Section 8.8.3) showed enhanced response to CpdA with saracatinib (HCC1937, MDA-
MB-468, MDA-MB-231 and HDQ-P1). Three of these cell lines also showed enhanced 
response to CpdA in combination with rilotumumab which suggests that HGF mediated 
signalling in TNBC cell lines may primarily signal downstream through Src. This result 
is novel and requires further investigation to characterise the mechanism. This 
combination warrants further testing in an appropriate in vivo model expressing 
recombinant huHGF [81] to determine its anti-tumour activity.  
8.8.2 c-Met (CpdA) and EGFR (neratinib) 
Previous data from our laboratory has shown that the first generation EGFR inhibitor, 
gefitinib has some activity in TNBC cell lines, particularly in combination with 
chemotherapy [74]. We evaluated neratinib, an irreversible and highly potent pan-erbB 
family receptor tyrosine kinase inhibitor. Although neratinib targets the erbB family, 
due to high levels of EGFR in TNBC the expected predominant effect would be as a 
result of EGFR inhibition. All nine cell lines tested showed sensitivity to neratinib with 
IC50 values ranging from 0.03 to 6.6 µM. The most sensitive cell lines were CAL-85-1 
and HDQ-P1 (as described in Section 8.6.2). Cell lines of basal A subtype demonstrate 
greater sensitivity to neratinib which is in agreement with our IC50 results [294]. The 
two basal B cell lines used in this study, MDA-MB-231 and BT549 have IC50 values of 
2.8 ± 0.2 µM and 6.6 ± 0.5 µM compared to IC50 <1 µM for all basal A cell lines tested. 
The M (including MSL) subtype of the TNBC cells showed the lowest sensitivity to 
neratinib with the IC50 greater than 1 µM in each of the cell lines. Neratinib has been 
determined to be effective at a dose of 240 mg given orally. Doses above this resulted in 
adverse grade 3 events [295, 296]. This dose results in peak plasma concentrations of 
approximately 100 nM implying that only three cell lines (CAL-85-1, MDA-MB-468 
and HDQ-P1) would be classed as sensitive.  
As mentioned above there is significant cross-talk between c-Met and EGFR and the 
reciprocal relationship between EGFR, c-Met and Src has been described in detail in 
Chapter 1. Many studies have shown that c-Met is implicated in resistance to EGFR 
inhibitors. We evaluated combined targeting of c-Met and EGFR in our 2D proliferation 
assays. The only cell line that showed a significant decrease in proliferation with the 
combination is MDA-MB-468. The MDA-MB-468 cells are among the most responsive 
to CpdA and are sensitive to neratinib. The only other cell line which showed sensitivity 
to neratinib and respond to CpdA is the HDQ-P1 although with a much higher IC50 and 
a trend toward significance, suggesting sensitivity to both agents is essential for 
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synergy. The MDA-MB-468 are EGFR amplified with mutated PTEN [244, 297]. 
Given the lack of synergism in our other EGFR amplified cell line BT20 we can 
conclude that EGFR amplification alone is not sufficient to cause a synergistic response. 
Synergy has been observed in the EGFR amplified breast cancer cell line SUM229 cells 
and SU11274 (selective c-Met inhibitor) [181]. It is also possible that HGF activation of 
c-Met may be necessary for synergy in response to dual targeting of c-Met and EGFR. 
In a xenograft model, human HGF production was required for synergy in a variety of 
cell types including breast [190]. Neratinib is additionally capable of inhibiting 
phosphorylation of c-Met, as observed in the multiplex luminex assay in the CAL-85-1 
cell line. In agreement with the 2D proliferation results no significant decrease in 
phosphorylation was observed in the combination of PRS110 and neratinib.  Neratinib 
as a single agent inhibited the phosphorylation of c-Met. This result suggests that there 
may be an interaction between c-Met and EGFR in this TNBC cell line. Previous 
studies have shown that c-Met inhibitors are capable of overcoming EGFR inhibitor 
resistance.  [181, 187, 213]. HGF and EGF synergy in activating both c-Met and EGFR 
have also been observed in NSCLC [298] therefore it is likely than neratinib may exert 
its effect on c-Met through downstream feedback loops. A potential candidate for this 
interaction is Src which has been previously implicated in crosstalk between c-Met and 
EGFR [213].  
8.8.3 c-Met (CpdA) and Src (saracatinib) 
Saracatinib is a selective small molecule inhibitor of Src and Abl kinases. In vitro 
saracatinib has the ability to block Src phosphorylation leading to reduced Src kinase 
activity; it inhibits anchorage dependent and independent growth in ER positive cell 
lines [299]. TNBC cell lines were markedly less responsive to growth inhibition by 
saracatinb when compared to dasatinib (dasatinib is a much more potent inhibitor of Src 
with an IC50 <0.8 nM compared to 2.7 nM for saracatinib). The MDA-MB-231 cells 
were among the most responsive when treated with either compound. HDQ-P1 showed 
the highest sensitivity to saracatinib. The maximum tolerated dose of saracatinib in 
patients was 175 mg daily which produces serum concentrations of approximately 1 µM 
[288]. Using this as a guideline for sensitivity four cell lines would be classed as 
sensitive (HCC1937, MDA-MB-231, CAL-85-1 and HDQ-P1). Development of 
saracatinib has been discontinued due to lack of efficacy in reducing primary tumour 
burden in multiple cancers including primary breast, however this does not negate its 
possibility for use in combination regimens [253].  
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The combination of CpdA and saracatinib significantly enhanced response in four cell 
lines, HCC1937, MDA-MB-231, MDA-MB-468 and HDQ-P1. As described above for 
neratinib, these cell lines all show sensitivity to both saracatinib and CpdA as single 
agents prior to combination. Interactions between c-Src and c-Met have been implicated 
in mediating resistance to c-Src inhibitors in head and neck cancers where dual 
inhibition produced a synergistic effect [251].  
The enhanced response to the combination regimens warrants further investigation, for 
example to determine if these combinations could enhance response to chemotherapy in 
TNBC. 
8.8.4 Clonogenic Assays 
Clonogenic assays test the ability of cells to propagate indefinitely from a single cell to 
large colonies. Not every cell will have the ability to form these colonies. This 
technique was initially described in the 1950s and used to assess cell response to 
radiation therapies [300]. We used automated software (ImageJ) to analyse the colonies 
formed using two parameters: (i) percentage area covered to represent the size of the 
colonies and (ii) average intensity of colonies to represent the number of cells. The 
thresholds for each of these can be adjusted to eliminate cells which have only 
undergone 2-3 divisions and growth arrested or cells which do not proliferate after 
seeding. ImageJ has been shown to be comparable to manual counting and minimises 
time required for analysis of clonogenic assays [301]. All five cell lines showed a 
decrease in clonogenic growth in response to 1 µM CpdA treatment, however only four 
achieved statistical significance. If we compare the effect 1 µM CpdA has on the cells 
in 2D proliferation assays, the cells were inherently more sensitive to Met inhibition in 
clonogenic assays. A similar trend is observed with treatment with PRS110. One 
possible explanation for the increased sensitivity may be the presence of luminal 
progenitors, from which basal breast cancer is derived, which show enhanced 
clonogenic growth properties in vitro. These luminal progenitors express high levels of 
c-Met relative to other epithelial cell populations and therefore may be more responsive 
to c-Met inhibition [174, 302]. If the progenitor cells are responsible for the increased 
sensitivity, a more differentiated cell line which correspondingly would have lower 
levels of progenitors would be less sensitive. This may explain why the MDA-MB-
231(post-EMT), which shows the highest sensitivity to CpdA in 2D proliferation assays, 
show no significant response in clonogenic assays. In contrast, HCC1143 cells, which 
are a poorly differentiated cell line showed high levels of sensitivity to CpdA in 
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clonogenic assays despite showing no significant response to CpdA in 2D proliferation 
assays.  Three of the five cell lines showed a statistically significant decrease in area 
covered after treatment with PRS110, however two cell lines showed an increase in 
clonogenic growth post treatment. PRS110 is highly selective for c-Met, however, 
CpdA like other small molecules inhibitors may inhibit other kinases explaining the 
different response to the two inhibitors.  It is interesting to note the similarities between 
the profile of neratinib sensitivities and response to PRS110 in the clonogenic assays. 
HCC1937, HCC1143 and MDA-MB-231 all showed significant decreases in area 
covered in response to neratinib and PRS110.  This raises the issue of cross talk 
between EGFR and c-Met in mediating resistance in the clonogenic assays. If PRS110 
is not at a saturating concentration, selective pressure may exist to form heterodimers 
with EGFR. The same situation may occur in reverse for EGFR inhibitor neratinib. The 
two cell lines (MDA-MB-468 and HDQ-P1) which showed little response in clonogenic 
assays were treated with substantially lower concentrations of neratinib than other cell 
lines, leaving free EGFR to bind to c-Met and elicit resistance. This hypothesis is 
supported by the statistically significant decreased clonogenic activity in MDA-MB-468 
when combining PRS110 with neratinib. The HDQ-P1 cell line also showed a decrease 
in clonogenic growth with the combination.  
Similarly to CpdA when the cell lines that are more sensitive to neratinib in 2D 
proliferation assays (MDA-MB-468 and HDQ-P1) are treated with neratinib as a single 
agent in a clonogenic assay, they show a limited response. The cell lines HCC1937, 
MDA-MB-231 and HCC1143 were significantly more sensitive to neratinib in 
clonogenic assays than 2D proliferation assays. In contrast, when treated with 
saracatinib the clonogenic assays showed little deviations in response between the cell 
lines, similarly to the 2D proliferation results. Again the cell lines were inherently more 
sensitive to saracatinib in the clonogenic assays than 2D proliferation. However, no 
significant enhancement of response to CpdA or PRS110 was seen in combination with 
saracatinib.  
Little literature exists about the signalling that occurs in the cells to stimulate colony 
formation and further investigation is warranted. Examination of c-Met and EGFR 
signalling pathways in cells isolated from clonogenic assays compared to cells grown in 
2D assays may help to elucidate the differences in the pathways activated in 2D or 
clonogenic assays.   
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8.8.5 3D Assays 
The cell lines which showed a response at 10 µM in 2D proliferation assays did not 
show similar responses in the 3D assays. The 3D assay used in this thesis is a modified 
version of an embedded matrigel 3D protocol carried out in 96 well plates to minimise 
cell number therefore allowing the more rapid quantification of the cells ability to form 
colonies [303]. 3D cell culture is thought to possess the ability to recapitulate the natural 
tumour environment. It has been shown that 3D culture is more representative of a 
tumours responsiveness to an agent and will often show higher resistance to cytotoxic 
agents [304]. Alternative signalling pathways may also be activated in 3D cell culture; 
one example includes EGFR and beta1-integrin. The signalling relationship between 
these two receptors is not fully functioning in 2D breast tumour cells however in 3D cell 
culture interaction it becomes one of the integral signalling pathways for these two 
receptors [305, 306]. This also accompanies an increased dependence on MAPK 
downstream signals and renders TNBC cells more sensitive to MAPK kinase inhibitors 
[305, 307]. Our results show marked less sensitivity to CpdA in 3D assays than 2D 
potentially for the reasons described above. A selective c-Met inhibitor EMD1214063 
has previously shown the ability to decrease 3D colony formation in the MDA-MB-468 
but not the MDA-MB-231 at a concentration of 5 µM. At 5 µM EMD1214063 also 
inhibits IRAK4, TrkA, Axl, IRAK1, and Mer suggesting that colony inhibition may not 
be solely due to c-Met inhibition [308, 309].  
8.8.6 Invasion and Migration assays 
Our invasion and migration assays showed no significant response to CpdA, PRS110, 
neratinib or saracatinib as single agents or in combinations in any of the TNBC cell 
lines tested. The efficacy of dasatinib inhibiting MDA-MD-231 invasion (see section 
8.9) and the efficacy of CpdA inhibiting rhHGF-induced migration in the MDA-MB-
468 served as validation for our experimental design however others have reported 
inhibition of invasion and migration using pre-treatment with inhibitors. c-Met 
inhibition by tivantinib significantly reduced migration in wound scratch assays in the 
MDA-MB-231 cells. In this experimental design however the cells were treated with 
tivantinib while still actively proliferating to reach confluence [81]. A monoclonal 
antibody against EGFR reduced the invasion of BT549 after 48 hrs pre-treatment [261]. 
In our migration assays, stimulation with HGF only had a significant effect on 
migration after 48 hrs. It has also been shown using a computer model in keratinocytes 
that transient c-Met activation and sustained EGFR signalling are imperative for 
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stimulating long-term cell migration [310]. All of these factors depict a time dependent 
role for c-Met and EGFR signalling in the regulation of invasion and migration. Thus, 
the invasion and migration experiments may need to be repeated using a pre-treatment 
for each of the inhibitors, or prolonging the experimental timepoints. If the experimental 
timepoints were to be extended, optimisation would be required. In migration assays, 
the cells are in SFM for the duration of the assay. As we have seen with HDQ-P1 (in 
Section 8.6.1) cell lines this may not be feasible for migration assays due to cell death 
and debris. The invasion assays would also require cell number optimisation. The cell 
lines are highly invasive after 24 hrs, thus to avoid saturation of the membrane cell 
numbers would need to be reduced.   
8.9 c-Met in resistant models of TNBC 
Given the numerous publications which characterise a c-Met/EGFR/SRC axis, it 
followed that c-Met could be implicated in resistance to these inhibitors. Dasatinib is a 
small molecule multi-kinase inhibitor which showed activity in vitro in TNBC cell 
lines. Previous work by Tryfonopoulos et al. within our group showed TNBC cell lines 
MDA-MB-231, MDA-MB-468 and HCC1937 had IC50 values of less than 1 µM when 
treated with dasatinib [193]. 
We have shown in two models of acquired resistance, increased sensitivity to c-Met 
inhibition via CpdA. In the 231-DasB cell line, acquired resistance to dasatinib is 
associated with maintenance of phosphorylation of Src at Y418. This site is highly 
conserved across the SFKs and as such it is possible that other members of the SFKs 
could be responsible for this constitutive phosphorylation. However based on a 
multiplex assay for several SFK family members, it appears that dasatinib does not 
inhibit phosphorylation of any of the SFKs tested in the resistant cells. We examined 
whether this constitutive activation was mediated through RTK signalling.  Of the 
RTKs examined, only c-MET showed an increase in phosphorylation consistent with 
increased sensitivity to CpdA. Although we have previously shown that activated c-Met 
is not a predictor of response to CpdA, it seems increased p-Met following treatment 
may predict increased sensitivity to Met inhibition. Interestingly, the combination of 
CpdA and dasatinib resulted in significantly enhanced growth inhibition in only the 
parental cell line. This enhancement of response was also seen in invasion assays. The 
reason for the higher sensitivity may be related to the ability of CpdA to inhibit 
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phosphorylation of the SFK members, FYN, YES, LCK, LYN, FGR and BLK, despite 
their resistance to dasatinib inhibition, while having no effect on Src.  
Results similar to those seen in the 231-DasB cell line were also seen in the cetuximab 
resistant cell line MDA-MB-468CR. Cetuximab is a monoclonal antibody which binds 
to EGFR and blocks binding of EGF thereby inhibiting downstream signalling [311]. 
EGFR inhibitors have shown promising pre-clinical activity in TNBC cell lines 
however clinical trials have been disappointing [74, 312]. Cetuximab has been tested in 
phase II and phase III trials with a combination of chemotherapeutic agents including 
docetaxel, carboplatin, ixabepilone and cisplatin [220]. Those studies with results 
available, report underwhelming effects of cetuximab, offering modest increases in 
overall response rate and progression free survival [313-315]. Cetuximab in 
combination with carboplatin produced responses in only 20% of metastatic TNBC with 
little effect on EGFR signalling. The authors suggest this is due to alternative methods 
of activation of EGFR. Based on our results, we would suggest this may involve 
enhanced c-Met signalling.  
In the MDA-MB-468 cells, the resistant variant again showed increased sensitivity to c-
Met inhibition by CpdA. Combined treatment with cetuximab and CpdA showed 
synergistic inhibition of growth in the parental cell line and no significant effect in the 
MDA-MB-468CR. This data may suggest a general escape mechanism for acquired 
resistance to therapies through a switch to dependency on c-Met signalling. The 
increased activation of c-Met occurs in a relatively rapid fashion after 48 hrs treatment 
in breast cancer cell lines, which would indicate that new protein synthesis is not 
required [181, 184, 213].  Blockade of EGFR encourages ligand independent activation 
of c-Met through a feedback loop of Src mediated activation in a number of cancer 
types including breast [184, 213, 298]. One limitation of this study is that we are 
assessing increased c-Met sensitivity in models where there is a stronger basal 
propensity to signal through c-Met after inhibition of EGFR or Src due to crosstalk 
between the receptors. c-Met has previously been implicated in other models of 
acquired resistance to other small molecule inhibitors, chemotherapy and radiotherapies. 
Cabozantinib a small molecule c-Met inhibitor was shown to overcome gemcitibine 
resistance in pancreatic cancer and quite encouragingly displayed only a very low level 
of acquired resistance despite long term treatment [316]. A similar situation was 
observed in two primary multiple myeloma cell lines which show increased p-Met at the 
development of resistance compared to the sensitive cell lines [317]. In the MDA-MB-
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231 cell line, ionising radiation increases the activation of c-Met and targeting the cells 
with a c-Met inhibitor sensitises the cells to radiation therapy [214]. Met has also been 
implicated in resistance to antiangiogenic therapies in bevacizumab resistant 
glioblastomas. Upregulation of c-Met was noted after exposure to bevacizumab, 
although the authors do not evaluate a c-Met inhibitor or its response.  We hope to 
obtain and evaluate other models of other acquired resistance in the TNBC setting to 
determine if increased dependence/activation of c-Met is a general escape mechanism in 
acquired resistance.  
Our results suggest that while c-Met may be a potential target in the acquired resistance 
setting, it may also be appropriate to target c-Met in combination with other therapies to 
prevent the development of resistance, as illustrated by the response of the parental cell 
lines to the combinations. Both of the parental cell lines tested were initially sensitive to 
c-Met inhibition. We do not know if c-Met would also play a role in acquired resistance 
to other drugs in cells that are not innately sensitive to c-Met inhibition. Testing this 
hypothesis in humans would require strong predictive biomarker for c-Met sensitivity. 
To our knowledge currently no biomarker exists for c-Met sensitivity in TNBC. Met 
amplification has been shown in other cancers as a potential biomarker however 
amplification has not been observed in breast cancer [318]. Some studies have used 
expression of c-Met to identify suitable patients and the results seem to indicate that the 
c-Met high groups are more responsive. These studies provide more reason to identify a 
strong clinical biomarker for c-Met response as patients grouped within the c-Met low 
groups trended towards worse prognosis after treatment with Met inhibitors [319].  
We are also aware of the limitations of using cell line models of resistance. Gillet et al. 
has shown that drug resistant cell lines are comparably more similar to each other than 
the tumour types from which they are derived. It would thus be important to evaluate 
changes in p-Met in TN tumours following drug treatment to determine the clinical 
relevance of c-Met in acquired drug resistance.  
8.10 c-Met as a therapeutic target in TNBC 
Our results do not support further evaluation of c-Met inhibitors alone as a first line 
treatment for TNBC. Similarly to EGFR, c-Met is expressed however, response to 
inhibition is limited. There are possible alternatives, for example using c-Met as a 
potential binding site for an antibody-drug conjugate (ADC), however our IHC studies 
in a cohort of Irish patients suggest that an ADC might not be effective as c-Met was 
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detected in the cytoplasm only. In search of a more effective therapy we evaluated the 
58 known RTKs in search of new targets. The implications of the results of this thesis in 
those aspects are discussed below. Another potential target implicated for TNBC in this 
thesis was that of the insulin receptor. 
8.10.1 Other RTKs implicated in TNBC 
The sub-type of TNBC is somewhat a controversial grouping, with many arguing that 
lack of known target does not justify the grouping of a vast array of diverse tumours 
into a single group. Many studies have identified different subtypes within 
TNBC/BLBC which may impact a tumours responsiveness to a target agent [31, 33, 
34]. Over 50% of RTKs have been implicated in proliferative disorders and as such are 
considered good options for targeted treatment of cancer [48, 49]. There are 58 known 
RTKs distributed across 20 families [62]. We examined the 58 known RTKs to identify 
other RTKs which may offer possible options for targeted treatment and/or the 
discovery of potential biomarkers in BLBC/TNBC. The RTKs which we identified as 
associated with a poor prognosis were EPHA5, FGFR1, FGFR3, VEGFR1, PDGFRβ 
and TIE1.  
The FGF receptors have been implicated in the development and progression of breast 
cancer particularly FGFR1 and FGFR2. FGFR1 has previously been identified as an 
independent prognostic marker and expression of FGFR1 may serve as a biomarker of 
response to chemoradiotherapy while FGFR2 has been implicated as a target for 
inhibition in TNBC [320, 321]. Breast carcinoma cell lines MDA-MB-134 (FGFR1 
amplified), SUM 52PE and MFM-2231 (FGFR2 amplified) harbouring an FGFR 
amplification have shown exquisite sensitivity when treated with a pan-FGFR inhibitor, 
ponatinib. This study also tested the T47D and TNBC cell line MDA-MB-231 which 
show WT FGFR expression and observed no significant sensitivity to ponantinib [322] 
A number of other inhibitors of FGFR are currently in clinical trials, making FGFR1 an 
appealing target in TNBC [220, 322]. 
Both VEGFR1 and PDGFRβ are involved in angiogenesis in cancer and have been 
associated previously with poor prognosis in breast cancer [323, 324].The VEGFR gene 
encodes two splice variants of VEGFR1, a full 200kDA VEGFR1 receptor and a 110 
smaller protein known as soluble VEGFR1. The soluble form of VEGFR1 functions as 
decoy receptor for VEGF thereby acting as a negative regulator for VEGF induced 
angiogenesis. Three breast carcinoma cell lines (MDA-MB-231, T47D and MCF-7) 
were examined for expression of VEGFR1. In the ER positive cell lines soluble 
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VEGFR1 (T47D and MCF-7) is down-regulated by oestrogen. This would consequently 
allow more free VEGF to activate angiogenic pathways in ER positive tumours [325]. 
VEGFR1 was also significantly associated with HER2 status and response to neo-
adjuvant radiotherapy. Similar to our results VEGFR1 expression (stratified using the 
75th percentile) was associated with a poorer DFS and OS [326]. Schmidt et al. 
associated VEGFR1 with VEGF expression and advanced tumour stage in node 
negative patients [327]. The VEGF receptors have also demonstrated the propensity to 
encourage metastases at different sites dependent on the host organ of the tumour. In 
renal carcinoma VEGFR1 is implicated in metastases to the liver [328]. The study by 
Schmidt et al. has implications for potential clinical applicability of VEGFR1 
inhibitors; VEGFR1 could potentially provide a viable treatment option for patients who 
have developed specific metastases.  
PDGFRβ has been correlated with invasive behaviour in mammary carcinomas and the 
development of metastases. PI3K signalling is the major signalling point through which 
PDGFR signalling occurs, activation of this pathway seems primarily to do with 
autocrine activation and is required for EMT transition [329][329]. Early studies found 
that PDGFRβ was localised to epithelial cells in breast carcinomas and was significantly 
decreased in post-menopausal tissue [330].  
Relatively little work has been conducted on TIE1 compared to its isoform TIE2 
however it is one half of the TIE RTK family, which function to promote angiogenesis 
through binding of angiopoietins (ANG-1 and ANG-2) and is expressed principally by 
endothelial cells. TIE1 is over-expressed in breast carcinoma and undergoes activation 
through regulated proteolytic cleavage by a number of proteins including VEGF 
suggesting possible redundancy between the functions of TIE1 and VEGFR1 [331, 
332].  
The three RTKs described above are involved in angiogenic pathways. Many anti-
angiogenic agents have been approved for other malignancies including renal cancer 
and colorectal cancer however the responses in breast cancer have been variable. It was 
initially thought that anti-angiogenics demonstrated the ability to reverse resistance and 
chemosensitise tumours, however other models demonstrated tumour regrowth with 
ongoing treatment and an increase of angiogenic activity once treatment was withdrawn 
[333]. One reason suggested for these variable responses is the heterogeneity of breast 
cancer, however our results support the hypothesis that TNBC/BLBC may respond 
preferentially to anti-angiogenic therapies. Angiogenesis has been shown to play a key 
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role in the progression of breast cancer. Increased angiogenic activity in pre-cancerous 
states such as fibrocystic disease and DCIS has been associated with increased risk of 
development of breast carcinoma [334, 335]. Microvessel density (MVD) has been 
established as one of the key parameters to evaluate angiogenic activity. High MVD has 
been associated with progression to IDC in DCIS; and with poor outcome/development 
of metastases in breast carcinomas [335-337]. MVD also shows an association with 
tumour stage and lymph node metastases [338]. In TNBC, MVD is significantly higher 
than other subtypes of breast cancer and was significantly associated with larger 
tumours of a higher grade [339]. No significant association was observed between 
MVD and DFS or OS [339]. MVD is a well established prognostic marker however 
criticism exists over its use as a method of examining angiogenic burden of a tumour. A 
study by Nalwoga et al. developed the vascular proliferative index (VPI) which is the 
ratio of the proliferative MVD (pMVD) (mm2) to the MVD (mm2) divided by 100.  In 
this study, VPI significantly associates with angiogenesis levels, EGFR, cytokeratin 5/6, 
P-cadherin, high grade tumours and p53 expression in BLBC.  
 
There are currently seven FDA approved anti-angiogenic TKIs which target the 
VEGFR, PDGFR, EGF and FGF receptors; sunitinib, sorafenib, pazopanib, axitinib, 
vandetanib, cabozantinib, and regorafenib. On the whole, trials of anti-angiogenic TKIs 
as single agents or in combinations with other therapeutics have been disappointing, 
with many not achieving primary endpoints, no increase in overall/progression free 
survival or showing serious adverse affects [340-345]. Clinical trials evaluating 
sorafenib in combination with cisplatin in early stage TNBC and cabozantinib in 
metastatic TNBC are currently underway and hopefully will yield more promising 
results [220].  
Despite the disappointing results, potential remains for TKIs targeting these angiogenic 
RTKs. A number of the RTKs described above have been implicated in metastases 
formation; therefore anti-angiogenics could potentially be used to lessen the metastatic 
burden of cancer. Combined inhibition of VEGF and VEGFR in BO2 cells abrogated its 
ability to metastasise to bone [346]. C-Met inhibitors have also previously shown the 
ability to inhibit bone metastases in mouse models [81]. Anti-angiogenic agent 
sunitinib, induced metastases through c-Met signalling, which was subsequently 
inhibited using crizotinib suggesting a potential role for combination therapy of c-Met 
and anti-angiogenic inhibitors in 4T1 (breast), H460 (lung) and Colo205 (colorectal) 
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cells [347]. Cabozantinib a dual c-Met/VEGFR inhibitor has shown activity in the 
treatment of metastatic patients with bone metastases in reducing cancer burden [348].  
 
We initially chose three RTKs for follow up from the results generated by analysis of 
the BreastMark dataset [239]. These were ROS1, FGFR3 and EPHA5. Aside from 
novelty of these receptors in TNBC, these receptors showed a significant association 
with decreased DFS and OS.  
ROS1 belongs to the sevenless subfamily of tyrosine kinase insulin receptors. It has 
been associated with a high KI-67 index in invasive breast carcinomas although seems 
to have a positive relationship with other poor prognostic indicators. Activation of 
ROS1 in lung cancer is primarily through ROS fusion proteins and signalling in breast 
cancer cells is mediated through PI3K [349, 350]. Low ROS1 expression is associated 
with higher grade, increased mitotic count and low oestrogen receptor [351]. In our 
results ROS1 mRNA was down-regulated in all of the cell lines relative to normal 
immortalised epithelial cells, therefore high expression may be due to detection of 
ROS1 mRNA from other cell types e.g. endothelial cells or tumour infiltrating immune 
cells. Expression in these cell types has not been previously reported and suggests a 
need for further examination. ROS1 expression may also be up-regulated in adjacent 
normal tissue. In this case the possibility exists that ROS1 may act as stimulator of 
tumour growth/angiogenesis from the normal tissue through cell/cell interaction 
supported by the association of ROS1 with KI-67 proliferative index [351]. 
We examined FGFR3 and EPHA5 in further detail using an mRNA screen of 13 TNBC 
cell lines and 7 TNBC patient samples (3 with paired tumour and normal samples). In 
the cell lines the fold change was calculated by comparing CT values against those of 
immortalised mammary epithelial cell line MCF10a. The CT values of the tumour 
samples were normalised to pooled values of normal adjacent tissue. Normal adjacent 
tissue has limitations as a comparison as it is likely to show some artefactual changes 
relative to normal tissue of a healthy person. The ideal situation would be to compare 
mRNA levels from a pooled collection of healthy tissues isolated from reduction 
mammaplasty [352] but this was not available for this analysis. FGFR3 showed higher 
levels of mRNA in both the cell lines and the tumours and EPHA5 showed higher levels 
in tumour samples compared to the non-cancerous samples. Initially, our intention was 
to functionally validate knockdown of these proteins in TNBC cell lines by siRNA to 
determine whether they were suitable targets to pursue. The CT values of the cell lines, 
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were high suggesting that mRNA levels are quite low. In an  attempt to examine the role 
of FGFR3 and EPHA5 in the cell lines we tested the effects of ligands on proliferation 
of the cell lines with the highest mRNA levels. We chose FGF9 and as FGFR3 binds 
FGF1and FGF9 [353, 354]However FGF18 has recently been reported as potential 
ligand may function as a FGFR3 ligand [355]. FGF9 was selected from the FGFR 
ligands as it does not bind to FGFR1. FGF9 additionally requires the presence of 
heparin sulphate to bind to FGFR3 [356]. The ephrin family of receptors are 
promiscuous receptors. The ephrin-A receptors have the ability to bind all of the ephrin-
A ligands. Ephrin-A4 was the only ephrin to show any significant association with DFS 
obtained from the BreastMark database. High levels of Ephrin-A4 significantly 
decreased DFS in basal-like breast cancer. Neither ligand showed any significant effects 
on the growth of the TNBC cells. Due to the difficulties encountered with functional 
validation of FGFR3 and EPHA5 in vitro, we chose to evaluate their expression in TN 
tumours to determine their clinical relevance.  
In our cohort of TNBC we detected expression of both FGFR3 and EPHA5. FGFR3 
was expressed cytoplasmically in 66% of tumours and 44% were positive for nuclear 
staining. The nuclear staining was statistical significant, with an association seen 
between intensity/expression levels and histological subtype. Cytoplasmic and nuclear 
staining of FGFR3 in breast cancer has been noted before [357]. FGFR3 consists of two 
splice variants FGFR3 IIIb and FGFR3 IIIc [358]. FGFR3 IIIb is predominantly 
expressed in epithelial cells while FGFR3 IIIc features more predominantly in cells of 
mesenchymal origin. The location of FGFR3 expression activates distinct pathways in 
pancreatic cancer. Epithelial cells signal through STAT kinases where FGFR3 
signalling in mesenchymal cells is through the MAPK pathway; however they also 
report that FGFR3 has tumour suppressive properties in epithelial cells [359]. Early 
studies detected the two isoforms of FGFR3 of which one predominately localises 
within the nucleus. FGFR IIIb, which has a lower molecular weight, is the form of 
FGFR3 localised in the nucleus [357]. FGFR3 has also been implicated in the 
development of bone metastases in breast cancer [360]. Currently, there are at least five 
clinical trials with inhibitors capable of inhibiting FGFR3; however no agent 
specifically targeting FGFR3 exists. Most are pan-FGFR or FGFR/VEGFR inhibitors 
which are being tested in metastatic or ER positive breast cancer. Most are early stage, 
proof of concept or efficacy trials [220]. Based on the frequent expression of FGFR3 in 
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the TN tumours, preclinical evaluation of inhibitors which target FGFR3 may be worth 
further pursuing. 
EPHA5 staining was detected in the cytoplasm and cell membrane of the tumour cells 
in our study and had a significant association with a younger age at diagnosis. Age is 
one of the strongest poor prognostic indicators used [275]. The Eph family of receptors 
are the largest subfamily of RTKs. Different Eph receptors have been shown to play a 
role in modulating the transition from non-invasive to invasive tumours through up-
regulation of genes involved in angiogenesis [361]. The role of EPHA5 has been 
explored somewhat in breast cancers; EPHA5 in cell lines has been found to be 
frequently epigenetically silenced by promoter methylation which corresponded to 
decreased protein expression in both primary breast tumours and breast cancer cell lines 
including the TNBC cell line MDA-MB-231. Silencing of EPHA5 was detected in only 
64% of primary breast tumours which may suggest that a subset of breast cancer may 
express EPHA5 as a poor prognostic indicator [362]. EPHA5 has been associated with 
tumour dormancy pathways. Tumour dormancy is one of the currently accepted theories 
for breast cancer recurrence and dormant tumour cells are known to be resistant to 
standard chemotherapies including doxorubicin [363]. It is possible that through its role 
in tumour dormancy EPHA5 participates significantly in progression of TNBC. This 
may suggest that introducing an EPHA5 inhibitor in combination with primary 
chemotherapy may delay recurrences and improve overall survival, however much 
further study and examination would be required prior to implementing this strategy. 
Inhibitors targeting EPHA2 and EPHA3 are currently in clinical trials and the 
University of Texas have a patent on a peptide that inhibits EPHA5 making studies of 
EPHA5 inhibition an exciting future prospect [220, 364].  
Although the Kaplan Meier survival curves for FGFR3 and EPHA5 did not achieve 
statistical significance (most likely due to small number of events occurring), the trends 
matched those observed in the BreastMark database. The combination of expression of 
FGFR3, EPHA5 and ROS1 mRNA results in a highly statistically significant survival 
curve with a hazard ratio of 3.08. Co-expression of FGFR3, EPHA5 and ROS1 mRNA 
may represent a biomarker panel to identify TNBC who have a poorer prognosis and 
require more aggressive treatment to improve survival. The Kaplan Meier survival 
curves for FGFR3 and EPHA5 combined expression from our cohort of TNBC did not 
reach statistical significance, however again the trend for both DFS and OS is worse for 
high expression of both.  
229 
 
8.10.2 Insulin Receptor in TNBC 
Another potentially interesting target for TNBC which we identified in the 9 TNBC 
tumours examined for phosphorylation of RTKs is the insulin receptor (IR). The 
phosphorylation levels of the IR were significantly higher than the other RTKs. The cell 
line panel when assessed did not show such significant differences between the 
phosphorylation of the IR and other RTKs. While this is potentially an accurate 
reflection of IR phosphorylation status in the tumours caution must be exercised when 
interpreting the results. The phospho proteome can show significant fluctuations even in 
the process of tissue procurement. IRS-1 (an insulin receptor related protein) has shown 
the ability to increase its phosphorylation levels >20% post-excision [365]. While every 
care is taken to freeze the tissues immediately, time to freezing can vary significantly 
and as such IR phosphorylation levels may be falsely elevated.  
 
However this does not negate the potential for the IR to be a target for therapies in 
TNBC. Early studies showed the overexpression of the IR in breast cancers compared to 
normal tissue and a significant association with age of the patient, tumour grade and ER 
positivity [366]. Insulin expression has also been confirmed in a number of ER positive 
cell lines which show increased responsiveness to insulin binding and activation of the 
IR via IGF-1 [367]. Additionally women with high levels of insulin have an increased 
risk factor in the development of breast cancer [368]. The phosphorylated IR has also 
been shown to be expressed in all subtypes of invasive breast cancer. In this study 
phosphorylated IR and total IR were shown to correlate with poorer overall survival 
[369]. IR is alternatively spliced to form two isoforms α and β. Examination of the 
mRNA levels of each isoform suggest the IRα may be the more dominant isoform in 
breast cancer. mRNA levels of IRβ are decreased relative to normal adjacent tissue 
while IRα was relatively similar [370].  
 
8.11 Conclusions/Limitations and Future Work 
c-Met is expressed at high levels in TNBC and at significantly higher levels than other 
breast cancer subtypes. We observed no significant association with progression or 
survival. c-Met/HGF inhibitors (CpdA, rilotumumab, PRS110, Crizotinib and BMS-
777607) show limited responses in in vitro assays. While activity of CpdA, PRS110 and 
crizotinib were confirmed by responses in 2D proliferation assays a positive control was 
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not tested for rilotumumab. The U87-MG-LUC2 would be an appropriate positive 
control cell line as evidenced by the results of the HGF ELISA and qRT-PCR. 
Clonogenic assays for c-Met inhibitors (CpdA and PRS110) showed the highest level of 
sensitivity to growth inhibition. These results suggest that c-Met signalling may have an 
active role in tumour initiation. This combined with the evidence supporting a role for 
c-Met in the initiation of BLBC in mouse models might suggest a potential role in 
cancer prevention in high risk cases.  
 
Targeting of c-Met and HGF through CpdA and rilotumumab showed a significant 
reduction in proliferation of three TNBC cell lines, however this result must be 
evaluated with caution as a positive control HGF expressing cell line was not included. 
We suggested the enhancement of response is due to interaction between human c-Met 
and bovine HGF. This hypothesis could be tested by examining phosphorylation levels 
of c-Met after rilotumumab treatment or co-immunoprecipation of human c-Met/bovine 
HGF to examine the presence of complexes. Thus the mechanism of the interaction 
between CpdA and rilotumumab requires further examination and may potentially be 
best evaluated in a recombinant huHGF expressing mouse model. 
 
Targeting EGFR/Src in combination with c-Met showed a significant decrease in 
proliferation in TNBC cell lines. However the concentrations of CpdA tested may not 
be therapeutically relevant as they were in the micromolar range. Further evaluation of 
the combinations in fixed ratio combination assays over a range of concentrations of 
CpdA may provide more insight into the therapeutic relevance of these combinations. 
Furthermore, drug scheduling assays could potentially enhance response as evidenced 
by Mueller et al. In this study resistance to EGFR inhibitor gefitinib in TNBC SUM229 
occurred in a time dependent manner and was mediated through c-Met/Src re-activation 
of EGFR signalling [213].  Finally combinations of c-Met with chemotherapy agents 
could also be beneficial for TNBC and warrant testing. Any potential clinical trial 
would be required to meet the current standard of care which involves chemotherapy 
regimens. Additionally c-Met has been implicated in resistance to chemotherapy in a 
number of clinical situations therefore c-Met blockade consecutively or in a scheduled 
manner as described above may enhance response  to chemotherapy [198, 316, 317].  
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In tumour samples EGFR expression was too low for evaluation, however co-
expression of c-Met and Src was seen in 83.3% of tumours. Phosphorylated Src was 
detectable in 38.8% of these tumours. No significant association was seen between any 
clinico-pathological variables and recurrence/OS. The trend in the Kaplan Meier curve 
for c-Met and phosphorylated Src suggest an increase in survival for high expressers, 
similar to what was previously reported. This highlights the need for selective 
biomarkers to identify patients who may benefit from c-Met/Src targeted therapies.  
We identified c-Met as an escape mechanism for acquired resistance to two targeted 
agents dasatinib and cetuximab. The resistant variants were more sensitive to c-Met 
inhibition than their parental cell lines. We believe this may represent a common escape 
pathway and future work would include evaluating this is other models of resistance, 
including models of chemotherapy resistance.  
We identified seven RTKs associated with poorer prognosis in TNBC, most of which 
have been previously implicated in angiogenic activity. Given the lack of success of 
anti-angiogenic agents in TNBC further examination is required to interrogate the 
possibility of combined expression of all or some of these RTKs could potentially form 
a protein signature to identify potential responders to antiangiogenic therapies.  
FGFR3 and EPHA5 are expressed in TNBC tumour samples however protein 
expression in cell lines was undetectable. FGFR3 nuclear staining was significantly 
associated with histological subtype and membrane staining of EPHA5 was 
significantly associated with age. Trends in the Kaplan Meier Curves show a decreased 
DFS/OS with high expression of these proteins. To truly determine the potential 
prognostic significance of these RTKs a much larger cohort of patients should be 
examined. Preclinical evaluation of inhibitors of FGFR3 and EPHA5, preferably 
specific inhibitors, would help to determine their potential as targets for TNBC. 
Additionally, patient derived xenografts (PDX) may be required for in vivo evaluation, 
due to the lack of expression of these RTKs in the cell lines analysed. Lastly, combined 
expression of FGFR3, EPHA5 and ROS1 should be evaluated as a novel prognostic 
biomarker panel of TNBC. 
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Appendix 1 
Table A1 - 1 Entrez Gene I.D.s and Probe I.D.s used for survival analsis in 
BreastMark Database 
RTK Entrez Gene Probe I.D 
ALK 238 208211_s_at 
ALK 238 208212_s_at 
LTK 4058 217184_s_at 
LTK 4058 207106_s_at 
AXL 558 202685_s_at 
AXL 558 202686_s_at 
MER 10461 211913_s_at 
MER 10461 206028_s_at 
MER 10461 211912_at* 
TYRO3 7301 211432_s_at 
TYRO3 7301 211431_s_at 
DDR1 780 1007_s_at 
DDR1 780 208779_x_at 
DDR1 780 207169_x_at 
DDR1 780 210749_x_at 
DDR2 4921 205168_at 
DDR2 4921 225442_at 
DDR2 4921 227561_at 
DDR2 4921 205168_at 
EGFR 1956 210984_x_at 
EGFR 1956 211607_x_at 
EGFR 1956 201984_s_at 
EGFR 1956 201983_s_at 
EGFR 1956 211551_at 
EGFR 1956 211550_at 
EGFR 1956 224999_at 
EGFR 1956 1565484_x_at 
- 2 - 
 
 
RTK Entrez Gene Probe I.D 
EGFR 1956 1565483_at 
ERBB2 2064 210930_s_at 
ERBB2 2064 216836_s_at 
ERBB2 2064 234354_x_at 
ERBB3 2065 202454_s_at 
ERBB3 2065 226213_at 
ERBB3 2065 215638_at 
ERBB3 2065 1563253_s_at 
ERBB3 2065 1563252_at 
ERBB4 2066 206794_at 
ERBB4 2066 214053_at 
ERBB4 2066 233498_at 
ERBB4 2066 233494_at* 
EPHA1 2041 205977_s_at 
EPHA2 1969 203499_at 
EPHA3 2042 206070_s_at 
EPHA3 2042 211164_at 
EPHA3 2042 206071_s_at 
EPHA3 2042 206070_s_at 
EPHA4 2043 206114_at 
EPHA4 2043 227449_at 
EPHA4 2043 229374_at 
EPHA4 2043 228948_at 
EPHA5 2044 215664_s_at 
EPHA5 2044 215664_s_at 
EPHA5 2044 237939_at 
EPHA6 285220 233184_at 
EPHA6 285220 1561396_at 
EPHA7 2045 206852_at 
EPHA7 2045 238533_at 
EPHA7 2045 1554629_at 
EPHA7 2045 229288_at 
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RTK Entrez Gene Probe I.D 
EPHA7 2045 229288_at 
EPHA8 2046 1554069_at 
EPHA8 2046 231796_at 
EPHB1 2047 210753_s_at 
EPHB1 2047 211898_s_at 
EPHB1 2047 230425_at 
EPHB1 2047 211898_s_at 
EPHB2 2048 209589_s_at 
EPHB2 2048 211165_x_at 
EPHB2 2048 210651_s_at 
EPHB2 2048 209588_at 
EPHB3 2049 1438_at 
EPHB3 2049 204600_at 
EPHB4 2050 202894_at 
EPHB4 2050 216680_s_at 
EPHB6 2051 204718_at 
FGFR1 2260 211535_s_at 
FGFR1 2260 210973_s_at 
FGFR1 2260 207937_x_at 
FGFR1 2260 215404_x_at 
FGFR1 2260 207822_at* 
FGFR1 2260 226705_at 
FGFR2 2263 211401_s_at 
FGFR2 2263 203639_s_at 
FGFR2 2263 208234_x_at 
FGFR2 2263 208228_s_at 
FGFR2 2263 203638_s_at 
FGFR2 2263 208225_at 
FGFR2 2263 211399_at 
FGFR2 2263 211400_at 
FGFR2 2263 208229_at* 
FGFR3 2261 204380_s_at 
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RTK Entrez Gene Probe I.D 
FGFR3 2261 204379_s_at 
FGFR4 2264 211237_s_at 
FGFR4 2264 204579_at 
FGFR4 2264 1554962_a_at 
IGF1R 3480 203627_at 
IGF1R 3480 203628_at 
IGF1R 3480 208441_at* 
IGF1R 3480 225330_at 
INSR 3643 213792_s_at 
INSR 3643 207851_s_at 
INSR 3643 226450_at 
INSR 3643 226212_s_at 
INSRR 3645 215776_at 
MET 4233 211599_x_at 
MET 4233 203510_at 
MET 4233 213816_s_at 
MET 4233 213807_x_at 
MET 4233 211599_x_at 
RON 4486 205455_at 
MUSK 4593 207633_s_at 
MUSK 4593 207632_at 
MUSK 4593 241122_s_at 
CSF1R 1436 203104_at 
FLT3 2322 206674_at 
KIT 3815 205051_s_at 
PDGFRA 5156 203131_at 
PDGFRA 5156 215305_at 
PDGFRA 5156 211533_at 
PDGFRA 5156 1554828_at 
PDGFRB 5159 202273_at 
PTK7 5754 207011_s_at 
PTK7 5754 1555324_at 
- 5 - 
 
RTK Entrez Gene Probe I.D 
RET 5979 205879_x_at 
RET 5979 215771_x_at 
RET 5979 211421_s_at 
ROR1 4919 205805_s_at 
ROR1 4919 211057_at 
ROR1 4919 232060_at 
ROR2 4920 205578_at 
ROS1 6098 207569_at 
RYK 6259 214172_x_at 
RYK 6259 202853_s_at 
RYK 6259 216976_s_at 
TEK 7010 217711_at 
TEK 7010 206702_at 
TIE 7075 204468_s_at 
TIE 7075 1560657_at 
NTRK1 4914 208605_s_at 
NTRK2 4915 207152_at 
NTRK2 4915 221796_at 
NTRK2 4915 221795_at 
NTRK2 4915 214680_at 
NTRK2 4915 236095_at 
NTRK2 4915 229463_at 
NTRK3 4916 217033_x_at 
NTRK3 4916 217377_x_at 
NTRK3 4916 206462_s_at 
NTRK3 4916 215115_x_at 
NTRK3 4916 215025_at 
NTRK3 4916 213960_at 
NTRK3 4916 215311_at 
NTRK3 4916 217033_x_at 
NTRK3 4916 1557795_s_at 
VEGFR1 2321 210287_s_at 
- 6 - 
 
 
RTK Entrez Gene Probe I.D 
VEGFR1 2321 204406_at* 
VEGFR1 2321 226498_at 
VEGFR1 2321 226497_s_at 
VEGFR1 2321 232809_s_at* 
VEGFR2 3791 203934_at 
VEGFR3 2324 210316_at 
VEGFR3 2324 234379_at 
VEGFR3 2324 229902_at 
AATYK 9625 205986_at 
AATYK2 22853 206223_at 
AATYK2 22853 226375_at 
AATYK3 114783 1557103_a_at 
STYK1 55359 221696_s_at 
STYK1 55359 220030_at 
 
